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There is limited knowledge on how to induce potent antiviral antibodies in HIV vaccine 
strategies. Studies of HIV infected individuals who develop potent anti-HIV antibodies could 
inform rational vaccine immunogen design approaches. Phenotypic characteristics of T and B 
cells, as well as interactions between these cells early in infection may affect the quality of 
antiviral antibodies. This study investigated the impact of the general and HIV-specific T and B 
cell phenotypes and interactions in early HIV infection on subsequent anti-HIV antibody quality. 
 
Using a cohort of 53 antiretroviral-naive HIV-infected adults that were longitudinally followed 
for approximately 48 months, the general and HIV-specific T and B cell subsets, as well as 
plasma CXCL13 and B cell-activating factor levels, as proxy for germinal centre activities, were 
determined in early infection and their association with subsequent development of antibody 
levels and their neutralising and Fc-mediated functions assessed.  
 
Atypical B cells were elevated in HIV, (20% [IQR, 12.15-29.55] versus 5.4% [IQR, 3.45-6.67] 
in HIV-naive donors, p<0.0001), whereas CD4+ T cells were depleted (41.6% [IQR, 32.2-53.1] 
versus 50.4% [IQR, 48.1-55.65], p=0.004). HIV-specific B and T-follicular helper (Tfh) cells 
were detected in infected individuals, 0.58% (IQR, 0.41%-0.9%) and 0.54% (IQR, 0.3-0.83), 
respectively. Antibody neutralization breadth was detected in 28.3% of the participants, while 
Fc-mediated functions were common, with 15.1% of the individuals showing quality Fc-
polyfunctionality over time. 
 
The Tfh subset, ICOS+ PD-1+ CXCR5+ CD4+, was associated with subsequent higher IgG titres 
(rho=0.3135, p=0.025), while HIV-specific Tfh cells predicted interferon-gamma release by 
natural killer cells (rho=0.3314, p=0.018). Activated B cells were positively associated with 
higher IgG1 levels (rho=0.4285, p=0.0014). Similarly, HIV-specific B cells and CXCL13 levels 
 xxii 
were associated with higher IgG3, (rho=0.3, p=0.029), and IgG levels (rho=0.37, p=0.006), 
respectively. 
 
The data suggest that early T and B cell features can be predictive of downstream antibody 
functions and levels. Immunological signatures identified early in HIV infection could be useful 
in shepherding desired antibody responses. 
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1.1: The biology of HIV 
 
Acquired immunodeficiency syndrome (AIDS) is caused by the human immunodeficiency 
virus (HIV), a lentivirus, that has its origins from chimpanzees (Pan troglodytes) following 
transmission of the chimpanzee simian immunodeficiency virus (SIVcpz) to humans [1]. 
Divergent simian precursors led to the emergence of two related viruses, HIV-1 and HIV-2 [2, 
3]. HIV-1 is the most pathogenic and is responsible for the worldwide pandemic. It comprises 
of four distinct lineages: groups M, N, O, and P. Group M is the most prevalent in the world, 
while group O, N and P are less prevalent, but capable of causing AIDS [4-6]. Group M has 
nine genetically distinct clades that may recombine to form hybrid forms of the virus. The 
clades include: A, B, C, D, F, G, H, J and K. Similarly, HIV-2 comprises of eight groups: A, 
B, C, D, E, F, G and H. 
 
HIV-1 is a ribonucleic acid (RNA) retrovirus that has 9 genes encoding 15 proteins [7]. The 
gag, pol and env genes are the dominant genes that encode for structural proteins and enzymes. 
Gag proteins, the matrix, capsid, nucleocapsid and p6 give rise to the core of the virion, whereas 
the surface Envelope (Env) protein gp120 and transmembrane Env protein gp41 give rise to 
the outer membrane. The reverse transcriptase, integrase and protease are enzymes that play a 
critical role in HIV replication. The other genes vif, vpr, vpu and nef encode for accessory 
proteins while Tat and Rev are regulatory proteins. Specifically, Vpu indirectly assists in virion 
release and evasion of host immune responses while Tat and Rev provide vital gene regulatory 
functions. Vif, Vpr, and Nef aid in immune evasion and promote virus replication [7]. For 
instance, Nef enhances infectivity of CD4+ T cells by activating them [8] and disrupts 
phagocytosis of HIV infected cells by reducing major histocompatibility complex (MHC) class 
I expression [9]. The disruption of the MHC class I trafficking by Nef leads to enhanced viral 
persistence since immune recognition by cytotoxic T lymphocytes is abrogated.  
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Viral entry begins with contact between gp120 and a CD4+ molecule on the target cell. This 
contact leads to conformational changes in gp120, thereby exposing the CCR5+ or CXCR4+ 
co-receptor binding site, which leads to the fusion of the virion’s Env with the host cell 
membrane. Once the viral core is delivered into the cytoplasm, viral transcripts are expressed, 
and Tat-dependent reverse transcription occurs. Viral deoxyribonucleic acid (DNA) in the form 
of a pre-integration complex is integrated into the host’s genome, forming a provirus. In the 
nucleus, proviral transcription, catalysed by host polymerase II, leads to transcription products 
which are then transported from the nucleus to the cytoplasm for translation, a step regulated 
by Rev.  
 
After successful translation in the endoplasmic reticulum, Gag, Gag-Pol and Env polyproteins 
are localized to the cell membrane. By assembling Gag and Gag-Pol polyproteins, Vif, Vpr, 
Nef and the genomic RNA to form the core particle, an immature virion is formed which buds 
out of the host cell and detaches. The immature virion will be mature and infectious once the 
proteolytic processing of Gag and Gag-Pol polyproteins is complete [7, 10, 11]. Figure 1.1 




Figure 1:1: The overview of the HIV replication cycle. HIV begins by attaching, which leads to viral–
cell membrane fusion and entry of the virus particle into the cell. Core shell uncoating facilitates reverse 
transcription. After reverse transcription, the pre-integration complex is exported to the nucleus and is 
integrated, transcripted before viral mRNAs are exported out of the nucleus to the cytoplasm. In the 
cytoplasm, viral mRNA is translated, and the proteins assembled. The immature virion then buds out 
of the host cell and matures to become infectious. Adapted from [10]. 
 
1.2: Transmission, disease progression and stages of untreated HIV infection 
 
It is still not clear if HIV is transmitted as a cell-bound or free virus [12]. However, in a 
macaque model study, cell-free simian immunodeficiency virus (SIV) was shown to infect the 
animals more efficiently than cell-associated infection by both vaginal and intravenous route 
[13]. This compelling evidence suggested that cell-free HIV is likely to be the preferred mode 
of HIV transmission, as compared to the cell-associated mode. HIV infection is instigated by 
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a lone viral variant that is derived from the quasi-species of the transmitting individual [14]  
and the virus may take up to 10 days before p24 antigen and viral RNA copies are detectable 
in blood [15]. However, in some instances, such as in cases of men who have sex with men 
(MSMs), intravenous drug use or even in genital inflammation associated HIV transmission, 
multiple founder viruses may be transmitted [16-18]. The transmission of a lone viral variant, 
despite the high diversity of HIV population in the donor, has been termed as the “transmission 
bottleneck” and the underlying mechanisms for this phenomenon remain incompletely 
understood. What is known is that multiple exposures are required for effective transmission 
and that intraepithelial dendritic cells may be the first cells to be infected, and thereby spreading 
the infection to other immune cells.  
 
Once transmitted, viral replication is enhanced by mechanisms mediated by innate cells [19] 
mainly through the recruitment of susceptible CD4+ T cells and the production of 
immunosuppressive cytokines. The presentation of virally infected cells by dendritic cells to 
activated CD4+ CCR5+ T cells at draining lymph nodes has widely been suggested to push for 
viral spread in the body [20]. Also, the binding of HIV-specific B cells to HIV through 
complement receptor CD21 has been shown to spread the virus [21]. These B cells are found 
both in peripheral blood and lymphoid organs and may then infect susceptible HIV-specific 
CD4+ T cells.  
 
Sixty per cent of infected CD4+ T cells become activated and die by apoptosis [22]. However, 
the B cell population with the bound virus is steady, although their function may remain 
impaired due to the destruction of germinal centres (GCs) in lymphoid organs [23]. As such, 
immune dysfunction is triggered soon after a successful HIV transmission, setting in the acute 
phase of HIV infection. Heterosexual sex is the primary route of transmission [24], but 
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homosexuality practices [25] and intravenous drug use [26] remain key risk factors of HIV 
transmission. 
 
The acute phase of HIV infection refers to the period immediately after HIV acquisition, when 
viremia increases exponentially, and widespread destruction of immune cells occurs. The acute 
period varies from individual to individual, but generally lasts for about 4 weeks and is 
characterised by very high rates of HIV infectiousness [27]. The stages of acute HIV infection 
have been described by the detection of viral particles and antibody responses; a classification 
termed as the Fiebig staging [28]. Immediately after transmission, there is a period of about 10 
days called the eclipse phase where the viral RNA is undetectable. This period is followed by 
the 6 Fiebig stages of acute HIV, as outlined in Table 1.1. In Fiebig stage 1, only HIV RNA 
can be detected, and this is shortly followed by Fiebig stage 2 that is characterised by the 
detection of the p24 antigen. Stage 3 occurs approximately 30 days post-HIV acquisition and 
is characterised by symptoms of an acute retroviral syndrome such as fever and rash. These 






Table 1.1: Fiebig stage classification of acute HIV infection. 
 
 
Unlike in the eclipse phase that HIV cannot be detected, HIV RNA can be detected in stage 1 of HIV, 
which lasts for 7 days, and up to 17 days post-HIV acquisition. After that, the p24 antigen can be 
detected up to 22 days after HIV acquisition, while enzyme-linked immunoassay (ELISA) can be used 
to test for HIV thereafter, at least 25 days after HIV infection. Western blot, which detects HIV proteins 
can accurately detect HIV proteins at approximately 31 days post-infection and p31, an HIV integrase 
antigen, can be used to detect HIV seroconverters with high sensitivity. Adopted from [28].   
 
Upon HIV infection, innate immune responses are quickly backed up by adaptive immune 
responses. Particularly, CD8+ T cell responses are responsible for bringing down the peak 
viremia to a stable level referred to as the viral set point. At the same time, a transient recovery 
of CD4+ T cell counts is observed [30] (Figure 1.2). The viral set point occurs 3 to 6 months 
post-infection [31] and is characterised by immune pressure selection of escape mutants and 
viral diversification and clinical latency [32]. The clinical latency is characterised by the 
absence of clinical symptoms, a gradual decrease in CD4+ T cell counts, with viral load counts 
generally maintained at the viral set point [33].  In the absence of antiretroviral therapy (ART), 
the CD4+ T cell counts decline continues, and once it passes a certain threshold, there is an 
exponential increase in viremia accompanied by susceptibility to opportunistic infections and 
results to AIDS [30, 34, 35]. 
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The World Health Organisation (WHO) has categorized HIV/AIDS in adults into four clinical 
stages [36]. In clinical stage 1, patients are asymptomatic and may experience persistent 
lymphadenopathy, where lymph nodes are inflamed due to direct viral effects. Stage 1 may last 
up to 10 years before clinical stage 2 kicks in with symptoms that range from mild weight loss, 
recurrent respiratory infections and dermatological conditions such as oral ulcers and 
dermatitis. As the disease progresses, clinical signs such as moderate weight loss, prolonged 
unexplained diarrhoea, systemic bacterial infections such as pneumonia, meningitis set in, and 
these are consistent with clinical stage 3 of the disease. Additionally, pulmonary tuberculosis 
may be observed in some patients. In clinical stage 4, HIV wasting syndrome, pneumocystis 
pneumonia, extrapulmonary tuberculosis, toxoplasmosis and Kaposi’s sarcoma are evident in 
most patients. 
 
Figure 1:2: The clinical course of untreated HIV infection. Upon HIV infection, there is an exponential 
increase in viremia accompanied by a steep decrease in CD4+ T cell counts. CD8+ T cell responses 
bring down the viremia to a stable level referred to as viral set point, and there is a transient recovery 
of CD4+ T cell counts. However, without ART treatment, viremia gradually increases as HIV disease 
progresses while CD4 T cell counts gradually decrease, leading to clinical cases of opportunistic 
infections. The left side y-axis represents CD4+ T cell counts while the right represents Log10 of viral 
load measurements. The x-axis represents the time after HIV infection. All curves are colour coded to 
represent the dynamics over time of CD4+ T cell counts (blue) and HIV viral load measurements (red). 
Adopted from [30]. 
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1.3: The epidemiology of HIV 
 
According to the United Nations Programme on HIV/AIDS (UNAIDS) 2020 global HIV and 
AIDS report, it is approximated that up to 75.7 million [55.9 million–100 million] people have 
become infected with HIV since the start of the epidemic in 1980 with about 32.7 million [24.8 
million–42.2 million] people dying. As at the end of 2019, HIV has infected approximately 
38.0 million [31.6 million–44.5 million] of whom, 1.8 million [1.3 million–2.2 million] were 
children below the age of 14 years. In this period, 25.4 million [24.5 million–25.6 million] 
people were accessing antiretroviral therapy (ART). The incidence rates remained as high as 
1.7 million [1.2 million–2.2 million] per year globally [37]. To aggravate this, the recent 
outbreak of the Coronavirus disease 2019 (COVID-19) collided with the HIV pandemic [38], 
and it remains unclear of what impact this will have in HIV infected individuals [39-41]. 
However, despite COVID-19 deaths being associated with immunosuppression [42], HIV 
infection was not found to be a risk factor for COVID-19 deaths. This is probably due to the 
HIV-related compromised immunity that results in a lack of intense immunological response 
in COVID-19 infection. Literature indicates that intense immunological responses immensely 
contribute to complicating the clinical course of COVID-19 [41, 43]. 
 
While the risk of acquiring HIV is significantly higher in MSMs, intravenous drug users (IDU), 
female sex workers and transgender people, young girls between the ages of 15-24 years are 
more likely to be living with HIV than men. The high HIV prevalence in girls and women is 
attributed to structural differences between the male and female genitalia. The high infectivity 
in women is because of the large mucosal surface area that is exposed to infectious fluids during 
intercourse. For instance, a study suggested that male to female transmission to be 1.9 (95% 
confidence interval 1.1 to 3.3) times more effective than female to male transmission [44]. 
 9 
Moreover, sociocultural factors such as younger girls having sex with older men and the 
subordinate position of women in society predispose women to HIV [45]. 
 
However, progress has been made in reducing new infections by adopting the UNAIDS 90-90-
90 guidelines [37]. The guidelines aim at ending the AIDS pandemic by making sure that by 
2020, 90% of all people living with HIV will know their HIV status, 90% of all people with 
diagnosed HIV infection will receive sustained ART and 90% of all people receiving ART will 
have viral suppression. As at the end of 2019, 81% [68–95%] of HIV infected people knew 
their status, and of this, approximately 82% [66–97%] were accessing ART. Of those on ART, 
59% [49–69%] were virally suppressed as at the end of 2019 [37]. 
 
 Furthermore, prevention of mother to child transmission (PMTCT) has had a significant 
contribution in reducing HIV incidence rates in infants born to HIV infected mothers, both 
prenatally and postnatally [46-48]. Moreover, pre-exposure prophylaxis (PrEP) [49], post-
exposure prophylaxis (PEP) [50], consistent condom use, prevention of sexually transmitted 
infections and male medical circumcision have all had an impact in reducing HIV incidences 
[51]. Despite the reduction in HIV incident rates, HIV prevalence is increasing due to the effect 
of ART, whereby HIV infected individuals have a better prognosis and hence better survival 





Figure 1:3: The estimated numbers of adults and children living with HIV in various countries as of 
2018. Adapted from [53]. 
 
1.4: HIV antiretroviral treatments 
 
In 2016, the WHO reviewed the guidelines on the use of ART [54] recommending lifelong 
ART to all HIV infected individuals regardless of their CD4 T cell count. Additionally, testing 
and treating of infections such as tuberculosis and cryptococcal meningitis that are associated 
with advanced HIV disease were officially implemented. Provision of PrEP to people at 
substantial risk of HIV infection was also introduced [55].  
 
Zidovudine was the first therapy against HIV approved by the United States Food and Drug 
Administration (FDA) in 1987 [56]. Zidovudine is a nucleoside reverse transcriptase inhibitor 
that inhibits DNA synthesis by competing with the natural deoxynucleotides and terminating 
DNA synthesis. There are currently six FDA-licensed classes of HIV antiretroviral drugs which 
are classified depending on the phase of HIV replication life cycle inhibited by them. Table 1.2 




Table 1.2: FDA-approved HIV antiretroviral drugs based on their mode of action [56]. 
 
Class of HIV antiretroviral 
drugs 
Mode of action Examples of FDA-approved 




Inhibit DNA synthesis by 










Bind to the reverse 
transcriptase enzyme and 
inhibit DNA synthesis  





Bind to the HIV protease and 
block the cleavage of protein 
precursors necessary for the 








Prevent the insertion of viral 
genome into the host DNA by 
blocking the action of the 
enzyme integrase 
Dolutegavir, 





Prevent the fusion of HIV 
virions into the human cell 






Prevent viral attachment to the 






Other interventions to control the replication of HIV include post-attachment inhibitors such 
as ibalizumab, a monoclonal antibody that inhibits viral entry into the cell by binding to the 
CD4 molecule on the cell membrane. The use of pharmacokinetic enhancers has also been 
explored. For instance, cobicistat inhibits the human cytochrome P4503A (CYP3A) protein 
and thereby, increasing the concentration of other HIV antiretroviral drugs in plasma [56]. 
The human CYP3A protein is responsible for drug metabolism since it is involved in the 
oxidative biotransformation of a large proportion of drugs [57]. 
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According to the recommendations by the WHO, the first-line ART in adults should include 
two nucleoside reverse-transcriptase inhibitors and a non-nucleoside reverse-transcriptase 
inhibitor or an integrase inhibitor except for stavudine which due to its metabolic toxicities, 
should not be used in the first-line regimens [55].  
 
1.5: Immune responses to HIV 
 
1.5.1: Early innate immune responses to HIV 
 
 
Early HIV-specific innate immune responses revolve around the production of acute-phase 
proteins, cytokines and chemokines by innate cells. Apart from interleukin 10 (IL-10) that 
increases at a gradual rate, interleukin 15 (IL-15), interleukin 22 (IL-22), type I interferons and 
CXC-chemokine ligand 10 (CXCL10) have been shown to increase in plasma rapidly [29]. 
This initial cytokine and chemokine storm functions to regulate adaptive immune responses 
but may also have antiviral effects. For instance, type I interferon was shown to inhibit HIV 
replication in mice with transplanted human U937 cells, suggesting that type I interferons 
preserve CD4+ T cells from virus-induced damage [58].  
 
On the other hand, prolonged exposure to cytokines and chemokines might lead to immune 
suppression. For example, HIV exposed dendritic cells produce indoleamine 2,3-dioxygenase, 
which prompts the differentiation of CD4+ T cells into T regulatory cells hence suppressing 
HIV-specific immune responses [59]. Moreover, findings from SIV infection suggested that 
natural killer (NK) cells undergo altered functions such as distorted cytokine production and 




1.5.2:  Early adaptive immune responses to HIV 
 
1.5.2.1: CD8+ T cell responses 
 
 
HIV-specific CD8+ T cell responses arise slightly before peak viremia, and they play a big role 
in controlling viremia [15]. Responses against HIV viral peptides within proteins such as Env, 
Gag and Nef are among the first HIV-specific T cell adaptive responses. Indeed, HIV-specific 
T cell responses against Gag p24 and Pol have been reported as being important in controlling 
the early viremia in HIV infection through cytolysis of infected cells [61, 62]. Furthermore, 
there is strong evidence that individuals who lack Gag-specific CD8+ T cells tend to progress 
to AIDS more rapidly [63]. Similarly, the elimination of CD8+ T cells led to the dramatic 
increase in SIV load in macaques, translating to poor prognosis [64].  
 
While the CD8+ T cell responses have a dramatic impact against HIV viremia initially, these 
responses are not sustained and rapidly decline due to exhaustion, leading to poor CD8+ T cell 
function. The production of perforin by CD8+ T cells significantly reduces as the disease 
progresses, leading to an uncontrolled increase in viremia [62]. Also, CD4+ T cells fail to 
secrete sufficient interleukin 2 (IL2), which translates to poor CD8+ T cell function [65]. 
Interleukin 2 is important for CD8+ T cell proliferation and function [65]. In support of this, 
in-vitro IL2 supplementation dramatically upregulates CD8+ T cell ability to lyse infected cells 
[65].  
 
Even when CD8+ T cell responses are maintained, immune responses eventually lead to the 
selection of HIV escape mutants with altered epitopes [66], thereby abrogating immune 
recognition of HIV infected cells by CD8+ T cells. 
 
There is controversy in the field on whether CD8+ T cells can traffic into B cell follicles and 
lyse HIV infected CD4+ T cells [67-71]. While this remains debatable, some studies have 
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shown that CXCR5+ CD8+ T cells exist and may play a role in controlling chronic viral 
infections. He and colleagues showed that CXCR5+ CD8+ T cells play a vital role in the 
control of chronic lymphocytic choriomeningitis virus (LCMV) in mice, as compared to 
CXCR5- CD8+ T cells [72]. Moreover, CXCR5+ CD8+ T cells expressed lower levels of 
inhibitory receptors and exhibited more potent cytotoxicity than the CXCR5− subset, 
highlighting their crucial role in viral replication control [72]. Similar data suggests that 
CXCR5+ CD8+ T cells play a role in controlling viremia in B cell follicles. Leong and 
colleagues conducted immunofluorescence staining of lymph node sections from both HIV 
infected and HIV uninfected individuals. They demonstrated significantly higher numbers of 
CXCR5+ CD8+ T cell in HIV infected individuals, suggesting that those cells are in the B cell 
follicles to lyse HIV infected CD4 T+ cells [73]. They further showed that these CXCR5+ 
CD8+ T cells were functional using a mouse model infected with LCMV [73]. These data 
suggest that CXCR5+ CD8+ T cells may play a key role in controlling HIV by lysing CXCR5+ 
CD4+ T cells, and this may be important in strategies designed to control and prevent HIV 
infection. While this uncertainty looms, a better understanding of this subset of CD8+ T cells 
is required.  
1.5.2.2: CD4+ T cell response 
 
 
HIV infects and significantly depletes memory CD4+ T cells [22]. This early depletion of 
CD4+ T cells can be partially reversed by administration of ART [74]. CD4+ T cells serve to 
coordinate the different arms of adaptive and innate immunity through the release of cytokines. 
Helper functions of CD4+ T cells have been studied in detail.  
It has been shown that effective CD8+ T cell function squarely relies on CD4+ T cell help. 
CD4+ T cells in HIV infection secrete insufficient IL2, which is essential for CD8+ 
proliferation and function, translating to poor CD8+ T cell function [65]. More critically 
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studied is the help B cells receive from CD4+ T cells. CD4+ T cells offer exclusive help to B 
cells through cell surface co-stimulatory molecules such as CD40 ligands or cytokines [75, 76] 
and are vital for the development of memory B cells [76].   
 
Also, CD4+ T cells maximize the bactericidal activity of macrophages and hence improve their 
immune responses [77]. Additionally, CD4+ T cells may play a role in lysing virally infected 
cells and have been implicated in controlling Epstein–Barr virus (EBV) [78], hepatitis C virus 
(HCV) [79] and HIV [80]. These cytolytic CD4+ T cells express CD107α, which enables them 
to have degranulation functions [80].  
 
1.5.2.2.1: T follicular helper cell responses in HIV 
 
 
T follicular helper (Tfh) cells are a CD4+ T cell subset that offers exclusive help to B cells 
through cell-surface co-stimulatory molecules such as CD40 ligands or cytokines [75, 76] and 
are vital for germinal centres (GCs) formation and the development of memory B cells [76].  
They are residents of B cell follicles in GCs and are identified by their high expression of 
CXCR5, which enables their migration to the border of the B cell follicle and PD-1 which is 
an activation marker [76]. These cells can further be characterised by their expression of 
inducible T cell costimulator (ICOS) - a T cell activation marker, B cell lymphoma 6 protein 
(BCL6) - a Tfh master transcription factor, IL-21 (T cell cytokine), and CXCL13 - a marker 
for GCs activity and chemokine for the CXCR5 receptor present on both Tfh and B cells [81-
83].  
Sufficient Tfh help to B cells drives B cell proliferation, differentiation and somatic 
hypermutations leading to the selection of B cells with superior affinity [84]. In HIV infection, 
extensive levels of somatic hypermutation, that is not commonly observed in other diseases or 
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vaccine responses have been associated with the production of antibodies with broadly 
neutralising functions (bnAbs) [85].  
 
As such, impaired Tfh cell help to B cells may be associated with reduced antibody quality as 
witnessed in a majority of HIV infected individuals, who fail to generate neutralising antibodies 
against HIV [86]. Ideally, as it is observed in other infections, adaptive immunity against HIV 
relies on the expansion of antigen-specific Tfh in lymphoid organs [87]. Unfortunately, HIV 
infects a large number of CD4+ T cell subsets, including Tfh leading to marked lymphopenia 
in early HIV infection and hence directly crippling the immune system.  
 
Similarly, the abnormal differentiation of Tfh cells that is driven by viral effects may deplete 
Tfh cells numbers. Both HIV and SIV infections have been shown to favour the expression of 
T-Bet in Tfh cells leading to poor differentiation of these cells [88]. Such Tfh cells offer 
suboptimal help since T-Bet antagonizes IL-21. Thus, T-Bet expression by Tfh cells not only 
diminishes their numbers but also their function in HIV infection. This altered differentiation 
may also downregulate the expression of key markers such as PD-1, critical for Tfh cell 
function, as shown in mice models [89]. 
 
Apart from distorting the Tfh cell numbers and transcriptional profiles, HIV replication and 
latency phase are majorly concentrated within the Tfh population in B cell follicles, where 
about 60-75% of HIV-producing cells are located [90]. This is worsened by the poor 
penetration of ART into B cell follicles, the lack of or very low frequencies of CD8+ T cells 
that can traffic into B cell follicles and the presence of millions of infective virions on the 
follicular dendritic antigen-presenting cells [90]. The high presence of infective virions may 
also contribute to the expansion of HIV infected Tfh cells [91] that may further act in infecting 
other uninfected Tfh, and other CD4+ T cell subsets, leading to depletion of these cells. 
Ironically though, there are reports of increased proportions of Tfh cells in the blood of HIV 
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chronically-infected individuals [92], than in HIV uninfected individuals [92, 93]. This may be 
as a consequence of constant antigenic stimulation or a relative decrease in the frequency of 
other CD4+ T cell subsets.  
 
The Tfh and B cell cognate interactions occur within the GCs, which are not easily accessible 
in most studies. The identification of a surrogate population in blood has, however advanced 
our knowledge of Tfh cells. Previously, human peripheral blood CXCR5+ CD4+ T cell subset 
has been shown to share functional properties with Tfh cells in the GCs and therefore, may be 
representative of the circulating Tfh memory compartment [94]. Indeed, these cells efficiently 
induce naïve B cells to produce immunoglobulins through their secretion of IL-21 [94]. 
Additionally, Havenith and colleagues suggested that the frequencies of GCs Tfh and 
peripheral blood CXCR5+ CD4+ T cells are associated, with the former being superior in 
providing help to B cells [95]. 
 
Moreover, CXCL13, a B cell follicle chemoattractant, is a marker of GCs activity [96]. 
Havenar-Daughton and colleagues reported a direct association between the levels of CXCL13 
in plasma, the magnitude of antibody responses, the frequency of ICOS+ Tfh cells in the blood 
and the quality of GCs reaction [96]. The B cell activating factor (BAFF) has also been 
suggested to influence the survival and class switching of B cells [97] and thus may be vital in 
GC reactions. Since both CXCL13 and BAFF levels are readily quantifiable by ELISA in 
plasma, they remain essential in understanding GCs activities.  
 
In a bid to understand basic GCs biology that may reveal immune correlates of protection in 
HIV, such as quality of anti-HIV antibody functions, various subsets of blood Tfh cells have 
been associated with bnAbs. Locci and colleagues identified blood circulating PD-1+ CXCR3- 
CXCR5+ CD4+ T cells to be the best subset that correlated with the generation of bnAbs in 
HIV [98]. Cohen, on the other hand, described global subsets of CXCR5+ PD-1+ CD4+ and 
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CXCR5+ PD-1+ ICOS+ CD4+ T cells in early HIV infection that positively correlated with 
the breadth of plasma neutralising antibody responses in chronic HIV infection [99]. Moreover, 
using a cross-sectional cohort of 34 untreated HIV infected controllers matched for viral load, 
Ranasinghe and colleagues reported a correlation of Gag-specific CD4+ T cells with antibody 
breadth in ART naïve HIV neutralisers [100]. Overall, current data suggest that a functional 
Tfh cell compartment may be vital in eliciting effective immune responses against HIV. 
 
It is critical to note that most of the studies conducted so far have been limited in sample sizes 
and hence may not have provided conclusive reports. Additionally, the majority of the studies 
did not study HIV-specific Tfh cells responses but investigated immune responses from a 
global perspective. The two studies that looked at HIV-specific Tfh cell responses were cross-
sectional and did not inform on the early immunological correlates that may have contributed 
to subsequent antibody function in chronic HIV. Although these previous studies gave a hint 
of potential immune correlates, it remains important to assess specific HIV immune responses 
as these are the cells that will offer the required specific help. 
 1.5.2.4: B cell responses 
 
 
The bone marrow is the site of B cell development before B cells traffic to the secondary 
lymphoid organs for further differentiation. In the absence of ART, HIV infection causes 
alterations of the B cell phenotypes. Such alterations include the increase of tissue-like memory 
(TLM) B cells, activated memory B cells, plasmablasts and a decrease of resting memory B 
cells [101]. It is speculated that a large proportion of the HIV-specific B cells lie within these 
altered B cell subsets. Indeed, there is evidence that HIV-specific B cells may develop from 
immature B cell population without Tfh help and with characteristics of polyreactivity [102]. 
The altered B cell compartment in HIV leads to decreased quality of HIV-specific response 
[103] and usually translates to the poor immune response to vaccines [104]. 
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Generally, upon antigen encounter, B and Tfh cells interact in the extra-follicular areas leading 
to the generation of short-lived plasmablasts. Germinal centres only form when activated B 
cells migrate to follicular areas that are densely packed with follicular dendritic cells (FDC), 
whereby, they undergo many rounds of proliferation. Only B cells with increased affinity for 
HIV antigens are selected and exit the GCs as memory B cells or long-lived plasma cells [105]. 
However, it should be noted that HIV disrupts these physiological differentiation processes by 
altering B cell phenotypes and frequencies, with consequences such as an increase of TLM B 
cells, activated memory B cells and a decrease of resting memory B cells. 
 
The role of B cell effector function has been controversial in some studies. For instance, while 
antibodies have been shown to control HIV viremia [106] and SIV viremia [107], B cell 
depletion in rhesus macaques showed no significant difference in survival or disease 
progression in cases and control subjects. More interestingly, macaques whose B cells were 
depleted had significantly better cellular immune responses than the controls, implying that B 
cell depletion may have been compensated by T cell functions or that certain B cell subsets 
have inhibitory functions on T cells [108]. Contrarily, HIV elite controllers have been shown 
to have similar numbers of circulating memory B cells to those observed in HIV-naïve 
individuals [109] suggesting that a compact B cell compartment may be vital in controlling 
viremia. 
 
While the role of B cells remains uncertain, what is known is that antibodies against HIV 
infection are majorly ineffective, with only 10-20% of infected individuals developing 
antibodies with broadly neutralising functions [110-112]. Indeed, the earliest antibody 
responses have been shown to target non-neutralising epitopes of the HIV Envelope, with the 
virus rapidly evading these responses through mutation [113, 114]. HIV-specific IgA responses 
at mucosal sites are generally low, despite the mucosal sites being the prevailing site of 
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transmission and infection [115-117]. A rapid decline in HIV-specific IgG3 antibodies during 
early HIV infection has been observed and could be reflective of possible GCs destruction 
[118].  
 
On their part, B cells are significantly susceptible to HIV induced hyperactivity [119]. 
Hyperactivation in the B cell compartment is manifested by hypergammaglobulinemia [120], 
elevated polyclonal B cell stimulation [120], increased frequency of B cell malignancies [121], 
increased B cell turnover [122], increased production of autoantibodies [123], and an increase 
of differentiation of B cells into plasma cells [122]. More directly, GCs B cells require IL-17 
from Tfh cells in order to mature into functional memory B cells [124], and the change in the 
levels of IL-17 reported in HIV infection may be crucial for the inadequate B cell responses 
observed. Indeed, B cell dysfunction in HIV has been illustrated to occur during the cognate 
interaction between Tfh and B cells, where the expression of PD-L1 directly undermines Tfh 
help [86]. PD-L1 expression is elevated on B cells during HIV infection, and the blockage of 
the PD-L1/PD-1 interaction in HIV has been shown to improve IgG secretion in Tfh-B cell in 
vitro co-cultures [86]. 
1.5.2.5: Association between Tfh function with the generation of broadly 
neutralising antibody responses in HIV 
 
Broadly neutralising antibodies (bnAbs) take years to develop and only occur in approximately 
5-20% of HIV infected adults. These antibodies often show high somatic hypermutation [84, 
125] and tend to exhibit elongated, hydrophobic complementary-determining regions (CDR) 
H3 residues, and autoreactivity in vitro [123]. Additionally, few HIV infected individuals 
develop antibodies that can neutralise the infecting virus. However, these antibody responses 
lag behind a rapidly diversifying virus, rendering the antibodies ineffective to the heterologous 
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viral strains. Given the strong suggestions that bnAbs can control viremia in SIV [126-128], it 
is crucial to understand the mechanisms leading to the generation of such effective antibodies. 
 
On the other hand, antibodies that neutralise autologous viruses take about 3 to 12 months to 
develop and do not inhibit heterologous viruses. More recently, bnAbs with lower 
hypermutation have been described in HIV infected infants after 1 year of infection, indicating 
a more direct path to their generation [129]. Despite the lower hypermutation, the infant 
neutralising activity compared with the second generation adult bnAbs. Such information 
provides renewed hope that neutralisation breadth does not necessarily require years of 
maturation and may be attainable through vaccination, although the exact pathways to achieve 
this remain undetermined.  
HIV bnAbs are more likely to be poly- and autoreactive than anti-HIV antibodies that lack 
breadth [130], suggesting that this may be key in developing bnAbs. It is hypothesized that 
poly- and autoreactive features lead to antibody heteroligation with both host, and HIV virions, 
increasing anchoring targets and thus resulting in better affinity and neutralisation [130]. This 
is termed as neutralisation selection bias [130]. Broadly neutralising antibodies from HIV 
infected individuals have previously been reported to offer protection in animal models after 
passive intravenous and vaginal transfer [126-128]. Additionally, neutralising antibodies have 
been evidenced to reduce the establishment of viremia in HIV infected humanized mice [131] 
and delaying virus rebound in ART-interrupted HIV chronic patients [132]. These data strongly 
suggest that bnAbs may be a critical component of an effective HIV vaccine. 
What triggers the generation of bnAbs remains unknown, however high viral load, HIV 
subtype, superinfection and host genotype may play a role. [96, 110]. Additionally, a robust 
cellular response may be beneficial in generating bnAbs. More specifically, the role of 
peripheral blood memory PD-1+ CXCR3- CXCR5+ CD4+ T cells in the development of 
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bnAbs has been highlighted in HIV, emphasizing that B cells are capable of generating 
functional antibodies if quality Tfh help is received [98]. In agreement, the frequencies of 
global CXCR5+ PD-1+ and CXCR5+ PD-1+ ICOS+ CD4 T cells in early HIV infection 
correlated with the breadth of plasma neutralising antibody responses in chronic HIV infection 
[99].  
Contrarily some studies have shown a lack of correlation between the frequencies of peripheral 
Tfh cell in early HIV infection with antibody function in chronic HIV infection [133]. In this 
particular study, they reported impaired antibody production in co-cultures that was 
accompanied by lack of neutralisation abilities. Lindquist and colleagues used lymph node 
samples to characterize Tfh cells in ART naïve, and ART-treated HIV positive individuals and 
showed a significant expansion of Tfh cells in chronic HIV that drove the perturbation of B 
cell differentiation leading to poor antibody function[93]. Their observations suggest that Tfh 
numbers may not necessarily improve antibody generation. A better understanding of how 
bnAbs are generated in HIV is, therefore still needed.  
1.5.2.5: Non-neutralising antibody responses 
 
 
There is growing interest in the role of non-neutralising (Fc-mediated) antibodies in the control 
of HIV infection. Unlike Fab-mediated antibody function that takes years to develop, Fc-
mediated functions are common and are induced earlier in infection [134].  Non-neutralising 
antibodies are capable of coating an HIV infected cell and recruit innate immune cells to kill 
the HIV infected cell. Such antibody functions include antibody-dependent complement 
deposition (ADCD), antibody-dependent cellular phagocytosis (ADCP) both which mediate 
the destruction of virally infected cells, antibody-dependent cell-mediated virus inhibition 
(ADCVI) that limits viral growth and antibody-dependent cellular cytotoxicity (ADCC) that is 
mediated through the recruitment of natural killer (NK) cells [135]. 
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These functions occur through the engagement of Fcγ receptor with cellular receptors on 
effector cells and thereby lysing virus-infected cells [136]. Natural killer cells (NK) are the 
primary effector cells mediating ADCC mechanism in HIV infection, whereby, once they are 
activated by ADCC mechanism, they release cytotoxic granules that kill the infected cell [137]. 
While the ADCC mechanism may be useful in controlling viremia, dysfunction of effector 
cells and the presence of immune escape variants still undermines its action [136]. For example, 
it has been suggested that NK cells lose their ability to secrete cytokines and undergo changes 
on their cell-surface markers leading to defective ADCC functions that may lead to HIV disease 
progression [138]. Another mechanism used by HIV to evade ADCC activity is through the 
HIV viral protein U (Vpu), which interferes with the function of the host restriction factor 
tetherin and thus enhances virus spread to uninfected cells [139, 140]. Without this 
interference, tetherin functions in restricting HIV particles on the surface of the infected cells, 
which enables non-neutralising antibodies to bind to infected cells and recruit natural killer 
cells. Nevertheless, it has been shown that these defects may partially be reversed after 
successful ART [141]. Monocytes and neutrophils can mediate phagocytosis after engaging 
the Fc portion of antibodies.  
 
Nevertheless, there is growing evidence that Fc effector function may play a role in controlling 
viremia. Various studies have described the role of ADCC in HIV infection. For instance, 
ADCC activity was reported to be the immune correlate of protection in the RV144 HIV 
vaccine trial in Thailand, where the vaccine efficacy was reported to be 31.2% [142]. Similarly, 
a ten-year longitudinal study involving 118 HIV infected men, classified as either non-
progressors, slow progressors or rapid progressors to AIDS revealed that ADCC plays a role 
in viremia control [143]. The study reported that high titres of antibodies that mediated ADCC 
correlated with successful host defence against AIDS, and this was evident in the non-
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progressors group [143]. A similar study assessing antibody responses in HIV controllers 
versus viremic individuals revealed significantly higher ADCC activity in the elite controllers 
and thus suggesting ADCC may be responsible for the low viremia [144].  
 
Antibody-dependent cellular cytotoxicity activity has been reported in breastmilk and has 
directly been associated with reduced risk of mother to child transmission [145]. Perhaps even 
more convincing is that elite controllers demonstrated more functionally coordinated Fc-
mediated responses [146]. Elite controllers were able to recruit ADCC, monocyte and 
neutrophil phagocytosis better than viremic individuals [146]. It is also worth noting that the 
Fc receptor-mediated non-neutralisation activity contributed to better broadly neutralising 
antibody function in the SIV macaque model. Macaques with antibodies that had deletions in 
both Fc receptor and complement system had poor neutralising activity when compared to 
macaques that either had deletions in the complement system alone or had unaltered antibody 
systems, highlighting the added value of Fc-mediated activity [147]. Thus, more information 
on cellular mechanisms that may confer better ADCC antibodies is required. 
 
In summary, it appears that strong cellular interactions between B and Tfh cells in the GCs are 
crucial in an individual’s ability to generate broadly neutralising antibody responses in HIV. 
This has been supported by various macaque studies that have shown evidence where broadly 
neutralising antibodies were able to control SIV viremia. Additionally, the HIV vaccine trial 
in Thailand together with other key studies in HIV infected individuals, macaque models and 
in-vitro studies strongly suggest that ADCC antibodies are crucial in the protection and viremia 
control in HIV and SIV. Thus, understanding basic Tfh and B cell interactions may be vital in 
informing us why and how good quality anti-HIV antibodies develop. This will be beneficial 
in informing which responses and interactions should be targeted for the development of an 
effective HIV vaccine development. 
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1.6: HIV vaccine development 
 
Despite the efforts in the last decades, there is no licensed HIV vaccine. The biggest challenge 
is the high degree of antigenic variation due to the mutability of the virus [148]. Additionally, 
the structure of the Envelope (ENV) glycoprotein that obscures conserved viral epitopes and 
the instability of the trimer provides further challenges [149]. 
 
The first two trials in 1998 using bivalent subunits of the gp120 receptor binding subunit of 
Env aimed at inducing protective antibodies [150, 151]. One of the trials was a randomized, 
double-blind, placebo-controlled efficacy trial called AIDSVAX B/E (VAX 003) that tested 
vaccine efficacy in injection drug users[151]. The vaccine design was unsuccessful and failed 
to protect the vaccinees. Similarly, a vaccine with a similar design, AIDSVAX B/B (VAX 
004), also failed to be protective [150]. A different vaccination approach using vectored – HIV 
proteins were tested in the STEP trial.  The STEP trial tested the ability of adenovirus five 
(Ad5)‐vectored internal HIV proteins (Gag, Pol, and Nef) in inducing cytotoxic CD8+ T cell 
responses [152]. However, the trials were stopped due to the lack of protection in vaccinated 
individuals [152]. Similar findings were evident in the Phambili trial that also sought to elicit 
T cell-mediated immune responses [153]. 
 
The only trial to show moderate efficacy was conducted in Thailand on participants that had a 
relatively lower risk of acquiring HIV [154]. The trial used a canary poxvirus prime (ALVAC) 
followed by an ALVAC + bivalent gp120 protein in alum boost to induce protection against 
HIV. The vaccine showed 31.2% efficacy, but this protection waned off rapidly. Similarly, the 
HVTN 705 trial conducted in MSMs using DNA priming and subsequent boosting with Ad5 
expressing a secreted form of the Env failed to offer protection [155, 156]. Other vaccine trials 
have either been tested in preclinical, phase 1 or phase 2 trials with poor outcomes. For 
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instance, a phase 2b trial (HVTN 505) using a DNA prime-recombinant adenovirus type 5 
boost (DNA/rAd5) vaccine regimen showed a lack of protection against HIV transmission 
[155]. 
 
More recently, HVTN 702 and HVTN 705 trials were initiated in Africa, but the former was 
stopped in January 2020 due to its ineffectiveness in preventing HIV transmission [157]. The 
HVTN 702 trial used an approach similar to the RV144 trial but replaced the clade B HIV Env 
proteins with HIV Env from clade C, the common clade circulating in the South African 
population. HVTN 705 is still ongoing and uses four Ad-26 vectored mosaic sequences 
followed by a trimeric gp140 Env boost as the immunogen, and initial reports have labelled it 
as safe, with limited side effects [149].  
 
With there being no effective anti-HIV vaccine to date, understanding the basic biology of how 
quality antibody responses are generated and the cellular mechanisms leading to their 
production, remains key in designing an effective HIV vaccine. In this study, I sought to 
understand the role of HIV-specific B and Tfh-cell phenotypes on the subsequent antibody 
function in HIV infection.  
 
1.7: General objective 
 
To understand the cellular mechanisms involved in the generation of functionally relevant 
antibodies in chronic HIV infection. 
 
1.8: Specific objectives 
 
1. To characterize peripheral blood HIV-specific Tfh and B cell subsets during early HIV 
infection. 
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2. To determine HIV-specific antibody levels, isotypes and subclasses during HIV 
infection and as a proxy of germinal centre activity, determine the plasma levels of 
BAFF and CXCL13 cytokines before and during HIV infection. 
3. To evaluate the quality of Fab- and Fc-mediated antibody functions in the course of HIV 
infection. 
4. To establish if any of the early immunological events are associated with better GCs 
activity, antibody quality and quantities in chronic HIV infection. 
1.9: Null hypothesis 
 
Early HIV-specific Tfh and B cells do not predict the quality of downstream Fab- and Fc-




In the recent past, several studies have addressed the relationship between Tfh cell frequencies, 
phenotypes and quality with antibody breadth. However, the majority of these studies analysed 
general populations without demonstrating the contribution of HIV-specific subsets and 
function to down-stream humoral responses. Also, the majority of these studies were cross-
sectional, thereby reporting immunological events at single time points and only considered 
neutralising antibody function.  
 
Describing HIV-specific cell subsets and interactions may provide a true reflection of these 
association as these are the cells that specifically drive the HIV-specific responses. In addition, 
analysing these cell subsets and interactions early in the infection may be a better predictor of 
subsequent antibody function in chronic HIV, since antibody function is often reflective of 
cellular events that occurred much earlier in an infection. Often Fc-mediated functions have 
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been ignored despite non-neutralising activity being the only function that so far has shown an 
association with protection in any vaccine clinical trial, albeit being modest efficacy. This 
project, therefore, sought to understand HIV-specific cellular events early in an infection on 
the resultant antibody functions using a systems approach. The outcomes of this project will 
improve our understanding on the role of early HIV-specific T and B cells in the generation of 
relevant humoral responses downstream, information that could assist in vaccination efforts 





























































2.1: Study design and participants 
 
This study used samples from a longitudinal retrospective cohort, referred to as ‘Protocol C’ 
that was established by the International Acquired immunodeficiency syndrome (AIDS) 
Vaccine Initiative (IAVI). In this cohort, adults at a high-risk of acquiring human 
immunodeficiency virus (HIV) negative adults were recruited across different sites in Africa, 
that is, Uganda, Rwanda, Zambia, Kenya and South Africa and followed longitudinally. Sites 
in Kenya included Kenya AIDS Vaccine Initiative - Kangemi (KAVI-Kangemi); Kenya 
Medical Research Institute - Centre for Geographic Medicine Research-Coast (KEMRI-
CGMRC) and Kenya AIDS Vaccine Initiative-Kenyatta National Hospital (KAVI-KNH).  
 
 The high-risk populations included men who have sex with men (MSMs), individuals who 
inject drugs (IDUs) and female sex workers (FSW) were followed up longitudinally. Upon 
recording a positive HIV test result either by ribonucleic acid (RNA), P24 or positive antibody 
test with evidence of a negative antibody test in the last 3 months, written informed consent 
was obtained and the individuals were enrolled into “The IAVI Protocol C cohort”. An 
estimated date of infection (EDI) was determined based on the last negative test before the first 
positive test results. Quarterly follow-ups were then done for the following ten years or until a 
participant‘s CD4+ T cell counts dropped making them eligible for antiretroviral treatment 
(ART) as per the World Health Organisation (WHO) guidelines for HIV care at the time of the 
recruitment [158]. Data including demographics, HIV viral load measurements (Appendix 1) 
and CD4+ T cell counts (Appendix 2) were collected during the visits and have been previously 
described elsewhere [159]. Blood samples were collected during each of the follow-up visits 
and peripheral blood mononuclear cells (PBMCs) and plasma stored for future studies. This 





2.2: Sample size calculation 
 
In a previous study, Locci and colleagues were able to identify differences in a rare 
subpopulation of circulating functional PD-1+ CXCR5+ CD4+ T cells in 43 HIV infected 
individuals with and without broadly neutralising antibodies (bnAbs) [98]. Using similar 
means and standard deviations as Locci and colleagues in the sample calculation, sampsi mean 
1 mean 2, (sd) (alpha) (power), initially described by Cohen [160], an estimation with the 
assumptions that: alpha = 0.0500, power = 0.9000, and n2/n1 = 1.00, a sample size of n1=22 
and n2=22, making a total of 44, gave a similar statistical difference for these rare subsets. 
Therefore, with the 53 individuals (more than the minimum required, n=44) who passed the 
inclusion criteria stated in Chapter 2, section 2.1, it was anticipated that this would provide 
enough statistical power and precision for the study. 
 
2.3: Study Approach 
 
With an overall aim of understanding the role of early immunological events on the subsequent 
antibody levels and quality, T and B cell phenotypes were determined at time point 1 (3 months 
PI) to determine early cellular events upon HIV infection and associated to downstream 
antibody levels and function. Antibody non-neutralising functions (Fc-mediated) were 
analysed at time points 1, 2 and 3 (3-, 12- and 48-months PI, respectively) since these are 
known to develop early after infection and persist throughout the infection. Antibody 
neutralisation function was only analysed at time point 3 (48 months PI), as these develop much 
later on in the infection. As antibody quantity may influence function, antibody levels and 
subclasses were determined at the three time points. In addition as a proxy for germinal centre 
(GCs) activities (BAFF and CXCL13 plasma levels as proxies) were determined at time points 
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1, 2 and 3 (3-, 12- and 48-months PI, respectively) and in the pre-infection plasma samples 
(sampled approximately 3 months before HIV infection) to understand if there are any intrinsic 
factors prior to HIV acquisition that influence downstream T-B cell interaction and the 
resulting antibody quantities and function. This also provided an opportunity to establish the 
kinetics of these cytokines pre- and post-HIV infection. T and B cell subsets and BAFF and 
CXCL13 plasma levels measured early in the infection (time point 1) were then associated with 
antibody functions and levels and HIV disease outcome (based on CD4+ T cell counts and HIV 







Figure 2:1: Longitudinal retrospective sampling design highlighting sampling time points when sampling and laboratory assays were done. Adults at high-risk 
for HIV infection were followed up every 3 months until they tested positive for HIV, at which point an estimated date of infection was determined, they were 
then recruited into the IAVI protocol C. Their last plasma sample to test negative before the infection was used to test for B cell cytokines levels, while their 
plasma samples at 3-, 12- and 48-months after HIV infection was used to run the assays as highlighted above. Additionally, PBMCs samples at 3 months PI 
were used for cellular phenotyping.
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2.4: Ethical considerations 
 
The study was reviewed and approved by the Kenya Medical Research Institute (KEMRI) 
Ethical Review Committee (ERC) under IAVI protocol C (SSC Protocol Number 1027) 
(Appendix 3). Written informed consent was obtained from every study participant (Appendix 
4). The HIV-naïve samples were obtained under the protocol KEMRI/SERU/CGMR-
C/022/3149 from adult’s bleed during the annual malaria surveillance cross-sectional bleed in 
within Kilifi (Appendix 5).  
 
2.5: Peripheral blood mononuclear cells sample preparation 
 
This study used samples frozen under the above cohorts. Frozen PBMCs at approximately 10 
million cells per vial were quickly thawed in a water bath at 37°C and transferred to a falcon 
tube containing 5 millilitres (mls) RPMI complete media (RPMI + 10% new-born bovine 
serum + L-glutamine + penicillin-streptomycin + hydroxyethyl piperazineethanesulfonic acid 
(HEPES) + β-mercaptoethanol). The cells were washed twice; each time being centrifuged at 
500 g for 5 minutes at 4°C and the supernatant discarded. Consequently, the cells were counted 
using a Vi-CELL cell counter (Beckman Coulter) and the median cell viability was 93.05% 
(IQR 89.65-95.3). Four million cells were used for B cell phenotyping (general and HIV-
specific subsets), 4 million cells used for the detection of HIV-specific T-follicular helper (Tfh) 
cells in overnight cultures and 1 million cells were used for baseline T cell phenotyping. 
Additionally, 200,000 cells per condition, taken from the HIV-naïve donors were used to set 
up the compensation panel for flow cytometry analysis and as a negative control to determine 
the baseline.  
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2.6: Characterization of peripheral blood HIV-specific and general B cell 
subsets during early HIV infection 
 
2.6.1: Preparation of the B cell probe 
 
The B cell probe, a biotin-labelled gp120 antigen, was a kind donation from Dr. Elise Landais, 
Scripps Research Institute. The probe was then fluorescently tagged with either streptavidin 
phycoerythrin (SAV PE) (Promega) or with streptavidin allophycocyanin (SAV APC) 
(Promega). Dual labelling of the B cells with these two probes, gp120-APC and gp120-PE, 
provided an optimized approach to enrich for the selection of HIV-specific B cells by 
minimizing non-specific selection of cells. 
 
Briefly, B cell probes were prepared freshly for each experiment. Biotinylated gp120 antigen 
was incubated separately with premium grade PE-labelled streptavidin (Promega) and APC-
labelled streptavidin (Promega) for at least 80 minutes on ice at a molar ratio of 4:1, to form 
tetramers. In order to create competition for the two-labelled streptavidin fluorochromes, the 
total volume of the fluorochromes to be added was divided into 8 equal volumes, and each one 
eighth added at intervals of 10 minutes and incubated on ice. The preparation was then mixed 
by vortexing and placed on ice in the dark until use.  
 
2.6.2: Identification of B cell subsets by multiparametric flow cytometry 
 
 
Approximately 4 million PBMCs to be stained for B cell phenotyping were aliquoted into a 
96-well plate and washed twice using fluorescence-activated cell sorting buffer ((FACS 
buffer (Phosphate Buffered Saline containing 2% Foetal Calf Serum (FCS)), 5mM 
ethylenediaminetetraacetic acid (EDTA) and 1% Sodium Azide). To reduce the binding of 
gp120 probe to the preferred CD4 target in the PBMC pool, 3 μl of anti-human CD4 blocking 
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antibody (Biolegend) was first added and cells incubated for 30 minutes at 4°C. 2 microliters 
(μl) each of gp120 SAV PE and gp120 SAV APC probes that had freshly been prepared as 
illustrated in section 2.6.1 were then added to the cells and incubated for 30 minutes at 4°C. 
 
A pool of the following monoclonal antibodies were then added, BV421 mouse anti-human 
CD19,  a lineage marker for B cells, BV711 mouse anti-human CD27, a marker for memory B 
cells,  PE-CY7 mouse anti-human CD10, a marker for B cell maturation, BV650 anti-human 
IgM, a marker for naïve B cells, BV605 anti-human CD20 (all from BioLegend), a marker co-
expressed with CD19 and found on all B cells but plasma cells, FITC mouse anti-human CD21 
(Beckman Coulter), an activation marker for B cells, Alexa Fluor 700 anti-human IgG (BD 
Pharmingen), a marker for B cell class switching and aqua viability dye (Life Technologies, 
Carlsbad, CA, USA) to exclude dead cells. The cells were incubated for a further 30 minutes 
at 4°C. Respective compensation control fluorochromes, including unstained cells were 
prepared and also incubated for 30 minutes at 4°C.  
 
After that, 150 ul FACS buffer was added to all wells and spun at 550g for 2 minutes at 4°C. 
The supernatants were discarded, and 200 ul FACS buffer added to the wells and spun at 550g 
for 2 minutes at 4°C in order to wash off unbound antibodies. The supernatant was then 
discarded, and cells fixed at 4°C for 7 minutes by adding 200 ul of 1% formaldehyde. The plate 
was then spun at 550g for 2 minutes at 4°C, supernatant discarded; and the cells washed once 
in 200 ul FACS buffer. The cells were then re-suspended in 300 ul FACS buffer and acquired 
on the LSR Fortessa (Becton Dickinson, Franklin Lakes, NJ, USA). Data were analysed on 
FlowJo version 10 (FlowJo LLC, Ashland, OR, USA) and then exported to Microsoft Excel 
(Microsoft), GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) and R Studio 
1.0.143 for statistical analyses.   
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2.6.3: Characterization of baseline peripheral blood T cell subsets during early 
HIV infection 
 
Approximately 1 million PBMCs, as described in section 2.5 above, were used for baseline T 
cell phenotypic characterization. The cells to be stained were plated in a 96-well plate and 
washed twice using FACS buffer. The following antibodies were then added, BV711 mouse 
anti-human CD27, a marker for T cell activation, BV421 mouse anti-human CXCR3, a 
chemokine receptor for T cell trafficking and function, BV605 anti-human CD45RA, a marker 
for naïve T cells, BV650 anti-human CCR7, a marker critical for lymphocyte trafficking into 
and within lymph nodes (all BioLegend), FITC mouse anti-human CD4, a co-receptor in major 
histocompatibility complex (MHC) class II-restricted T cell activation (Beckman Coulter), 
Alexa Fluor 700 anti-human CD3, a T cell co-receptor that is involved in activating both CD8+ 
and CD4+ naive T cells, APC anti-human CXCR5, a chemokine receptor which contributes to 
Tfh and B cell localization in B lymphoid follicles, PE anti-human PD-1, an inhibitory receptor 
that is expressed by all T cells during activation, PERCP e710 anti-human inducible T cell co-
stimulator (ICOS), a marker for activation on T cells, (all e-Bioscience) and aqua viability dye 
(Life Technologies) to exclude dead cells.  
 
Antibodies were incubated at 4°C for 30 minutes, before adding 150 ul FACS buffer to all 
wells and spinning the plate at 550g for 2 minutes at 4°C. The supernatant was discarded and 
200 ul FACS buffer added to the plates and spun at 550g for 2 minutes at 4°C to wash off 
unbound antibodies. The supernatant was then discarded, and the cells fixed by adding 200 ul 
of 1% formaldehyde added and incubating at 4°C for 7 minutes. Plates were then spun at 550g 
for 2 minutes at 4°C, the supernatant discarded; and the cells washed once in 200 ul FACS 
buffer and spun (550g for 2 minutes, 4°C). The cells were then re-suspended in 300 ul FACS 
buffer and acquired on the LSRFortessa (Becton Dickinson, Franklin Lakes, NJ, USA). Data 
were analysed on FlowJo version 10 (FlowJo LLC, Ashland, OR, USA) and then exported to 
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Microsoft Excel (Microsoft), GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) 
and RStudio 1.0.143 (PBC, Boston, MA) for statistical analyses. 
 
2.6.4: Characterization of peripheral blood HIV-specific T cell subsets in early 
HIV infection 
  
To identify HIV-specific T cells, the Activation Induced Marker (AIM) assay that has been 
previously described [161, 162] was adapted. In summary, PBMCs are stimulated with antigen-
specific peptides and the expression of the activation surface markers CD25 and OX40 
measured. Both CD25 and OX40 are expressed on CD4+ T cells following T cell receptor 
(TCR) stimulation [161, 162]. OX40 interacts with OX40 ligand on B cells to ensure cognate 
T and B cell interactions while CD25 is an interleukin-2 (IL-2) receptor and important for Tfh 
activation [161, 162]. The AIM technique is more superior to the conventional intracellular 
cytokine assay, as it offers better sensitivity and specificity in detecting antigen-specific CD4+ 
T cells and has been reported to have significantly minimal by-stander activation [161, 162].  
 
Peripheral blood mononuclear cells from HIV infected and uninfected individuals were tested 
under four conditions: RPMI complete media alone with no stimulant (as the negative control), 
staphylococcal enterotoxin B (SEB) (Toxin Technology, Sarasota, FL) stimulation (as the 
positive control), cytomegalovirus (CMV) (MyBioSource) (as another endemic virus in the 
study region) and the test antigen (HIV peptide pool – targeting Envelope gene) provided by 
the Human Immunology Laboratory, London. Each condition was set up using 1 million 
PBMCs. In addition, PBMCs from HIV-naïve individuals were also tested under the same 





In brief, PBMCS samples were prepared as described in section 2.6.3 above. One million cells 
per condition were then plated into a 96 well plate and stimulated as follows:  
 
i) RPMI complete media - no stimulant (negative control to check for background 
signals)  
ii) Staphylococcal enterotoxin B (SEB) [1ug/ml] (positive control)  
iii) HIV peptide pool [A3 ENV] (1.5ug/ml) (test antigen)  
iv) Cytomegalovirus (CMV) [1.5ug/ml] (another viral antigen that study participants 
are likely to have been exposed to). 
 
The cells were then incubated for 18 hours at 37°C. After the 18-hour incubation, the cells were 
spun at 550g for 2 minutes at 4°C and the supernatant discarded. The cells were then washed 
twice with 200 ul FACS buffer before being stained with the following monoclonal antibodies; 
BV711 conjugated anti-human CD27, BV421 mouse anti-human CXCR3, PE-CY7 mouse 
anti-human OX40, BV785 anti-human CD25 (all BioLegend), FITC mouse anti-human CD4 
(Beckman Coulter), Alexa Fluor 700 anti-human CD3, APC-H7 anti-human CD8 (BD 
Pharmingen), PE anti-human PD-1, APC anti-human CXCR5, PERCP e710 anti-human ICOS 
(e-Bioscience) and aqua viability dye (Life Technologies, Carlsbad, CA, USA). Similarly, cells 
from HIV-naïve individuals were used to set compensation controls.  
 
The cells were then incubated at 4°C for 30 minutes before washing off unbound antibodies 
using 200 ul FACS buffer and the supernatant discarded after centrifuging at 550g for 2 
minutes. The cells were then fixed by adding 200 ul of 1% formaldehyde and incubating at 4°C 
for 7 minutes. Plates were then spun at 500g for 2 minutes at 4°C and the supernatant discarded. 
The cells were then washed once in 200 ul FACS buffer and the supernatant discarded after 
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centrifuging at 500g for 2 minutes. The cells were then re-suspended in 300 ul FACS buffer 
and acquired on the LSRFortessa (Becton Dickinson, Franklin Lakes, NJ, USA).  
 
Data were analysed on FlowJo version 10 (FlowJo LLC, Ashland, OR, USA) and then exported 
to Microsoft Excel (Microsoft), GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) 
and RStudio 1.0.143 (PBC, Boston, MA) for statistical analyses. 
 
2.7: Enzyme-linked immunosorbent assay for determination of HIV-specific 
antibody quantities  
 
For HIV-specific titres, plasma samples were tested for 94UG103 Clade A (provided by E. 
Landais (IAVI Neutralising Antibody Centre, La Jolla, California)) specific antibodies using a 
standard in house enzyme-linked immunosorbent assay (ELISA) protocol [110]. In summary, 
Nunc MaxiSorp™ plates (Thermo Scientific) were coated with 50 ul of 1 μg/ml of 94UG103 
(Clade A) antigen in PBS (50 μl/well) and incubated overnight at 4 °C. After discarding the 
coating antigen, plates were blocked with phosphate-buffered saline containing 0.1% Tween 
20 (PBST) and 3% skim milk for 2 hours at room temperature. The block buffer was then 
discarded, and the plates were incubated at room temperature for 1 hour with 50 μl of test 
plasma sample diluted in PBST and 5% skimmed milk: 1:1000 for total IgG, 1:500 for IgG1 
and 1:100 for IgG2, IgG3, IgG4, IgM and IgA.  
 
The respective anti-human secondary antibodies conjugated to alkaline phosphatase (Sigma) 
were added per well and incubated for one hour at room temperature. To wash off unbound 
anti-human secondary antibodies, the plates were centrifuged thrice with PBST at 500g for 3 
minutes. The assays were then developed by adding P-nitrophenyl phosphate (Sigma) 
substrate. The substrate reaction was stopped with 50 μl per well of 2 molars (M) sodium 
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hydroxide before being read at 405 nm in a Synergy™ plate Reader (BioTek Instruments Inc). 
Pooled HIV hyperimmune plasma samples were used as standards. Relative arbitrary antibody 
units were calculated by interpolating optical density readings to the standard curve of pooled 
hyper-reactive HIV positive plasma where the highest plasma concentration on the standard 
curve was assigned an arbitrary value of 1000 arbitrary units (AU). The HIV-specific antibody 
concentrations were expressed as arbitrary units after interpolation on GraphPad Prism 7 
(GraphPad Software, San Diego, CA, USA) (GraphPad Software, San Diego, CA, USA). The 
data generated was then transformed for normalization. 
 
2.8: Enzyme-linked immunosorbent assay for the determination of 
quantities of BAFF and CXCL13 cytokine levels before and during HIV 
infection 
 
HIV pre-infection plasma samples (3 months pre-infection) and samples collected at 
approximately 3, 12- and 48-months PI were used to determine BAFF and CXCL13 levels 
using the Human BAFF and CXCL13 Quantikine ELISA kit (R&D Systems, Minneapolis, 
MN, USA) as per the manufacturer’s protocol.  
 
Briefly, plasma samples were thawed at room temperature, spun at 500g for 5 minutes and the 
clear supernatant used for the assays. For both cytokines, all reagents and pre-coated plates 
were brought to room temperature before use. 50 μl of plasma diluted in two-fold using an 
assay diluent was added to each well and ran in duplicates. After a 2-hour incubation for 
CXCL13 and a 3-hour incubation for BAFF at room temperature, unbound soluble factors were 
discarded and the plates washed four times using 200 μl per well of the wash buffer. After the 
washes, plates were carefully inverted and blotted against a clean paper towel. The plates were 
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then incubated at room temperature with 200 μl per well with either human BAFF/BLyS 
conjugate or human BLC/BCA-1 conjugate for 1 and 2 hours respectively.  
 
The plates were then washed 4 times, blotted on a clean paper towel and incubated with 200 μl 
per well of the substrate solution for 30 minutes at room temperature. The substrate reaction 
was then stopped by adding 50 μl per well of the stop solution. The optical density of each well 
was determined within 10 minutes using a Synergy™ plate Reader (BioTek Instruments Inc) 
set at 450 nm. Cytokines concentrations were calculated against the standard curve for 
respective plates and expressed in pg/ml after interpolation on GraphPad Prism 7 (GraphPad 
Software, San Diego, CA, USA) using the sigmoidal four-parameter logistic. 
 
2.9: Multiplex assay for the detection of HIV-specific antibody isotypes 
against multiple clades 
 
To ease the detection of HIV-specific antibodies isotypes and subclasses against multiple 
antigens from different clades, a multiplex microsphere bead assay was used. Briefly, Luminex 
MagPlex carboxylated beads (Luminex Corporation) were coupled to HIV peptides through 
covalent NHS-ester linkages with 1–ethyl–3–(3-dimethylaminopropyl) carbodiimide 
hydrochloride and N-hydroxysulfosuccinimide (Thermo Fisher Scientific) following the 
manufacturer’s recommendations.   
 
HIV antigen-coupled beads (45 µl of a 20 microspheres / µl solution in 0.05% Tween and 
0.1% bovine serum albumin (BSA) in PBS) were added to each well of a 384-well plate 
(Greinier). Plasma at 1:100 (IgG2, IgG3, IgG4 and IgM), and 1:1000 (Total IgG, IgG1) diluted 
in PBS were added to beads and incubated at 37 °C for 2 hours on a shaker. The coupled beads 
were then washed three times with, 200 µl of PBS containing 0.05% Tween and 0.1% BSA.  
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Consequently, individual isotypes and subclass detection reagents (Total IgM, Total IgG, IgG1, 
IgG2, IgG3, IgG4) conjugated to phycoerythrin (Southern Biotech) were added to the plates and 
incubated at room temperature for 2 hours on a shaker. The coupled beads were then washed 3 
times with 200 µl PBS containing 0.05% Tween and 0.1% BSA and resuspended in 25 µl QSol 
Buffer (IntelliCyt) and read on an IQue Screener Plus (IntelliCyt). Each plasma sample was 
tested in duplicate and median fluorescence intensities (MFIs) of PE-conjugated detection 
agents used as the final readout. A pooled HIV hyperimmune plasma sample was used as a 
positive control while PBS was used as a negative control. All analyses were done on Microsoft 
Excel and GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). 
 
The HIV antigens used were: MN gp120 Clade B, BG505 SOSIP Clade A, JRFL gp140 Clade 
B, 92RW020 gp140 Clade A, IAVI22 gp120 Clade A, TV-1 gp140 Clade C, 94UG gp120 
Clade A and Q461 gp120 Clade A. The flu and tetanus antigens were used as positive controls. 
 
2.10: Fc-mediated functional assays 
 
2.10.1: Coupling of fluosphere NeutrAvidin beads to biotinylated gp120 antigen  
 
 
The Invitrogen, fluosphere NeutrAvidin (Ref 8775) was used for antibody-dependent cellular 
phagocytosis (ADCP) and antibody-dependent neutrophil phagocytosis (ADNP), while 
Invitrogen fluosphere NeutrAvidin (Ref 8776) was used for antibody-dependent natural killer 
degranulation (ADNK) and antibody-dependent complement deposition (ADCD). 
 
In order to coat beads, the 94UG103 (Clade A) antigen, a kind donation from Jardine’s 
laboratory at the Harvard Medical School (Massachusetts, USA), was used to coat 1.0 um 
fluorescent Neutravidin beads (Liofe Technology) mentioned above, overnight at 4°C. Briefly, 
beads and biotinylated antigen were mixed in a ratio of 1:1 before the overnight incubation at 
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4°C. After the incubation, 500 ul of 0.1% BSA in PBS was used to wash off unbound beads by 
centrifuging at 13000 revolutions per minute (rpm) for 2 minutes. Carefully, without disturbing 
the pellet, the supernatant was aspirated, and the step repeated twice. A final spin without 
adding any 0.1% BSA in PBS was then done in order to get rid of any remaining supernatant. 
Finally, 0.1% BSA in PBS was used to resuspend the pellet. 1000 ul of 0.1% BSA in PBS was 
used to resuspend 10 ul of beads and 10ug of biotinylated antigen and the coupled antigen 
stored at 4°C, until use. The coupled beads were always prepared a day before the experiment 
and any remains were discarded after use to provide consistency in the assays. 
 
2.10.2: Antibody-dependent cellular phagocytosis (ADCP) 
 
 
All plasma samples were diluted 1:100 using RPMI complete media (RPMI + 10% new-born 
bovine serum + L-glutamine + penicillin Streptomycin + HEPES + β-mercaptoethanol).  While 
using a THP-1 monocytic cell line (ATCC® TIB-202™), ADCP was performed as previously 
reported [163]. Briefly, the 94UG103 (Clade A) protein was used to coat 1.0 um fluorescent 
NeutrAvidin beads (Liofe Technology) overnight at 4°C as described above. The coupled beads 
were then incubated with plasma samples, each in duplicate, for 2 hours at 37°C in U-bottomed 
plates. After the incubation, plates were washed using 100 ul of RPMI complete media per well 
and spinning at 550g for 10 minutes. The supernatant was then discarded and 200 ul of THP-1 
cells (50,000 per well) were added to each well. Plates were then incubated overnight at 37°C 
to allow phagocytosis of opsonized Neutravidin beads. THP-1 cells were then fixed using 200 
ul per well of 4% paraformaldehyde by incubation at room temperature for 15 minutes. After 
the incubation, the cells were pelleted by centrifuging at 500g for 5 minutes and the supernatant 
discarded. After the centrifugation, 100 ul of PBS was added per well to resuspend the cells. 
The ability of antibodies in plasma to mediate monocytic phagocytosis was then assessed by 
flow cytometry on a BD LSR II flow cytometer (BD Biosciences) equipped with a high-
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throughput sampler system at a standard flow rate of 2 ul per second and a mixing volume of 
40 ul.  
 
2.10.3: Antibody-dependent complement deposition (ADCD) 
 
Antibody-dependent complement deposition was assessed by measuring the amount of 
complement component C3b deposited on 94UG103 (Clade A) antigen coupled with 
fluorescent Neutravidin beads (Liofe Technology) after incubation with plasma samples for 2 
hours at 37°C. Briefly, plasma samples, in duplicates, diluted in 5% BSA in PBS at 1:50 and 
were incubated for 2 hours at 37°C with 94UG103 (Clade A) coupled antigen. While the 
incubation was ongoing, cold distilled water was used to reconstitute the low tox guinea pig 
complement (Cedarlane). An aliquot of complement (24 ul) was also heat inactivated at 56°c 
for 30 minutes.  Both the heat inactivated and active complement were centrifuged at 13000 
rpm, at 4°C for 5 minutes to remove debris. Once the plasma and coupled antigen incubation 
was done, 150 ul of PBS was added to each well on the plate and pelleted at 1000g for 5 
minutes. The supernatant was then discarded before adding 196 ul of veronal buffer (Sigma) 
and 4 ul of the prepared complement to each well. Plates were then incubated for 20 minutes 
at 37°C.  
 
During the incubation, goat anti-guinea pig C3b FITC (MP Biomed) was thawed and 
centrifuged at 3500g for 5 minutes to remove debris. This was then diluted at 1:100 in 5% BSA 
+ PBS + 15mM EDTA and 50 ul of this was added to each well after the 20 minutes incubation. 
The plates were then incubated for a further 15 minutes in the dark, at room temperature, 
followed by washing by addition of 150 ul of PBS to each well and spinning at 1000g for 3 
minutes. The supernatant was then flicked, and the beads were resuspended in 100 ul/well of 
PBS. Complement deposition was then assessed by flow cytometry on a BD LSR II flow 
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cytometer (BD Biosciences) equipped with high-throughput sampler system at a standard flow 
rate of 2 ul per second and a mixing volume of 40 ul.  
 
2.10.4: Antibody-dependent neutrophil phagocytosis (ADNP) 
 
Neutrophil cells were isolated from an HIV-naïve donor’s blood. Briefly, fresh blood was 
mixed with Ammonium-Chloride-Potassium (ACK) lysis buffer (Thermo Fisher Scientific) in 
a ratio of 1:10 and incubated for 5 minutes at room temperature to lyse the red blood cells. 
Cells were then were spun down at 500g for 10 minutes, the supernatant discarded, and cells 
then resuspended at 2.5x105 cells/ml using RPMI complete media and kept at 37°C until use.  
 
In order to determine antibody-mediated neutrophil phagocytosis (ADNP), coupled gp120 
antigen was incubated with plasma samples, diluted 1:100 in RPMI complete media for 2 hours 
at 37°C. After the incubation, plates were washed with 100 ul PBS per well and spun at 500g 
for 10 minutes. After discarding the supernatant, 50,000 neutrophils suspended in 200 ul of 
RPMI complete media were added per well and incubated for 1 hour at 37°C and plates then 
washed using PBS. To each well, 0.25 ul of the following antibodies were added: Alexa Fluor 
700 anti-human CD3 (BD Pharmingen), APC-CY7 anti-human CD14 (a marker for 
monocytes) (BD Pharmingen) and Pacific blue anti-human CD66b (a marker for neutrophils) 
(Biolegend).  
 
Additionally, 19.25 ul of PBS was added to each well and the plates incubated at room 
temperature for 15 minutes.  After the incubation, the cells were washed using 200 ul of PBS 
per well and washed at 500g for 5 minutes. After that, 100 ul of 4% paraformaldehyde per well 
was used to fix the cells by incubation at room temperature for 15 minutes. The cells were then 
pelleted at 500g for 5 minutes and the supernatant discarded. The cells were then resuspended 
in 100 ul/well of PBS and neutrophil phagocytosis assessed by flow cytometry on a BD LSR 
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II flow cytometer (BD Biosciences) equipped with a high-throughput sampler system at a 
standard flow rate of 2 ul per second and a mixing volume of 40 ul.  
 
2.10.5: Antibody-dependent natural killer degranulation (ADNK) 
 
In order to assess ADNK activity, natural killer cells were first isolated from a HIV-naïve 
donor’s blood using the RosetteSep™ Human NK Cell Enrichment Cocktail kit (STEMCELL 
Technologies) as per the manufacturer’s protocol. Briefly, using a serological pipette, 
RosetteSep buffer was added to the blood in a ratio of 1:40 in a sepmate conical tube. After 15 
minutes incubation at room temperature, 15 mls of histopaque 1077 (Sigma) was added to the 
RosetteSep treated blood and spun at 1200g for 10 minutes. The RosetteSep treated blood was 
then transferred to a new 50 ml conical tube and the cells spun down at 500g for 5 minutes. 
The supernatant was discarded, and natural killer cells resuspended in 25 ml of prewarmed 
RPMI complete media. The cells were then counted and resuspended in RPMI complete media 
supplemented with 0.001ug/ml IL-15 at 2.5x105 cells/ml and rested overnight. These purified 
natural killer cells were used in the set up below to assess antibody-dependent natural killer 
cell degranulation. 
  
To do this, ELISA plates were coated using 0.2ug/ml of gp120 antigen per well overnight. The 
following day, plates were washed 3 times using 200 ul of PBS per well. Plates were blocked 
using 200 ul/well of 5% BSA+PBS overnight at 4°C. The plates were then washed 3 times 
using 200 ul of PBS per well and 100ul of diluted plasma samples (1:100) added into each well 
and incubated at 37°C for 2 hours. After the incubation, plates were washed as described above 
and 200 ul of natural killer cells at a concentration of 2.5x105 cells/ml added to each well. 
Additionally, the following antibodies/reagents were added to each well: 2.5 ul of anti-human 
CD107α Pe-cy5 (a marker for degranulation) (Sigma), 0.4 ul of brefeldin A (Sigma) and 10 ul 
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of golgi stop (BD Biosciences). Plates were then incubated for 5 hours at 37°C. After the 
incubation, cells were transferred to a V bottom plate and 1 ul/well of the following antibodies 
added: Alexa Fluor 700 anti-human CD3 (BD Pharmingen), PE-Cy™7 Mouse Anti-Human 
CD56 (a marker for NK cells) (BD Biosciences) and APC-Cy™7 Mouse Anti-Human CD16  
(a marker for NK cells)  (BD Biosciences). The plates were then incubated for 15 minutes at 
room temperature. 
 
 After the incubation, cells were pelleted through centrifuging at 500g for 5 minutes. The 
supernatant was discarded and 50 ul of Perm A (Life technologies) added to each well and the 
plates incubated for 15 minutes at room temperature. The plates were then washed with 150ul 
of PBS and centrifuged at 500g for 5 minutes to pellet the cells. Following the centrifugation, 
the following antibodies/reagents were added to each well: 1 ul of APC Mouse Anti-Human 
IFN-g (BD Biosciences), 1 ul of PE-Cy™7 Mouse Anti-Human MIP-1α  (Sigma) and 48 ul of 
Perm B (Life technologies). The plates were then incubated for 15 minutes at room 
temperature. Following the incubation, cells were pelleted by centrifuging at 500g for 5 
minutes. Thereafter, to each well, 100 ul of PBS was added to resuspend the cells. Cells were 
then acquired using a BD LSR II flow cytometer (BD Biosciences) equipped with a high-
throughput sampler system at a standard flow rate of 2 ul per second and a mixing volume of 
40 ul. Figure 2.2 presents a summary of the methodology used in the 4 Fc-mediated assays and 
their readouts on analysis. 
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Figure 2.2: A summary of the methods and readouts used to determine the activity of ADCD, 
ADCP, ADNP and ADNK. Fluorescent beads were coupled to gp120 antigen and added to 
either plasma, monoclonal antibodies or media and incubated, after which, either guinea pig 
complement, THP-1 cells, PBMCs or purified NK cells was added and incubated. Scores were 
determined as highlighted above. 
 
2.11: Neutralisation assay 
 
Briefly, pseudoviruses were generated via co-transfection of 293T cells (NIH AIDS Research) 
with different clades of Envelope-expressing plasmid and an Envelope-deficient genomic 
backbone plasmid (pSG3ΔEnv) (NIH AIDS Reagent Program) in Dulbecco's Modified Eagle's 
Medium (Gibco BRL Life Technologies) as described previously [164]. Before producing 
pseudoviruses, the 293T cells were spun at 1200 rpm for 10 minutes and resuspended in 50 
mls of DMEM containing 10% FBS PSG NaPyr media. The cells were then counted. For the 
transfection, 1600 ul of OptiMEM (Thermo Fisher), 40 ug of psG3 vector, 20 ug of the 
Envelope plasmid and 100 ul of Fugene (Promega) were added to a culture dish. The Envelope 
(Env) plasmid used were: 92BR020 (Clade B), 92TH021 (Clade AE), 93IN905 (clade C), 
94UG103 (Clade A), IAVIC22 (Clade C) and JRCSF (Clade B) [165]. Murine retrovirus 
Envelope (MLV) and MN (B tier-1) Envelope were used as specificity and positive control, 
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respectively. The culture dishes were then incubated for 72 hours at 37°C. Following the 
incubation, the supernatant containing the pseudoviruses was collected using a pipette and 
stored at 37°C until use. The Fifty-percent tissue culture infective dose (TCID50) was used to 
determine the pseudoviruses’ titres. This dilution is used to determine the amount of 
pseudovirus required to kill 50% of the target cell [166]. 
 
The neutralising activity was determined as previously described [110]. Briefly, each 
pseudovirus was mixed with fourfold dilutions of plasma and monoclonal control antibodies 
starting at a dilution of 1:25. After a 1 hour incubation at 37°C, the antibody-virus mixture was 
added to TZM-bl indicator cell line (NIH AIDS Research) that enables analysis of HIV 
infectivity using luciferase as a reporter. Briefly, TZM-bl cells diluted at 0.1x106 cells/mL in 
Dulbecco's Modified Eagle's Medium (Gibco BRL Life Technologies) were seeded in 96 well 
sterile plates at 50 ul/well. Plates were then incubated overnight at 37°C. The following day, 
pseudoviruses were harvested, and 50,000 pseudoviruses mixed with fourfold dilutions of 15 
ul of plasma or monoclonal control antibodies per well, starting at a dilution of 1:25. This was 
then incubated at 37°C for 1 hour.  
 
Following the incubation, 25 ul/well of the pseudoviruses and antibody/plasma mix was added 
to TZM-bl cells and incubated overnight at 37°C. After the 24-hour incubation, 75 ul of 
Dulbecco's Modified Eagle's Medium (Gibco BRL Life Technologies) was added to each well 
and the plates were incubated for a further 48 hours at 37°C. Thereafter, the supernatant from 
each well was aspirated and 40 ul of 1X lysis buffer (Promega) added to each well. The plates 
were then incubated at room temperature for 20 minutes. A Phelios luminometer (ATTO) was 
used to distribute 30 ul per well of the substrate (Promega) to each well, before reading the 




(Pseudovirus titres in wells without plasma - Pseudovirus titres in wells with plasma) X 100 
Pseudovirus titres in wells without plasma 
 
The plasma breadth was accounted for by the number of pseudoviruses neutralised, while the 
potency was determined by the concentration of plasma required to neutralise the 
pseudoviruses. Presence of neutralising ability was defined as 50% inhibition of TZMbl cell 
line infection by an HIV pseudovirus. Using Microsoft Excel (Microsoft) and GraphPad Prism 
(GraphPad Software, San Diego, CA, USA), the infective dose (ID50) was calculated as the 
reciprocal dilution at which 50% of the virus was inhibited using the nonlinear regression- 
inhibitor versus response (3 parameters) analysis. 
 
2.12: Data storage  
 
All the data were stored in password protected computers, external hard disks and backed up at the 
KEMRI Wellcome Trust Research Programme’s server. 
 
2.13: Statistical analysis  
 
The data were analysed using RStudio 1.0.143 (PBC, Boston, MA), Microsoft Excel 








Chapter 3    Phenotypes of general and HIV-specific 








































3.1 The biology and responses of B and T cells  
 
The primary effector function of B cells is antibody production. However, B cells can perform 
other functions, including antigen presentation and cytokine production [167]. For instance, 
regulatory B cells (Bregs), a B cell subset that inhibits autoimmune, inflammatory and 
transplantation reactions, secrete high concentrations of interleukin 10 (IL-10) [168, 169].  
 
3.1.1: B cell development in the bone marrow 
 
The bone marrow is the primary site of B cell development before B cells traffic to the 
peripheral blood for further differentiation. Specifically, B cells differentiate from pluripotent 
hematopoietic stem cells (pHSCs) during embryonic development [170]. In foetal life, these 
pHSCs migrate to the liver for further development before finally trafficking to the bone 
marrow, where they undergo continuous development to immature B cells. In the bone marrow, 
B cells undergo several molecular processes that rearrange the heavy and light chains of their 
immunoglobulin (Ig) genes via the variable (V), diversity (D) and joining (J)  (V-D-J) and (V-
J) recombination processes, respectively [171]. This process is heavily dependent on 
interleukin-7 (IL-7), from stromal cells [172].  
 
Two internal checkpoints confirm, first, the fitness of the IgH chain pairing with an IgL chain 
resulting in the formation of the pre-B cell receptor and the autoreactivity of the IgH chain of 
the pre-B cell receptor (BCR) leading to the formation of a BCR. Secondly, the BCR is then 
interrogated for autoreactivity by presenting it to different autoantigens leading to the 
elimination of B cells with high-affinity autoreactive BCRs. The B cells that exhibit no affinity 
to self-antigens exit the bone marrow, expressing a unique [173] and functional BCR and IgM 
or IgD [170]. Complete B cell maturation occurs in the spleen with resident B-2 type cells 
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remaining in the spleen while naïve B cells expressing CD19, CD20, IgM and IgD exit the 
spleen [170].   
 
3.1.2: B cell differentiation in secondary lymphoid organs 
 
 
Upon antigen encounter by a naïve B cell, its BCR internalizes the antigen and delivers it 
intracellularly to endosomal compartments [174] where antigens are degraded into peptides 
and loaded onto major histocompatibility complex (MHC) class II molecules and displayed on 
the surface of the B cell.  
 
Other surface markers such as CD27, CD70, CD71, CD80, CD86 and CD38 are expressed 
[175-177]. Other cytokine receptors include CD40, CD80, IL21-r, IL6-R, IL4-r, IL10-r, 
interferon (IFN) -α, β, γ receptors, inducible T cell co-stimulator (ICOS) ligand and 
programmed cell death (PD) -1-ligand, which may play a role in modulating immune 
responses. For instance, CD40 is a membrane-bound receptor belonging to the tumour necrosis 
factor receptor superfamily that interacts with CD40 ligand on activated helper CD4+ T cells 
[178], leading to the formation of germinal centres (GCs). Similarly, IL-21 and its receptor 
(IL-21r on B cells) are essential in enhancing the proliferation and differentiation of B cells, 
leading to quality antibody production [174].  
 
In human immunodeficiency virus (HIV) infection, IL-21 has been associated with HIV 
viremia control and better disease outcome [92, 179, 180]. Other cytokines such as interferon-
gamma (IFN-γ), IL-4 and IL-6 modulate B cell proliferation and isotype class switching [181-
184] while IL-10 functions in regulating B cell responses [168, 169]. Interferon alfa (IFN- α) 
and interferon beta (IFN-β) regulates B cell development and increased B cell receptor (BCR) 
sensitivity [185, 186].  
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Toll-like receptors (TLRs) are germline coded receptors that recognise conserved structural 
patterns [187] and initiate and modulate adaptive immune responses [188-190]. In human B 
cells, up to eight TLRs are expressed [187, 191, 192] with TLR1, TLR2, TLR5, TLR6 and 
TLR10 expressed on the B cell membrane, while TLR3, TLR7 and TLR9 are located in 
endosomes [193]. The expression of TLR1, TLR7 and TLR9 is, however lower on naïve B 
cells, while memory B cells subsets express high levels of TLR6, TLR7, TLR9 and TLR10 
[187].  
 
In HIV infection, there is a disruption in the B cell compartment that leads to additional B cell 
subsets that are not normally present in peripheral circulation (Figure 3.1). Such subsets include 
immature transitional B cells, activated mature B cells, exhausted tissue-like memory (TLM) 
B cells and short-lived plasmablasts. Expansion of these subsets during HIV infection affects 












Figure 3:1: HIV-induced alterations in the B cell compartment. In principle, immature B cells 
expressing CD10++ CD19+ CD20+ exit the bone marrow into the periphery circulation where they 
express CD10- CD19+ CD2Ihi CD27-, as naïve mature B cells. However, in HIV infection, upon exiting 
the bone marrow as immature B cells, they may either express CD10++ CD19+ CD2Ihi CD27- or 
CD10++ CD19+ CD2Ilow CD27-, subsets referred to as immature transitional B cells (panel a). Chronic 
HIV is associated with the expansion of activated mature B cells that have downregulated the expression 
of CD21 and express CD27, short-lived Ki-67+ plasmablasts that have downregulated their expression 
of CD20 and CD21 and express high levels of CD27, and tissue-like memory B cells that have 
downregulated their expression of CD21 and do not express CD27 (panel b). Frequencies of resting 
memory B cell that express CD2Ihi CD27+ are decreased in HIV infection (panel c). Adapted from 
[119]. 
 
3.1.3: T cell development in the bone marrow and thymus 
 
 
Like B cells, T cells arise from a common lymphoid hematopoietic stem cell but exit the bone 
marrow to the thymus for maturation [194]. T cell maturation involves T cell receptor (TCR) 
gene rearrangement and thymocyte selection that leads to the development of a mature T cell. 
Like the immunoglobulin heavy and light chains, TCR α and β chains, each consist of a variable 
amino-terminal region and a constant region [195]. Even though the TCR gene segments 
rearrange in the thymus, the process is similar to the gene rearrangement in the BCR. T cell 
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receptor gene rearrangement involves a Vα gene segment rearranging to a Jα gene segment to 
create a functional V-region exon in the α chain (Figure 3.2).  
 
 
Figure 3:2: The TCR α- and β-chain gene rearrangement and expression. The TCR α- and β-chain genes 
comprise of discrete germline DNA segments that are joined by somatic recombination during the 
development of a T cell, whereby, functional α- and β-chain genes segments are generated in the same 
way that immunoglobulin genes are created. The α chain (upper row of the figure), is composed of a 
Vα gene segment that rearranges with a Jα gene segment to create a functional V-region exon. The 
functional VJα exon undergoes transcription and splicing and combines with a Cα gene segment and 
hence generating an mRNA that is translated to yield the TCR α-chain protein. Likewise, the β chain 
(upper row of the figure), which is encoded in three gene segments, Vβ, Dβ, and Jβ undergoes 
rearrangement to generate a functional VDJβ V-region exon that is transcribed and spliced to join to 
Cβ, resulting into mRNA that is further translated to yield the TCR β chain. The α and β chains pair 




During T cell development, thymocytes migrate in the thymic microenvironments, where they 
come in contact with pMHC on distinct thymic antigen-presenting cells. This contact is critical 
for shaping the TCR for antigen recognition, the TCR thymic selection process, and the 
expression of surface molecules such as CD4 and CD8 [196, 197]. The thymic selection 
process solely relies on TCR affinity, whereby only thymocytes bearing TCR of intermediate 
affinity to pMHC are selected and differentiate into CD4+ and CD8+ mature T-lymphocytes 
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[197, 198]. Mature CD4+ T cells exit the thymus for secondary lymphoid organs where they 
are tasked in recognizing pMHC II molecules [199]. 
 
3.1.4: T cell differentiation in the secondary lymphoid organs 
 
 
Upon interaction of TCR (CD4+) with a pMHC II, CD3 activation is required to induce 
downstream signalling pathways, that will lead to cellular proliferation and differentiation into 
specific effector cells [200].  Additionally, the cytokine milieu of the microenvironment, the 
antigen concentration and other costimulatory molecules influence the lineage a CD4+ T cell 
will differentiate into [200, 201]. 
 
Of importance to this study is the T follicular helper (Tfh) cells, often described by the 
expression of CXCR5+ CD4+ and are known to provide help to B cells. The downstream 
differentiation of CD4+ T cells to Tfh cells relies on IL-6 and IL-21 cytokines [202, 203]. 
Upregulation of the transcription factor B cell Lymphoma 6 (BCL6) favours Tfh 
differentiation [75] and has been shown to inhibit the differentiation of other lineages by 
inducing Tfh related genes in CD4+ T cells and is thus central in the programming of Tfh cell 
differentiation [82]. Other transcriptional factors such as the signal transducer and activator 
of transcription 3 (STAT3) and c-Maf have been shown to play a role in Tfh differentiation 
[204, 205]. In contrast, the signal transducer and activator of transcription 5 (STAT5) were 
shown to be a negative regulator of Tfh differentiation [206]. Interferon regulatory factor 4 
(IRF4) is necessary for the secretion of IL-21, an essential cytokine for offering B cell help 
and differentiation of Tfh cells [207, 208]. Also, ICOS enhancement of Tfh differentiation 
has been reported [209]. The peptide-MHC (pMHC)-II complexes presented by B cells can 
be recognised by Tfh cells that had earlier been primed by dendritic cells recognizing a 
 59 
similar antigen. This cognate interaction leads to the provision of Tfh help to B cells and 
consequently leading to the generation of antibodies. 
 
3.1.5: The germinal centre reaction  
 
Germinal centres are highly specialized, localized anatomical sites in lymphoid organs, which 
develop in B cell follicles in response to antigenic stimulation. T-follicular helper cells traffic 
to the T–B border and provide the B cell help necessary for B cell differentiation into memory 
B cells and long-lived plasma cells.  
 
Follicular dendritic cells (FDC), which are resident within the GCs, aid with the selection of 
high-affinity B cells by continuously presenting antigen on their dendrites [210]. The GCs have 
two zones; the dark zone where the B cells undergo several rounds of proliferation and somatic 
hypermutation (SHM) in the variable region of their BCR [105] and a light zone where B cells 
capture more antigen from the follicular dendritic cells and present them on MHC class II 
molecules to Tfh cells for affinity maturation and class switching [210] (Figure 3.3).  
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Figure 3:3: The GC reaction. The GC is divided into anatomical compartments, the dark and light zones. 
After the B cells present an antigen to a Tfh cell, the cells enter the dark zone of the GC where B cells 
undergo somatic hypermutation and may undergo one or more rounds of proliferation and somatic 
hypermutations. The B cells then migrate to the light zone where they are exposed to immune 
complexed antigens on dendritic cells for affinity maturation selection. B cells with low affinity undergo 
apoptosis while ones with higher affinity receive survival signals and compete for limited Tfh help. 
These B cells can either re-enter the dark zone and undergo further proliferation and somatic 
hypermutation or can exit the GC as plasma cells or memory B cells. Adapted from [211]. FDC; 






3.1.5.1: Cognate interactions within the germinal centre 
  
The cognate interaction between B and Tfh cells is dependent on the cytokines and 
costimulatory molecules present. For instance, CXCL13 [chemokine (C-X-C motif) ligand 
13]–CXCR5 [chemokine (C-X-C motif) receptor 5] chemokine axis is vital in organizing B 
cell follicles and GCs [212, 213] and is responsible for the migration of CXCR5+ B and Tfh 
cells to the B cell follicle. The cytokine IL-21 favours the selection of high-affinity B cell 
clones while IL-4 enhances the high expression of CD40 ligand and directs isotype class-switch 













Figure 3:4: The Tfh, dendritic and B cell interaction in the GCs. (1) Dendritic cells (DC) present an 
antigen to a naïve CD4+ T cell through MHC II, leading to the differentiation of the naïve human CD4+ 
T cells to the Tfh cell phenotype, a process mediated by IL-12, IL-6, and TGF-β signalling. IL-6 and 
IL-12 phosphorylate the transcription factors STAT3 and Activin A favour the production of IL-21 and 
are critical in the differentiation of Tfh cells. (2) The activated Tfh cell interacts cognately with the B 
cell presenting the same antigen via MHC II. The B cell contributes to the activation of the Tfh cell via 
the secretion of IL-6 and IL-10 cytokines. (3) Activated Tfh cells produce IL-21 and IL-4 cytokines 
that support B cell differentiation. In the dark zone of GC, IL-21 favours the selection of high-affinity 
B cell clones while in the light zone, IL-4 enhances isotype class switching and somatic hypermutations. 
STAT3; signal transducer and activator of transcription 3; IL; interleukin, CTLA-4; cluster of 
differentiation 154, Blimp-1; B cell lymphocyte-induced maturation protein-1, TGF; transforming 




Since HIV perturbs both the Tfh and B cell compartments, I sought to characterize in peripheral 
blood, general and HIV-specific B and Tfh cell phenotypes during early HIV infection (3 
months post infection). HIV-specific B and Tfh-cell subsets were detected using a probe 









3.3.1: Demographics of the study participants 
 
Of the 98 individuals enrolled in Protocol C at the Kilifi site, 53 individuals met the inclusion 
criteria for this study, which was the availability of a PBMC sample at 3 months post-HIV 
infection (PI) and a plasma sample at 3 months PI (Time point 1), at 12 months PI (Time point 
2) and at 48 months PI (Time point 3). Also, the last HIV pre-infection plasma sample, 
collected approximately 3 months before HIV infection, was available for each study 
participant. The median days before HIV infection was 91 (interquartile ranges (IQR), 72-118). 
As samples were not collected on the exact dates for the selected time points, a range in days 
before and after these time points was considered. The mean age of participants at the time of 
HIV infection was 24.94 [IQR 19.2-39] years. Out of the 53 recruited individuals, 48 had no 
more than secondary school education, and 42 belonged to the risk group of MSMs. Thirty-
nine of the participants were infected with HIV subtype A, 6 with subtype C, 4 with subtype D 
and another 4 with the recombinant subtype AD.  
 
Participants’ clinical data, including CD4+ T cell counts and HIV viral load measurements 
were collected during the quarterly clinic visits and were available for analysis in the current 
study (Appendix 1 and 2). Table 3.1 summarises the clinical characteristics of the study 
population across the three time points. There was higher viremia during the first time point (3 
months PI), probably indicating that the viral set point had not yet been attained. However, 
there were no significant differences in the median CD4+ T cell counts across the three-time 
 64 
points, (Kruskal-Wallis test p=0.207) nor viral load measurements (Kruskal-Wallis test 
p=0.167). 
 
Table 3.1: The clinical characteristics of study participants across the three time points, n=53. 
 3 months PI 12 months PI 48 months PI Kruskal-
Wallis test  
(p-value) 
































Data shown in cells are medians (IQR). Data were collected at clinic visits at approximately 3 months 
PI (Time point 1), approximately at 12 months PI (Time point 2) and approximately at 48 months PI 
(Time point 3). There was no significant difference in HIV viral load measurements across the time 
points. The median CD4+ T cell counts were also similar across the three time points. p<0.05 was 
considered statistically significant. PI – post HIV infection. Test, Kruskal- Wallis test.  
 
 
3.3.2: Gating strategy for the characterization of total and HIV-specific B cell 
subsets during early HIV infection 
 
Mature B cells were defined by the expression of CD10- CD19+, class switched B cells by 
CD10- CD19+ CD20+ IgG+, resting memory (RM) B cells by CD10- CD19+ CD21+ CD27+, 
activated memory (AM) B cells by CD10- CD19+ CD21- CD27+, naïve B cells by CD10- 
CD19+ CD21+ CD27- and tissue-like memory (TLM) B cells by CD10- CD19+ CD21- 
CD27+. HIV-specific B cells were defined by gating using the gp120 probe. To reduce cross-
reactivity, two fluorochromes attached to the similar antigen probe were used and the double-
positive gp120 APC and gp120 PE that appear on the diagonal, gated from the switched (IgG+) 




Figure 3:5: Gating strategy used to determine total and HIV-specific B cell subsets. Plots are from representative HIV infected and uninfected individuals. 
Mature B cells (CD19+ CD10-), class switched B cells (CD19+ CD20+ CD10- IgG+), resting memory B cells (RM) (CD19+ CD10- CD21+ CD27+) activated 
memory B cells (AM) (CD19+ CD10- CD21- CD27+), naïve B cells (N) (CD19+ CD10- CD21+ CD27-) and tissue like memory (TLM) (CD19+ CD10- CD21- 





3.3.3: Frequencies of total B cell subsets are altered by HIV infection  
 
When the B cell subsets within the mature B cell compartment (CD10- CD19+) were 
considered, HIV-naïve individuals had a significantly higher proportion of naïve B cells 
(CD10- CD19+ CD21+ CD27-) 54.3% [IQR, 47.1%-65.85%] compared to the HIV infected 
46.6% [IQR, 29.45%-56.25%], Mann-Whitney test p =0.0051. There was a significant increase 
in activated memory B cells (CD19+ CD10- CD21- CD27+), in HIV infected individuals, 12% 
[IQR, 6.65-21] versus 4.1% [1.7-7.7] in HIV-naïve individuals, Mann-Whitney, test p<0.0001.  
 
Similarly, TLM B cells (CD19+ CD10- CD21- CD27-) were significantly expanded in HIV 
infected individuals, 20% [IQR, 12.15-29.55] compared to the negative controls 5.4% [IQR, 
3.45-6.67], Mann-Whitney test, p<0.0001 (Figure 3.6). However, the resting memory B cells 
(CD19+ CD10- CD21+ CD27+) population was significantly higher in HIV-naïve individuals 
36.8% [IQR, 26.6%-40.35%] versus 18% [IQR, 9.64-24.3] in HIV infected individuals, Mann-
Whitney test p<0.0001. These findings imply that HIV infection contributes to the overall 
depletion of RM B cells while driving the expansion of other B cell subsets such as TLM and 










Figure 3:6: Altered frequencies of B cell subsets in early HIV infection. Each triangle represents a study 
participant. Y-axis; % of B cell subsets in the mature B cell population (CD19+ CD10-), x-axis; HIV 
infection status. Panels A, B, C and D represents naïve, activated, TLM and resting memory B cell 
percentages respectively, in HIV infected and uninfected individuals. Tissue like memory; (TLM). The 
median and interquartile ranges (IQRs) are indicated. p<0.05 is considered statistically significant. 
Mann-Whitney test was used to determine the difference between the two group medians.  
 
3.3.4: Proportions of HIV-specific B cells 
 
When HIV-specific B cells were considered, a median proportion of 0.58% (IQR, 0.41%-0.9%) 
of HIV-specific B cells was observed in HIV infected individuals. These frequencies were 
significantly higher than the background signals in HIV-naïve individuals; median 0.12% 
(IQR, 0.02%-0.22%), Mann-Whitney test p<0.0001 (Figure 3.7). In 8 individuals, very low 
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Figure 3:7: Identification of HIV gp120-specific memory class-switched B cells in HIV infected 
individuals. Each triangle represents an individual; y-axis shows the frequencies (%) of HIV-specific B 
cells in the memory class-switched B cells CD19+ CD10- CD20+ IgG+, x-axis; represents HIV 
infection status, y-axis. The horizontal green dotted line represents median of the background signal as 
determined by the HIV-naïve individuals (blue triangles). The median and IQR are indicated. Mann-
Whitney test was used to determine the difference between the two group medians. 
 
3.3.5: Association between B cell subsets and clinical parameters 
 
Since HIV infection has been shown to drive various B cell defects [217, 218], I assessed for 
the correlations between the frequencies of various B cell subsets with CD4+ T cell counts and 
HIV viral load measurements; two measures often used to assess HIV disease progression. 
 
No association was found between B cell subsets determined at 3 months PI with CD4+ T cell 
counts at 3, 12- and 48-months PI. However, when B cell subsets determined at 3 months PI 
were associated with HIV viral load measurements at 3, 12- and 48-months PI, both TLM B 
cells and mature B cell subsets showed significant associations with HIV viral load 
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measurements at 48 months PI and this may suggest a role of HIV viremia in driving B cell 
defects. However, mature B cells negatively correlated with HIV viral load measurements at 3 
months PI and this may be an indication of an intact B cell compartment earlier in the infection, 
in individuals with lower viremia (Table 3.2).  
 
Table 3.2: Association of B cell subsets determined at 3 months post-HIV infection with 
markers of HIV disease progression over time. 
 CD4+ T cell counts Viral loads measurements 
3 mths PI 
Rho (p-value) 
12 mths PI 
Rho (p-value) 
48 mths PI 
Rho (p-value) 
3 mths PI 
Rho([p-
value) 
12 mths PI 
Rho (p-value) 
48 mths PI 
Rho (p-value) 























































































CD4+ T cell counts and viral load measured at 3, 12 and 48 months (mths) post infection were 
associated with B cell subsets determined early in the HIV infection (3 months PI). In each cell, the 
Spearman’s rho value and the associated p-value is shown. Bold blue indicates significant associations. 




3.3.6: Characterization of general T cell subsets in early HIV infection 
 
The following gating strategy was used to define general T cell subsets in peripheral circulation 
in early HIV infection (Figure 3.8). T helper cells were defined by expression of CD3+ CD4+, 
naïve T helper cells by CD3+ CD4+ CD45RA+, memory T helper cells by CD3+ CD4+ 
CD45RA-, memory blood Tfh cells by CD3+ CD4+ CD45RA- CXCR5+, memory blood Tfh 
cells expressing activation markers PD-1 and ICOS by CD3+ CD4+ CD45RA- CXCR5+ 
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ICOS+ PD1+, central memory T helper cells by CD3+ CD4+ CD45RA- CD27+ CCR7+ and 





Figure 3:8: Gating strategy used to determine general T cell subsets. Plots are from a representative HIV infected individual. T helper cells are defined by 
expression of CD3+ CD4+, naïve T helper cells by CD3+ CD4+ CD45RA+, memory T helper cells by CD3+ CD4+ CD45RA-, memory blood Tfh cells by 
CD3+ CD4+ CD45RA- CXCR5+, central memory T helper cells by CD3+ CD4+ CD45RA- CD27+ CCR7+ and effector memory T helper cells by CD3+ 





3.3.7: Frequencies of general T cell subsets are altered in HIV infection 
 
 
A significant depletion of CD4+ T cells and CD4+ effector memory T cells (CD27- CCR7- 
CD4+) and an expansion of CD4+ central memory T cells (CD27+ CCR7+ CD4+) in early 
HIV infection was observed (Table 3.3). The proportion of Tfh cells (CD45RA- CXCR5+ 
CD4+) was expanded in HIV infected individuals. Both the expansion and depletion of Tfh 
cells have been reported in HIV [86, 219]. A significant expansion in CD4+ cellular subsets 
expressing PD-1, which represents the activated cellular subsets, CD45RA- CXCR5+ PD-1+ 
CD4+ and CD45RA- PD-1+ CD4+ was observed in HIV infected individuals. 
 
Table 3.3: Key CD4+ T cells are significantly depleted in early HIV infection. 
 HIV infected 









(% of total CD3+ lymphocytes) 
41.6 (32.2-53.1) 50.4 (48.1-55.65) 0.004 
CD45RA+ CD4+ 41.88 (21.6-54) 46.38 (38-51.6) NS 
CD45RA- PD-1+ CD4+ 9.5 (4.7-19.8) 5.01 (3.1-9.9) 0.002 
CD27+ CCR7+ CD4+ 67.4 (58.7-74.8) 47.43 (34.3-66.7) 0.004 
CD27- CCR7- CD4+ 16.71 (9.04-35.5) 31.11 (16.5-56.8) 0.005 
CD45RA- CXCR5+ CD4+ 7.6 (5.7-10.6) 6.18 (4.1-8) NS 
CD45RA- CXCR5+ PD1+ CD4+ 1.87 (0.4-5.31) 0.72 (0.28-1.97) 0.021 
 
The frequencies of CD4+ T cell subsets determined early in the HIV infection (3 months PI) and 
compared between HIV infected and HIV-naïve individuals. Medians and with their associated IQRs 
and p-values are shown. NS; not significant. (Mann-Whitney test).
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3.3.8: Detection of HIV-specific Tfh cells in early HIV infection 
 
 
The gating strategy presented in Figure 3.9 below was used to define HIV-specific Tfh cells in 
early HIV infection. T helper cells were defined by the expression of CD3+ CD4+, memory 
blood Tfh cells by CD3+ CD4+ CD45RA- CXCR5+, and HIV-specific, Cytomegalovirus 
(CMV)-specific, and Staphylococcal enterotoxin B (SEB)-activated Tfh cells by CD3+ CD4+ 
CD45RA- CXCR5+ CD25+ OX40+ expression after respective stimulations as described in 





















Figure 3:9: Gating strategy used to determine antigen-specific Tfh subsets. Plots are from a representative HIV infected individual. T helper cells are defined 
by the expression of CD3+CD4+, memory blood Tfh cells by CD3+CD4+CD45RA-CXCR5+, and HIV-specific, CMV-specific and SEB-activated Tfh cells 
by CD3+CD4+CD45RA-CXCR5+CD25+OX40+ expression after respective stimulations.  
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The presence of HIV-specific Tfh cells was defined by the upregulation of CD25+ and OX40+ on 
memory CXCR5+ CD4+ T cells after an 18-hour stimulation with HIV envelop peptides, while 
SEB and CMV peptides were used to assess for non-specific cellular responses to another virus 
other than HIV, respectively.  
 
HIV infected individuals had an increased proportion of Tfh cells after stimulation with HIV 
peptides, 0.54% (IQR, 0.3-0.83) having subtracted the background signal in the HIV-naïve 
individuals (0.13%, IQR, 0.06-0.24), Mann-Whitney test p<0.0001. The median frequencies of 
CMV-specific memory Tfh cells in HIV-naïve and infected individuals were statistically similar, 
suggesting that one does not lose CMV-specific memory Tfh cells after exposure to HIV, [0.68% 
(IQR, 0.49-1.13) in HIV infected versus 0.9% (IQR, 0.5-1.7)] in HIV-naïve individuals. Similarly, 
in unstimulated conditions, no differences were observed in Tfh frequencies between HIV infected 
individuals and HIV-naïve individuals, 0.46% [IQR, 0.295-0.78] versus 0.35% [IQR, 0.22-0.78], 
respectively. Responses to SEB were also the similar, irrespective of an individual’s HIV status; 











Figure 3:10: Activated memory Tfh cells (CD3+ CD4+ CD45RA- CXCR5+ CD25+ OX40+) in HIV 
infected and HIV-naïve individuals. HIV-specific memory Tfh cells (A) were detected after stimulating 
PBMCs with an HIV Envelope peptide while the controls were; no stimulation (B), CMV peptide 
stimulation (C) and SEB stimulation (D). Each dot represents an individual; the y-axis shows the percentage 
frequency of activated Tfh cells while the x-axis represents the HIV infection status. The horizontal green 
dotted line in panel A represents the background signal as determined by the cellular frequencies in HIV-
naïve individuals (blue dots). The medians and IQR are indicated. (Mann-Whitney test.
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3.3.9: Association between T cell subsets and HIV clinical parameters  
 
Since HIV directly impacts on the CD4+ T cell population, correlations between the frequencies 
of various T cell subsets and markers of HIV disease progression represented by HIV viral load 
measurements and CD4+ T cell counts were determined. The CD4+ T cell subsets determined at 
3 months PI were associated with CD4+ T cell counts and viral load measurements at 3-,12- and 
48 months PI (Table 3.4). Only ICOS+ PD-1+ CXCR5+ CD4+ T cells negatively correlated with 
CD4+ T cell counts at 3 months PI and with HIV viral load measurements at 12 months, suggesting 
a role of HIV viremia in activating Tfh cells, while depleting CD4+ T cell counts.  
 
Table 3.4: Association of T cell subsets determined at 3 months PI with markers of HIV disease 
progression over time. 




12 mths PI 
Rho (p-
value) 
48 mths PI 
Rho (p-
value) 
3 mths PI 
Rho (p-
value) 
12 mths PI 
Rho (p-
value) 




































































































CD4+ T cell counts and viral load measured at 3,12 and 48 months (mths) post infection were associated 
with T cell subsets determined early in the HIV infection (month 3). In each cell, the Spearman’s rho value 
and the associated p-value are shown. Bold blue indicates significant associations. Test; Spearman’s non-




3.3.10: B and T cell interactions in early HIV disease  
 
Since B cells receive help from Tfh cells in the GCs, associations between various total and HIV-
specific B and T cell subsets populations were investigated (Table 3.5). Notably, CD4+ T cells 
positively correlated with some of the B cell subsets but not with class-switched memory B cells, 
HIV-specific B cells and TLM B cells. These positive associations with mature, naïve, AM and 
RM B cell subsets may suggest significant CD4+ T cell help to B cells.  
 
Effector memory CD4+ T cells (CD27- CCR7- CD4+) positively correlated with RM B cells and 
negatively with TLM B cells, probably due to direct and indirect effects of HIV infection on these 
cellular compartments [220]. Notably, a positive association between HIV-specific Tfh cells and 
class-switched memory B cells was observed implying that quality GCs activities may be critical 
for class-switching. This would enable antibodies to gain other Fc-mediated effector functions and 




























































































































































General and HIV-specific T and B cell subsets determined at 3 months PI were associated. In each cell, the 
Spearman’s rho value and the associated p-value are shown. Bold blue indicates significant associations. 





The integrity of the B and T cell compartments in HIV has been explored in-depth, in a bid of 
understanding how quality anti-HIV antibodies are generated. Despite many studies done in both 
macaques and human participant samples [86, 96, 99, 100, 111, 117, 126, 129, 221-223], we are 
still not certain how quality anti-HIV antibodies are generated. This study focused on 
understanding the early T and B cells interactions in HIV disease. T follicular helper cells are the 
CD4+ T cell subset that offers help to B cells in the B cell follicles [75], and the recent discovery 
of memory blood circulating Tfh cells [98] has enabled this study to characterize and evaluate the 
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interaction of these two subsets in HIV infection using PBMCs. Additionally, this study evaluated 
the association between the described early HIV-specific and general T and B cell subsets with 
downstream HIV-specific antibody levels and functions in chronic infection, as will be discussed 
later in chapters 4 and 5. 
 
In the current study and also consistent with existing literature [86], an expansion of memory Tfh 
cells despite the depletion of the general CD4+ T cell frequencies was observed. The expansion 
may probably be attributed to the constant antigenic stimulation in HIV infected individuals or the 
relative decrease in the frequencies of other circulating CD4 T subsets [220]. Depletion of CD4+ 
effector memory T cell compartment was also observed, and this is supported by reports where 
effector memory T cell subsets were shown to be more likely to undergo apoptosis due to direct 
and indirect viral effects [220]. Upregulation of PD-1 on CD4+ T cells was also observed in HIV 
infected individuals. The higher signalling of PD-1 on CD4+ T cells has been documented [224] 
and is attributed to the direct HIV viral effects that may lead to cell activation or exhaustion [86]. 
Indeed, it has been previously suggested that increased expression of PD-1 in HIV infected 
individuals may limit quality antibody generation in HIV infection. Cubas and colleagues showed 
that PD-1/PD-L1 interaction leads to reduced cellular proliferation and inadequate IL-21 secretion 
and that the blocking of PD-1 signalling enhanced HIV-specific antibody generation in vitro [86]. 
Higher PD-1 signalling may, in a way present one of the earliest Tfh-cells’ dysfunction, but is also 




Despite these alterations in CD4+ T cells, this study has provided evidence that HIV-specific Tfh 
cells exist and circulate, albeit at low frequencies. Perhaps, the low frequencies of HIV-specific 
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Tfh cells in blood may be due to their sequestration in lymphoid tissue B cell follicles during an 
active HIV infection as proposed elsewhere [225]. Their identification through the co-expression 
of T cell activation markers (CD25 and OX40) is more sensitive and specific, as previously 
illustrated [161, 162]. However, these HIV-specific Tfh cells did not negatively correlate with HIV 
viral loads or positively with CD4 counts, and this may be due to, at least in part, the low 
frequencies of HIV-specific Tfh cells that were detected. However, there were significant 
associations between HIV-specific CD45RA- CXCR5+ CD4+ T cells and ICOS+ PD-1+ CXCR5+ 
CD4+ T cells, and ICOS+ PD-1+ CXCR5+ CD4+ T cells and PD-1+ CXCR3- CXCR5+ CD4+ T 
cells, suggesting a coordinated GCs activity. The GCs activity has previously been reported to be 
mechanistically linked [134].  
 
Worth noting is that the frequency of CMV-specific memory Tfh cells in HIV-naïve and infected 
individuals were similar, suggesting that one does not lose CMV-specific memory Tfh cells after 
exposure to HIV. This may suggest that vaccinating HIV infected individuals against some 
diseases may still bear favourable vaccine efficacies. Activation due to SEB yielded similar 
cellular responses in both HIV infected and naïve individuals suggesting that CD4+ T cells respond 
similarly to a superantigen, regardless of HIV status, unlike in previous findings [226, 227]. 
However, despite the constant activation by HIV antigens in HIV infected individuals, there was 
no significant difference in the background immune activation between HIV infected and 
uninfected individuals, as determined by the unstimulated control. Perhaps a reflection of the still 
relatively stable immunological environment in the HIV infected individuals as this analysis were 
done 3 months post infection, prior to immunological deterioration. 
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Similar perturbations due to HIV infection were reported in the B cell compartment with an 
expansion of the TLM and activated memory B cell subsets being observed in HIV infected 
individuals, as has previously been reported [101]. Notably, TLM B cell subset had a positive 
correlation with HIV viral load measurements at 48 months PI, suggesting that high HIV viremia 
drives extensive immune activation and exhaustion that may lead to an expansion of the TLM 
subset over time [218]. Alternatively, TLM B cells may be involved in the spread of HIV to CD4+ 
T cells. B cells have been described to bind to HIV virions via the CD21 receptor that is expressed 
on mature B cells and later spread these virions to susceptible cells [21]. Notably, while it is 
generally agreed that HIV cannot productively infect and replicate in B cells, CD21 receptor 
interacts with HIV virions bound to complement proteins and hence facilitating HIV transmission 
from B cells to activated CXCR5+ CD4+ T cells [21, 228]. Since TLM B cells may either be 
CD10low/CD10- [119], there is a possibility of their involvement in HIV transmission to susceptible 
CD4+ T cells.  
 
HIV-specific memory B cells were detected at low frequencies in HIV infected individuals as has 
been previously observed, suggesting a depletion in the resting memory compartment as a result 
of HIV infection. Several studies have shown that HIV infected individuals have lower antibody 
levels against HIV-unrelated vaccines and pathogens due to the high HIV viremia and low CD4+ 
T cell counts [229-231]. In this study, cellular responses to CMV suggested that despite HIV 
infection, robust cellular responses against CMV were maintained, implying that revaccination 
against other pathogens would be beneficial. In the advent of test and treat in HIV infections as 
recommended by WHO [54], it would be important to explore the antibody responses of HIV-
unrelated vaccines in individuals on ART. This would create a clearer understanding of vaccine-
antibody responses to different pathogens in HIV infected individuals who are on ART.  
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Vaccination of HIV infected children who are on ART has been shown to maintain vaccine 
responses [232]. Similar to the HIV infected children on ART, it has been shown that the prior 
exposure to HIV in HIV-exposed uninfected infants did not affect serological responses in the first 
2 years of life [233]. 
 
To gain insights into the interaction between T cell and B cell subsets in HIV, the frequencies of 
both subsets were associated. The frequencies of CD4+ T cells were positively associated with 
mature B cells, naïve B cells and AM B cells. The association with AM B cells may imply the 
importance of CD4+ T cells help to B cells in the GCs. As suggested elsewhere, it is not clear if 
the high concentration of HIV antigens in the draining lymph nodes drives the activation of RM B 
cells [217]. However, since the present study reveals a negative association between CD4+ T cells 
and RM B cells, and ART has been shown to block changes in the B cell compartment [217], it is 
plausible that HIV viremia is a significant driver of the perturbations in the B cell compartment.  
 
Further analysis revealed that memory Tfh cells positively correlated with class-switched B cells. 
This association suggests that memory Tfh cells are critical for B cell class-switching in the GCs, 
and is consistent with the literature [105, 210]. Indeed, other general Tfh cell subsets in the 
peripheral circulation such as CXCR3+ CXCR5+ and PD-1+ CXCR3- CXCR5+ have been shown 
to offer better B cell help in T and B cell co-cultures [98, 234]. The CD27+ CCR7+ CD4+ T cells, 
which are memory T cells, were inversely associated with TLM B cells, probably due to the effect 
of HIV on the T and B cell compartments as earlier discussed. Since HIV viremia favours an 
increase of central memory CD4+ T cells [235], biologically, the HIV viremia would also deplete 
RM B cells.  
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Nevertheless, key associations reported here create a basic understanding of cellular biology in 
HIV disease, which is vital in understanding which cellular subsets may be correlates of quality 
antibodies in HIV. For instance, mature B cells and ICOS+ PD-1+ CXCR5+ CD4+ T cells 
negatively correlated with HIV viral load, suggesting that they may be key in controlling HIV or 
may represent markers of disease progression. Similar to these findings, the frequencies of memory 
B cells were reported to positively correlate with CD4+ T  cell counts and thus represent a marker 
of disease progression [229]. Thus, future studies should address approaches that favour the 
preservation of functional subsets, as that may be key in the effective control of HIV infection. 
Such an approach may either include the potential use of appropriate adjuvants that will favour the 
generation and maintenance of relevant subsets or the exclusion of proteins in potential 
immunogens that would trigger unforeseen and unfavourable immunological consequences that 
lead to perturbations in these functional subsets. 
 
This data suggests that the frequencies of HIV-specific T- and B cell subsets may describe HIV 
disease progression rates and that high HIV viremia may be required for stimulating and sustaining 
HIV-specific B cell responses. In summary, the results in this chapter showed that: 
• HIV infection depletes RM B cells and drives the expansion of TLM and AM B cells. 
• HIV-specific B cells circulate at low frequencies and this may be due to the direct and 
indirect effects on the B cell compartment by HIV infection. 
• HIV depletes CD4+ T cells and CD4+ effector memory T cells and expands CD4+ central 
memory T cells. 
• HIV-specific Tfh cells circulate at low frequencies in blood, perhaps as a result of the 




While these findings should be treated with caution due to the low frequencies of HIV-specific T 
and B cells detected, this study has described early HIV-specific T- and B cell subsets which may 
help to understand HIV-specific responses. Future larger studies could confirm these findings and 























Chapter 4 Plasma levels of CXCL13, BAFF and HIV-
specific antibody isotypes and subclasses in the course 








































4.1: Literature review 
 
It is widely accepted that the development of a successful anti-human immunodeficiency virus 
(HIV) vaccine will likely require the elicitation of antibodies against HIV, and more desirably, 
antibodies with potent neutralising abilities [110, 236-239]. However, Fc-mediated antibody 
functions may potentially play a role [240-244]. Apart from antibody functions (quality), antibody 
quantities may also be critical. For instance, anti-HIV antibody levels have been linked with 
quality Fab-mediated antibody responses in a large longitudinal Sub-Saharan HIV primary 
infection cohort [110]. Moreover, mice vaccinated with the immune complexes from HIV 
neutralisers displayed higher levels of overall antibody titres than those vaccinated with immune 
complexes from HIV non-neutralisers [245]. This may suggest an association between antibody 
quantities and qualities in HIV infection. Since all these critical immunological processes occur in 
the germinal centres (GCs), GCs activities may, therefore, determine the quality and quantity of 
antibody responses, with an increased GCs activity favouring both [246], since there is a 
mechanistic link between the Fc and Fab-mediated antibody responses [134].  
 
The chemokine CXCL13 and the B cell activating factor (BAFF) are critical in GCs formation. 
The chemokine CXCL13 is involved in organising and maintaining the B cell follicles in GCs that 
may lead to the generation of broadly neutralising antibodies (bnAbs), as reported in HIV infection 
[162]. Through its receptor CXCR5, CXCL13 is responsible for the migration of B and T-follicular 
helper cells (Tfh cells) to the B cell follicle [212, 247]. BAFF is also present in the lymph node 
and is key in B cell-related immune responses. BAFF plays a vital role in B cell homeostasis and 
has been shown to influence the survival and class switching of B cells in general [97, 248]. Also, 
BAFF has been shown to support the survival of autoreactive B cells that are capable of generating 
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cross-neutralising anti-HIV antibodies [249-251]. Despite both CXCL13 and BAFF cytokines 
acting locally in the lymph node tissues, both are readily quantifiable in plasma. CXCL13  has 
previously been associated with the level of GCs activity [96] and the development of anti-HIV 
antibodies with cross-reactive activities [101]. 
 
In addition to supporting T and B cell interaction that results into B cell differentiation, antibody 
production and affinity maturation, the GCs reactions also support class switching from 
immunoglobulin (Ig) M and IgD expression to IgG, IgE and IgA expression. Furthermore, 
depending on the cytokine environment in the GCs, IgG could class switch to any of the subclasses 
IgG1, IgG2, IgG3 or IgG4 [174] with interleukin (IL) -4, IL-5, interferon-gamma (IFN-γ) and 
transforming growth factor-beta (TGF-β) being the cytokines mainly involved in antibody class 
switching. Interleukin 4 induces switching to IgG1 and IgE while inhibiting switching to IgG3. The 
TGF-β similarly inhibits switching to IgG3 and favours switching to IgG2 and IgA. The cytokine 
IFN-γ cytokine induces switching to IgG3 and IgG2 while inhibiting switching to IgG1 and IgE. 
Interleukin-5 only favours switching to IgA and does not affect the other isotypes [174]. 
 
Antibody class switching confers new effector functions (Fc-mediated) to the antibody without 
changing its specificity. In HIV infection, anti-Env antibodies are predominantly IgG and IgG1 
[252, 253], with the latter associated with antibody-dependent cellular cytotoxicity (ADCC) of 
HIV-infected cells [254]. Despite anti-ENV IgG2 being detected throughout HIV infection [144, 
255], the levels are lower relative to other subclasses [252, 256, 257]. Anti-Env IgG3 is the second 
most predominant IgG subclass after IgG1 [258] and has been shown to have superior in-vitro 




Unlike the other subclasses, HIV-specific IgG4 is mostly detectable in chronic HIV infection [254, 
260], suggesting that chronic antigenic stimulation may be critical for their switching. Indeed, 
HIV-specific IgG4 responses have been reported in individuals in regions where there are constant 
multiple exposures to viral, bacterial, and parasitic antigens [261], further highlighting the role of 
chronic antigen stimulation of IgG4 predominance. Other subtypes such as IgA antibodies also 
play a crucial role in protection against HIV. For instance, HIV-specific IgA is protective against 
HIV infection [262]. HIV-specific neutralising IgA in HIV uninfected sex workers was associated 
with protection from HIV acquisition [263, 264]. Despite these data, it is not clear if HIV mucosal 
vaccination will be protective or not. However, these anti-HIV responses of multiple isotypes and 
subclasses have been reported to be similar in Env, Gag, and Pol proteins [265]. In disease, the 
different antibody subclasses and isotypes mediate varying effector functions with different 
efficacies as summarized below in Table 4.1.  
 
Table 4.1: The effector functions of different immunoglobulin isotypes and subclasses. 
Fab/Fc 
functionality 






- + +++ ++ ++ ++ - ++ 
Natural killer 
cell killing 
- - ++ - ++ -  - 
Mast cell 
sensitization 
- - + - + - +++ - 
Complement 
activation 
- +++ ++ + +++ - - + 
Neutralisation 
ability  
- + ++ ++ ++ ++ - ++ 
 
(+++) represents major effector function, (++) lesser effector function, and (+) minor effector function. 
(From Janeways Immunobiology [174]). 
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In this chapter, I determine the plasma quantities of HIV-specific total IgG, IgG1, IgG2, IgG3, IgG4, 
IgM, IgA1 and IgA2 and the plasma levels of the B cell cytokines, CXCL13 and BAFF. I further 
establish associations of the soluble factors CXCL13 and BAFF and resulting antibody levels with 




To determine HIV-specific antibody levels, isotypes and subclasses during HIV infection and the 
plasma levels of BAFF and CXCL13 cytokines, as a proxy of germinal centre activities, before 




4.3.1: HIV-specific antibody isotypes and subtypes levels 
 
 
HIV-specific antibody isotypes and subtypes levels were determined by an in-house enzyme-
linked immunosorbent assay (ELISA) and a Luminex isotype assay as described in Chapter 2, 
subsections 2.8 and 2.9.  
 
By ELISA, HIV-specific IgG, IgG1, IgG2, IgG3 and IgA were detectable at all time points assessed 
(3-, 12- and 48- months PI). HIV-specific IgG, IgG1 and IgA levels significantly increased as the 
disease progressed, p<0.0001, p<0.0001 and p=0.002 respectively. The levels of HIV-specific 
IgG2 and IgG3 increased up to 12 months PI, before slightly decreasing at 48 months PI. HIV-
specific IgM was only detected at 3 months PI. HIV-specific IgG4 levels were below the limit of 




Figure 4:1: The kinetics of HIV-specific antibody isotypes and subclasses levels after HIV infection as detected by ELISA. The median concentration 
for each sub-group and IQR value is shown. The x-axis represents time in months after HIV infection while the y-axis represents the arbitrary units 
of concentration of each sub-group. Test, Kruskal-Wallis. Ns; not significant.
p<0.0001  p<0.0001  
P=0.002  p=NS  
p=NS  
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In order to test a broader range of antigens, a multiplex microsphere bead assay was used. A similar 
pattern of HIV-specific antibody subclasses and isotypes levels was observed. Similar to the 
ELISA data, higher levels of IgG and IgG1 were observed. However, unlike the ELISA data, HIV-




Since a wide range of HIV antigens from clades A, B and C were used in the Luminex assay, the 
presence of cross-reactivity antibodies was determined. Cross-reactive antibodies were detected at 
different levels for each antigen tested. The 94UG, although a clade A protein, representing the 
clade prevalent in this region, consistently showed lower responses across all time points. The flu 
and tetanus antigens were used as controls based on prior exposure and vaccination respectively. 
As would be expected, high responses to tetanus antigens were observed while those to the flu 
antigens were moderate across all the time points. High levels of tetanus specific IgM levels were 
observed throughout the follow up period (Appendix 7). Since IgM is the first antibody to be 
generated in the humoral immune response [266], we would have expected that these levels wane 
during follow up. It is not exactly clear why these levels were maintained. It is however possible 
that by stander activation in these highly immune activated individuals may be contributing to 
these levels as reported elsewhere [267]. It is also possible that some of the participants could have 
had booster doses or natural exposure in adulthood. While only data of IgG and IgG1 antibodies 
levels to all antigens are presented in Figure 4.2, data on all antibody isotypes and subclasses to 





                          3 months PI                                      12 months PI                                    48 months PI 
 
Figure 4:2: The dynamics of HIV-specific IgG and IgG1 levels after HIV infection as detected by the Luminex assay. 
Eight HIV antigens spanning across clades A, B and C were used to detect HIV-specific responses while flu and 
tetanus antigens were used as controls. The median concentration for each sub-group and IQR values are shown. The 
y-axis represents mean fluorescence intensity (MFI) values; the x-axis represents different antigens used. PI represents 
post-HIV infection. Test, Kruskal-Wallis. 
 
The different HIV antigens used showed similar patterns of antibody levels across time, and the 
data from the BG505 clade A antigen, representative of the prevailing clade in the region, was 
therefore used for downstream analysis and is presented in Figure 4.3. BG505 SOSIP Clade A 
gp120 specific antibody levels increased over time as HIV disease progressed (Figure 4.3). Higher 
levels of HIV-specific IgG1 and IgG3 were observed compared to the levels IgG2 and IgG4 
responses, which remained low. Interestingly, while all isotypes and subclasses significantly 
increased over time, there was no significant increase in IgG3 (p=0.189). In summary, HIV 






Figure 4:3: The dynamics of BG505 clade A HIV-specific antibody isotypes and subclasses levels after HIV infection 
as detected by the Luminex assay. The median concentration for each antibody isotypes and subclasses and IQR values 
are shown. The y-axis represents mean fluorescence intensity (MFI) values; the x-axis represents the different time 
points of sampling, 3-, 12- and 48-months PI. Test, Kruskal-Wallis. 
 
4.3.2: The kinetics of CXCL13 and BAFF before and during HIV infection 
 
To check if intrinsic GCs activity influences HIV disease outcomes, BAFF and CXCL13 levels 
were determined before HIV infection as a proxy for GCs activity, and longitudinally after HIV 
infection to check for the effect on the B cell cytokines after to HIV infection. A drop in BAFF 
 95 
and CXCL13 was observed after HIV infection compared to levels in pre-infection samples; 1556 
versus 1018, p<0.0001 and 170.4 versus 131.7, p=0.034 respectively (Figure 4.4). 
 
Figure 4:4: Dynamics of plasma BAFF and CXCL13 levels following HIV subtype A infection. 
Panels (A, B) show kinetics of BAFF and CXCL13 plasma levels determined by ELISA on HIV pre-
infection plasma samples (3 months before infection) and on plasma samples at 3 months PI.  Horizontal 
lines represent median values and the associated IQR values. p-values were calculated by Mann-Whitney 
test. p-values <0.05 was considered significant. 
 
The median BAFF concentration at 3 months PI was 1018 pg/ml (IQR, 800.4-1214), at 12 months 
PI, 759.7 pg/ml (759.7 (464.8-1337) and 48 months PI, 1065 pg/ml (IQR, 503.3-1627) (Figure 
4.4). The median CXCL13 concentration at 3 months pre-infection was 170.4 pg/ml (IQR, 134.1-
245.3), at 3 months PI, 131.7 pg/ml (IQR, 60.63-223.6), at 12 months PI, 146.9 pg/ml (83.67-294) 
and 48 months PI, 110.2 pg/ml (IQR, 65.9-19).  
 
After HIV infection, BAFF levels transiently decreased earlier in HIV infection but returned to 
similar levels observed prior to infection by 48 months PI. CXCL13 plasma levels decreased after 
HIV infection and remained relatively low up to towards 48 months PI. It appears that HIV 
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infection drives a transient decline in the levels of the B cell cytokines, BAFF and CXCL13, soon 
after infection (Figure 4.5). 
 
Figure 4:5: The dynamics of BAFF and CXCL13 plasma levels 3 months before HIV infection (0) 
and 3-, 12- and 48 months after HIV infection. Panels on the right and left show the kinetics of median 
levels of BAFF and CXCL13, respectively, that were longitudinally obtained from HIV pre-infection (0) 
to 48 months post-HIV infection. There were no significant differences between the time points. (Kruskal-
Wallis test). 
4.3.3: Association between BAFF and CXCL13 cytokines levels 
 
As BAFF and CXCL13 cytokines are essential in driving GCs activities, their association during 
HIV infection was done. At 3 months PI, BAFF and CXCL13 levels were positively associated 
rho=0.31, p=0.024, but this association was lost as the disease progressed at 12- and 48- months 
PI (Figure 4.6). Notably, unlike BAFF levels, individuals who generated high levels of CXCL13 
earlier in HIV infection maintained high levels at later stages of the infection and vice versa, 
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implying that HIV infected individuals who develop quality responses earlier in infection are likely 
to consistently make such responses in chronic infection (Appendix 7). 
 
 
Figure 4:6: Correlation between BAFF and CXCL13 at 3 months PI. The x-axis represents BAFF 
concentration in pg/ml while the y-axis represents CXCL13 concentration in pg/ml. Statistical test: 
Spearman’s correlations. P-values <0.05 was considered significant. 
 
4.3.4: Correlation between the levels of B cell cytokines and HIV-specific antibody 
levels 
 
In order to assess the association between HIV-specific antibody levels and B cell cytokines, 
Spearman’s correlation was done. The levels of the cytokine BAFF had no significant association 
with any of the HIV-specific antibody isotype or subclass. However, CXCL13 levels positively 
associated with most antibody subclasses and isotypes at 3 months PI. This positive association 
was maintained as HIV disease progressed to 48 months PI, at least for IgA1, IgG1, IgG, and IgG3 
(Table 4.2).   
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Table 4.2: Correlation between HIV-specific antibody isotypes and subclasses levels at 3 months 
PI with CXCL13 levels at 3-,12- and 48 months PI. 
  IgA1  IgA2 IgG1 IgG IgM IgG3 
CXCL13  






































The top row represents HIV-specific antibody isotypes and subclasses at 3 months PI while the left column 
represents CXCL13 levels at 3-, 12- and 48 months PI. Spearman's rank correlation was used, and all p-
values are shown in brackets in the cells. PI- post-HIV infection. Only significant associations are shown. 
 
Similarly, only CXCL13 had significant positive associations with HIV-specific antibodies at 12 
months PI. The HIV-specific antibody subclasses and isotypes that had significant associations 
included IgA2, IgG1, IgG, IgM, IgG2 and IgG3 (Table 4.3). BAFF levels measured at different time 
points had no significant association with any of the HIV-specific isotype or subclass levels. 
 
Table 4.3: Correlation between HIV-specific antibody isotypes and subclasses levels at 12 months 
PI with CXCL13 levels at 3-, 12- and 48 months PI. 
   IgA2 IgG1 IgG IgM IgG2 IgG3 
CXCL13  














(12 months PI) 











(48 months PI) 
      0.33 
(0.014) 
  0.27 
(0.04) 
 
The top row represents HIV-specific antibody isotypes and subclasses at 12 months PI while the left column 
represents CXCL13 levels at 3-, 12- and 48 months PI. Spearman's rank correlation was used, and all p-
values are shown in brackets in the cells. PI- post-HIV infection. Only significant associations are shown. 
 
At 48 months PI, both CXCL13 and BAFF levels at 3 months PI had significant positive 
associations with some of the HIV-specific antibody subclasses and isotypes (Table 4.4). 
Specifically, CXCL13 levels at 3, 12 and 48-months PI had significant associations with either 
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IgA2, IgG1, IgG or IgG2 at 48 months PI. Unlike CXCL13 plasma levels, BAFF plasma levels at 
3 months PI only had significant associations with IgA2 and IgG levels at 3 and 12-months PI 
respectively.  
Table 4.4: Correlation between HIV-specific antibody isotypes and subclasses levels at 48 months 
PI with CXCL13 levels at 3- ,12- and 48 months PI. 
   IgA2 IgG1 IgG IgG2 
CXCL13  










(12 months PI) 






(48 months PI) 
0.29 
(0.038) 





(3 months PI) 
0.31 
(0.004) 
      
BAFF 
(12 months PI) 




The top row represents HIV-specific antibody isotypes and subclasses while the left column represents 
CXCL13 and BAFF levels at 3-, 12- and 48 months PI. Spearman's rank correlation was used, and all p-
values are shown in brackets in the cells. PI- post-HIV infection. Only significant associations are shown. 
 




HIV disease progression was determined based on HIV viral load measurements and CD4+ T cell 
counts change over time. When associating HIV-specific antibodies with markers of HIV disease 
progression, a positive correlation was observed; IgA1 versus CD4+ T cell counts at 3 months PI 
(rho=0.295, p=0.03), IgM versus CD4+ T cell counts at 48 months PI (rho=0.295, p=0.03), IgG1 
versus viral load measurements at 3 months PI (rho=0.38, p=0.05) and versus viral load 
measurements at 48 months PI (rho=0.28, p=0.04). Similar associations were seen for IgG and 
IgG2 with viral load measurements at 3 months PI, (rho=0.29, p=0.03) and (rho=0.36, p=0.026), 
respectively. There was no correlation between CD4+ T cell counts and viral load measurements 
at 12 months PI (Table 4.5). 
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Table 4.5: Correlation between HIV-specific antibody isotypes and subclasses levels at 3 months 
PI with CD4+ T cell counts and HIV viral load measurements at 3-, 12- and 48 months PI. 
  IgA1 IgM  IgG1 IgG IgG2 
CD4 counts  
(3 months PI)  
0.295 
(0.03) 
        
CD4 counts  
(12 months PI) 
          
CD4 counts 
(48 months PI) 
  0.31 
(0.02) 
      
Viral load 
(3 months PI) 







(12 months PI) 
          
Viral load 
(48 months PI) 
    0.28 
(0.04) 
    
 
The top row represents HIV-specific antibody isotypes and subclasses, while the left column represents 
markers of HIV disease progression at 3-, 12- and 48 months PI. Spearman's rank correlation was used, and 
all p-values are shown in brackets in the cells. PI- post-HIV infection. Only significant associations are 
shown. 
 
On investigating the association of antibodies to disease progression at 12 months PI, IgA1 was 
positively associated with absolute CD4+ T cell counts determined at 3-, 12- and 48-months PI: 
(rho=0.35, p=0.01) at 3 months PI, (rho=0.37, p=0.0065) at 12 months PI and (rho=0.41, 
p=0.0023) at 48 months PI. Additionally, IgG1, IgG and IgG2 positively correlated with HIV viral 
load measurements at 3 months, (rho=0.27, p=0.04), (rho=0.3, p=0.04) and (rho=0.36, p=0.008) 
respectively. These positive associations were also observed with viral load measurements at 12 
months PI for IgG1, IgG and IgG2 with (rho=0.4, p=0.0032), (rho=0.38, p=0.005) and (rho=0.38, 
p=0.005) respectively (Table 4.6). However, no significant associations were observed between 
HIV-specific antibody levels at 48 months PI with the B cell cytokines levels, HIV viral load 
measurements and CD4+ T cell counts at different time points. 
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Table 4.6: Correlation between HIV-specific antibody isotypes and subclasses levels at 12 months 
PI with CD4+ T cell counts and HIV viral load measurements at 3-, 12- and 48 months PI. 
  IgA1  IgG1 IgG IgG2 
CD4 counts  
(3 months PI)  
0.35 
(0.01) 
      
CD4 counts  
(12 months PI) 
0.37 
(0.007) 
      
CD4 counts 
(48 months PI) 
0..41 
(0.002) 
      
Viral load 
(3 months PI) 







(12 months PI) 







(48 months PI) 
        
 
The top row represents HIV-specific antibody isotypes and subclasses while, the left column represents 
markers of HIV disease progression at 3-, 12- and 48 months PI. Spearman's rank correlation was used, and 
all p-values are shown in brackets in the cells. Only significant associations are shown. P-values <0.05 were 
considered significant. 
 
4.3.6: Correlation between the levels of B cell cytokines with the markers of HIV 
disease progression 
 
On assessing associations between the B cell cytokines with the markers of HIV disease 
progression (HIV viral load measurements and CD4+ T cell counts), there was no significant 
correlation of BAFF levels with either of the markers of HIV disease progression. However, 
CXCL13 levels at 3 months PI positively correlated with viral load measurements at 3 months PI 
(Spearman rho=0.49, p=0.0002) and negatively correlated with CD4+ T cell counts at 3 months 
PI (rho=-0.36, p=0.00077). This may suggest that HIV viremia drives quality GCs activity, albeit, 
at the cost of depletion of CD4+ T cell counts. Similarly, it may point out to the migration of Tfh 





This study investigated the levels and kinetics of BAFF, a cytokine important for B cell survival 
[97], and CXCL13, a chemokine responsible for B cell trafficking to GCs [268] before and during 
HIV infection. Unlike in previous studies where HIV has been associated with a cytokine storm 
after infection [29, 269-273] and an increase in BAFF and CXCL13 levels [217], the current data 
suggests otherwise. Perhaps this is likely due to the disparity in the sampling time points, where 
other studies used samples from earlier time points post HIV infection [273].  An initial 
observation of low BAFF and CXCL13 levels at 3 months post HIV infection prompted the 
measurement of these cytokines prior to infection and thus confirming the drop of these cytokines 
at 3 months PI. BAFF levels only significantly increased at 48 months PI, while the CXCL13 
levels remained relatively low up to 48 months PI. It is not clear why the levels of CXCL13 
decreased after HIV infection despite the effects of HIV immune activation and continuous viral 
replication within lymphoid tissues, which has been shown to elevate CXCL13 levels [217]. 
Perhaps the different findings may be due to the clade-specific effects, where Mabuka and others 
used a cohort of individuals infected with HIV clade C [217], unlike HIV clade A used in this 
study. HIV clade C has previously been associated with higher viral loads, lower CD4+ T cell 
counts and thus a faster HIV disease progression as compared to HIV clade A, perhaps due to 
increased replicative fitness [274], and this would drive robust immune activation and thus higher 
CXCL13 levels [217]. In addition to HIV clade-specific replicative fitness, CXCR4-tropism has 
been reported to influence HIV disease progression [275]. Also, it is possible that the cytokine 
storm may have occurred earlier than the 3 months PI, when the sampling was done. 
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Nevertheless, CXCL13 and BAFF levels had a positive association at 3 months PI suggesting a 
coordinated GCs activity since both cytokines act locally in the lymph nodes to enhance B- and T 
cell interactions and activations [276]. Additionally, individuals with high CXCL13 levels 
maintained similar responses and vice versa, which may imply that quality GC activities may be 
sustained throughout an infection. Moreover, this may also point out that early priming of GCs 
activities in disease may be necessary for quality GCs activities in chronic infection. This is further 
supported by the positive correlation between CXCL13 levels and viral load measurements, which 
emphasizes the need for high antigenic stimulation for quality GCs activity. The positive 
association between CXCL13 levels and viral load measurements has been reported elsewhere 
[277-279].  
 
As expected, CXCL13 levels and CD4+ T cell counts were inversely associated possibly due to 
the migration of Tfh cells from the peripheral circulation to the lymph nodes in the presence of 
CXCL13. The weak association of BAFF and the markers of HIV disease progression has been 
described elsewhere, where, BAFF levels failed to show any association with viral load 
measurements [217]. However, HIV viremia is known to cause a depletion of B cells through 
inducing decreased responsiveness of B cells to BAFF, leading to apoptosis due to lack of pro-
survival signals [280]. 
 
To determine the levels of HIV-specific antibody isotypes and subclasses, this study used a 
standard ELISA assay but later incorporated a multibead Luminex assay that permitted the 
measurement of a broader range of antigen responses. Results from the two assays were in 
agreement. However, the limit for detection was lower for the inhouse ELISA than for the Luminex 
assay. This is consistent with the findings from a Zaire Ebola study, where the Luminex-based 
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assay was shown to be as sensitive as ELISA and more specific and accurate in detecting the Zaire 
Ebola virus IgG in human plasma [281]. Indeed, the Luminex assay has successfully been used in 
different studies to assess antigen-specific antibody levels, cytokines, chemokines and heat shock 
proteins [134, 282-285]. Cross-reactivity to antigens from other HIV clades was observed due to 
antibodies in plasma targeting epitopes within conserved regions of the HIV ENV, as described 
elsewhere [286].  
 
Despite the decreasing levels of the B cell cytokines reported, there was a significant increase in 
HIV-specific isotypes and subclasses antibody levels as HIV disease progressed. This may be 
attributed to the increase of HIV viremia, as reported in an HIV-elite and non-controller cohort 
[287]. Consistent with the literature, IgA isotype was found to circulate at low levels in plasma 
[288], with IgA1 being more prevalent than IgA2. This is consistent with the literature, where serum 
IgA1 has been shown to circulate at higher levels than IgA2 with a ratio of 9:1 [289]. While both 
IgA1 and IgA2 share significant sequence similarities, IgA1 has an insertion of duplicated amino 
acids which creates an extension in its hinge region [290] and is more glycosylated [291]. 
 
Furthermore, and similar to other reports, IgG1 was the most predominant subclass, IgG3 the 
second most predominant while IgG4 was the least dominant [256, 258, 292, 293]. However, 
despite the low levels of IgG4 antibody responses, these responses significantly increased as HIV 
disease progressed. Similar findings have been shown in studies where HIV-specific IgG4 antibody 
responses were readily available in chronically HIV infected patients [254, 260]. IgM was 
detectable, though in low levels in chronic HIV infection. This isotype IgM has previously been 
shown to be detected in chronic HIV disease, at least in low levels [112]. More likely, the 
significant increase in HIV-specific IgM as HIV disease progresses may be due to the constant 
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antigenic stimulation at the GCs that may lead to its generation, before class switching occurs [28, 
287].  
 
HIV-specific isotypes and subclasses antibody levels were associated with preservation of CD4+ 
T cell counts despite the positive correlation with HIV viral load measurements too. As previously 
discussed in a review [294], this may suggest that while the high viral load is required for higher 
antibody titres, preservation of CD4+ T cells (Tfh cells) is critical to achieving quality GCs activity 
that results in higher antibody titres. 
 
As expected, CXCL13 levels were positively associated with HIV-specific isotypes and subclasses 
antibody levels. The cytokine CXCL13 organizes the B cell follicles of secondary lymphoid organs 
via recruiting antigen-specific B and T cells through the CXCR5 receptor [295]; thus, its 
association with antibody levels is expected. Similarly, BAFF was associated with higher levels 
of HIV-specific IgG. Since BAFF is essential for B cell survival factor [97], it is plausible that 
higher levels of BAFF would favour higher frequencies of B cells that would translate to higher 
levels of antigen-specific antibodies. 
 
It appears that the overall increase in HIV-specific antibody isotypes and subclasses over time is 
due to the high viremia since all study participants were ART naïve, and ART is known to cause 
HIV viral suppression which leads to a progressive decline in antibody responses [287]. The 
implications of increasing titres of anti-HIV antibodies as HIV progresses differ. For instance, due 
to the narrowness of antibody responses against a quickly mutating HIV, antibody responses, 
despite their magnitude, may fail to control viremia leading to rapid viral escape [113, 114]. 
Additionally, while most anti-HIV antibody responses target the ENV on the viral surface [296], 
very few can recognise the conserved regions on the trimeric ENV [297, 298] and thus ineffective.  
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Paradoxically, HIV-specific antibodies may be beneficial to the virus through a process called 
complement-mediated antibody-dependent enhancement of viral infection, as shown in-vitro [299, 
300]. The process involves the binding of an antibody to either gp-41 or gp-120 which initiates a 
complement cascade. Once the opsonized virions bind to CD21, the engagement of CD21 with 
CD4 leads to enhanced HIV replication [301]. However, higher HIV antibody titres have been 
have been associated with quality Fc polyfunctionality [134] in HIV infection and the development 
of bnAbs [134, 159], which may be beneficial for vaccine design. 
 
In summary, these data show that: 
• HIV infection drives higher HIV-specific antibody levels as the disease progresses.  
• HIV infection drives a transient decline in the levels of the B cell cytokines, BAFF and 
CXCL13, soon after infection. 
• BAFF and CXCL13 levels were positively associated earlier in early HIV infection and 
hence suggesting an immunological link in GCs activities. 
• Unlike BAFF plasma levels, CXCL13 levels positively associated with most HIV-specific 
antibody subclasses and isotypes and thus implying that CXCL13 levels in early HIV 
infection may be a good predictor of HIV-specific antibody levels in chronic infection. 
• Most of the HIV-specific antibody levels were positively associated with viral load 
measurements at different time points and thus suggesting a role of HIV viremia in driving 
higher levels of HIV-specific antibodies. 
• The positive associations between plasma CXCL13 levels with HIV viral load 
measurements may imply that HIV viremia is necessary for quality GCs activity. 
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In this chapter, I have demonstrated that GCs activities, HIV viral load and HIV-specific antibody 
levels are positively associated, suggesting that they are immunologically linked. However, since 
B cells require help from CD4+ T cells, which are depleted in HIV infection, more studies will be 
needed to elucidate how these immunological activities could be exploited for the realization of 

































Chapter 5  Fc-mediated and Fab-mediated antibody 





























5.1: Literature review 
 
Antibodies are the secreted form of the B cell receptor (BCR) and hence identical in structure 
except for a small portion of the C-terminus of the heavy-chain constant region. While the C-
terminus in the BCR is a hydrophobic membrane-anchoring sequence, the C-terminus of the 
antibody is a hydrophilic sequence that allows its secretion [302]. Typically, antibody molecules 
are Y-shaped structures consisting of two identical light chains and two identical heavy chains that 
are paired by disulphide bonds to create three structural domains, two Fragment antigen-binding 
(Fab) and one Fragment crystallisable (Fc) fragments. The two Fab fragments have the variable 
(V) region at the amino terminus, which contributes to the antigen-binding. In contrast, the Fc 
fragment bears the constant (C) region that determines the antibody’s isotype [302].  
 
The Fc fragment is formed by a heavy chain dimer of the constant heavy 2 (CH2) and constant 
heavy 3 (CH3) segments. In contrast, the Fab fragment is a mixed light-heavy chain dimer of 
variable light (VL)-constant light (CL) paired with variable heavy (VH)-constant heavy 1 (CH1) 
segments. The high variability in the Fab fragment is created by V(D)J (heavy chain) or VJ (light 
chain) recombination and thus creating extensive diversity. Furthermore, the Fab fragment 
recognises antigen using its six complementarity-determining regions (CDR) loops (L1, L2, L3, 
H1, H2, and H3) loops. Because the CDR H3 is formed at the VDJ junction where there are 
deletions or insertions of extra nucleotide sequences, the CDR H3 is the most variable in length, 







Figure 5:1: The representative structure of an immunoglobulin (Ig) -G antibody and a membrane-bound 
IgM molecule on the surface of a B cell. The Fab region is made up of the heavy (shown in blue and red) 
and light region (shown in green) and is the region that binds to antigens and is responsible for antibody 
neutralisation function against invading pathogens. The Fc portion is made up of the heavy chain and 
mediates non-neutralising functions such as antibody-dependent cellular phagocytosis [304]. 
 
The Fc portion is the part that mediates additional non-neutralising activities such as antibody-
dependent cellular phagocytosis (ADCP), neutrophil phagocytosis (ADNP), complement 
deposition (ADCD) and cellular cytotoxicity (ADCC) [305]. Monocytes and neutrophils mediate 
antibody-dependent cellular phagocytosis while complement proteins in plasma are responsible 
for ADCD through the cell lysis of antibody-flagged infected cells. More specifically, complement 
component C3b activates the formation of membrane attack complexes leading to cell death or the 
recruitment of innate cells which will phagocytose the infected cells [304].  Natural killer (NK) 
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cells play a critical role in ADCC where infected cells are actively lysed via an antibody dependant 
mechanism [304]. These functions are guided by the antibody isotype class, which mainly relies 
on the cytokine milieu present in germinal centres (GCs) [306, 307]. The isotype class switching 
selects for constant regions, which, in turn, determines the scope of Fc effector functions [134]. 
Five antibody isotypes exist, IgA, IgD, IgE, IgG, and IgM. Isotypes IgD and IgGs have one 
variable and three constant domains while IgAs, IgEs and IgMs have one variable, four constant 
domains and an additional J-chain. The J chain allows the formation of dimers for IgEs and IgAs 
and pentamers for IgMs. Isotypes IgAs, IgDs, and IgGs are monomers [308].  
 
Apart from isotype subclasses, the function of the Fc effector is modulated by their affinity for 
activating and inhibiting Fc receptors on innate cells and complement proteins [309]. For instance, 
activating Fc receptors include Fcγ 2a and Fcγ 3a, while Fcγ 2b is known to be an inhibiting Fc 
receptor. These activating Fc receptors are therefore capable of mediating pathogen clearance 
through phagocytosis by neutrophils, macrophages and monocytes, ADCC or direct lysis by 
natural killer cell activity and complement deposition among others. Lastly, Fc-mediated antibody 
functions are also dependent on the Fc domain glycosylation at the conserved site in the CH2 
region, with both galactosylated and agalactosylated glycoforms being associated with improved 
human immunodeficiency virus (HIV) antiviral activity [306, 307, 310].  
 
In human immunodeficiency virus (HIV) infection, Fc-mediated functions have been suggested to 
play a role in protection against HIV infection [240] and the control of viremia [305]. More 
convincing is that HIV elite controllers mount robust ADCC activity, that is thought to play a part 
in the suppression of viremia without antiretroviral treatment (ART) [143, 146, 311]. Moreover, 
coordinated Fc responses that involve the recruitment of various Fc effector functions have been 
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reported in elite controllers [146] and in HIV infected and vaccinated individuals [312]. More 
recently, it was shown that ADCP and ADCD are readily detectable as early as 6 months post-HIV 
infection and that, their early detection is predictive of the development of neutralisation breadth 
later in chronic HIV [134]. These mounting data strongly suggest that Fc-mediated function may 
be essential in the design of an effective antibody-based HIV vaccine. 
 
Unlike Fc-mediated antibody functions that rise early in HIV infection [134], broadly neutralising 
antibodies (bnAbs) take years to be generated in adults and can only be detected in approximately 
20% of HIV infected individuals [313]. These bnAbs exhibit high levels of somatic hypermutation 
in the complementarity determining regions due to extensive affinity maturation [314, 315] and 
are capable of neutralising most circulating HIV strains. It is plausible that the delay or lack of 
bnAbs development may be due to the immunodominance of non-conserved regions of the 
Envelope (Env) spike and the high variability in antigenic regions of the Env which favours viral 
immune escape. Additionally, the HIV spike is naturally unstable and tends to only express Env 
in conformations that favour the induction of non-neutralising antibodies over neutralising 
antibodies [316, 317].  
 
The dominant epitopes targeted by bnAbs include the CD4 binding site (CD4bs), the V1-V2 apex, 
the V3-high mannose patch, the gp41 membrane-proximal external region (MPER) and the 
gp120/gp41 interface [318, 319]. More recently, another epitope targeted by bnAbs was 
discovered. The fusion peptide, which is located at the N terminus of the Env-gp41 subunit mainly 
aids in the entry of the virus into the host cell and is targeted by the bnAb N123-VRC34.01. The 
bnAb N123-VRC34.01 prevents viral entry into the host cells by hindering conformational 
changes in gp120 and gp41 subunits of Env that are necessary for cell entry [320]. Unlike in adults, 
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bnAbs in infants may develop earlier and target up to four distinct epitopes, with breadth achieved 
by a combination of these responses and hence enhancing the poly-clonality [321]. Currently, 
various epitopes on the HIV Envelop spike that are targeted by different monoclonal antibodies 




Figure 5:2: The structure and antibody recognition of the HIV Envelope spike. The approximate locations 
of epitopes targeted by monoclonal antibodies are shown by the arrows. Each red box represents the number 
of monoclonal antibodies targeting an epitope. Glycans are shown in purple. MPER; membrane-proximal 




In order to achieve a functional antibody-based HIV vaccine, assessing bnAbs may provide critical 
information that is crucial for optimal immunization strategies. Studies have suggested that bnAbs 
can protect against HIV acquisition in macaques [236, 322, 323] and in delaying viral rebound in 
HIV infected individuals off ART [132].  
 
  
While the bnAbs only target few epitopes on the virus’ Envelope, broadly neutralising monoclonal 
antibodies are resourceful in identifying key candidate epitopes more precisely [318]. It is thought 
that incorporating various targeted epitopes that generate bnAbs would be a good approach for 
vaccine design. However, all attempts have been futile. Attempts to design immunogens based on 
the CD4 binding site (CD4bs) have failed due to the specific directional targeting to the CD4bs 
required. The directional targeting is necessary to access epitopes that are occluded and can only 
be targeted through constrained angles of approach by the bnAbs.  Similarly, targeting of the 
glycan epitope requires unique domain-exchanged configuration of this antibody that is necessary 
for the recognition of the glycan shield, which complicates the design [324].  
 
The most promising target, MPER of Env gp41, has previously achieved some success in eliciting 
strong responses [325]. However, the proximity of the epitopes to the membrane has raised 
concerns in eliciting MPER antibodies [325, 326]. Additionally, MPER antibodies have been 
shown to be highly autoreactive and this may present problems moving forward in utilizing it as 
an immunogen in a vaccine [327].  
 
Our knowledge of factors influencing the generation of bnAbs remains scarce. Several studies 
have suggested: high HIV viral load, low CD4+ T cell counts, subtype C infection and HLA-
A*03(-) genotype [159], time after HIV infection [313], ethnicity [328], virologic characteristics 
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[329], increased frequencies of some subsets of T follicular helper (Tfh) cells and plasma levels of 
CXCL13 in early HIV infection [98, 99, 268] to play a role in bnAb development. Cellular 
frequencies of Tfh cells, critical in providing B cell help and key in the formation of GCs [210, 
330], have been associated with the quality and quantity of anti-simian immunodeficiency virus 
(SIV) IgG antibodies in macaque models [331]. Similarly, the entire International Acquired 
immunodeficiency syndrome (AIDS) Vaccine Initiative (IAVI) protocol C cohort, Landais and 
others showed that the development of breadth was associated with high viral load, low total CD4+ 
T cell counts, virus subtype C infection and human leukocyte antigen (HLA) *A3(-) genotype 
[159].  
 
Also, higher titres of total IgG and anti-Env binding antibodies have positively correlated with 
bnAbs generation. High viral load drives low CD4+ T cell counts, higher titres of anti-Env 
antibodies and may be determined by HLA type. It is plausible that the generation of bnAbs is 
influenced by the genotypic features of the transmitted virus. Indeed, some HIV subtype C features 
such as shorter V1–V4 loops have been shown to favour the development of bnAbs [332].  
 
In this chapter, I determined the Fc and Fab functions of antibodies in HIV infected individuals. 
Specifically, I assessed ADCP, ADCD, ADNP and natural killer cells ability to express CD107α,  
macrophage inflammatory protein-1alpha (MIP-1α) and interferon-gamma (IFNγ) in plasma 
taken from HIV infected individuals over time (3-, 12-, 48- months post-HIV infection (PI)), 
using a gp120 coated bead assay at 3-, 12-, 48- months PI. For the Fab-mediated antibody 
function, plasma samples at 48 months PI were screened for broadly neutralising function against 





To determine Fc- and Fab-mediated antibody functions in HIV infection. 
 
5.3: Results 
5.3.1: Gating strategy for the Fc-mediated functions 
 
 
Plasma samples were processed as described in chapter 2, section 9. All data were analysed on 
Flowjo version 10 (FlowJo LLC, Ashland, OR, USA). To gate on C3b deposition, gp120 coupled 
beads were gated on forward and side scatter plots, singlets selected, and positively labelled beads 
selected. The ability of antibodies to mediate complement deposition (ADCD) was then assessed 
by gating on the positively labelled beads that expressed C3b on the FITC fluorochrome (Figure 
5.3). ADCD scores were determined by (% C3b deposition x MFI of deposited C3b). 
 
In order to assess for neutrophil phagocytosis (ADNP), neutrophils were gated on the forward 
versus side scatter plot and were defined as CD3- CD14- CD66b+. Neutrophils that expressed 
FITC fluorochrome had phagocytised the gp120 FITC labelled beads. (Figure 5.4). The THP-1 
cells were gated on the forward versus side scatter and ADCP determined by their ability to 
phagocytise FITC coupled beads (Figure 5.5). ADNP scores were determined by (% fluorescent 
bead phagocytosed x mean fluorescence intensity (MFI) of phagocytosed beads). ADCP scores 
were determined by ([% THP-1 cells that have taken up antigen coupled beads] x [MFI of THP-1 




Antibody-dependent natural killer cell degranulation (ADNK) activity was determined through 
gating on natural killer cells on the forward versus side scatter plot (Figure 5.6). The natural 
killer cells were defined as CD3- CD16+ CD16- CD56+ CD56-. Their ability to degranulate was 
defined with the frequencies of the CD107α marker, ability to be activated by the interferon-
gamma (IFNγ) marker and their ability to be chemo-attractive by the macrophage inflammatory 






Figure 5:3: Representative gating strategy of ADCD. Beads were identified on forward scatter-side scatter plot. Within the beads gate, only gp120 




Figure 5:4: Representative gating strategy of ADNP. Neutrophils were identified on forward scatter-side scatter plot. Within the neutrophil gate, the 
markers CD3- CD14- CD66B+ was used to clean up the neutrophil population. Thereafter, gp120 FITC was used to determine which neutrophils 





Figure 5:5: Representative gating strategy of ADCP using a THP1 cell line. Monocytes (THP1 cell line) were identified on forward scatter-side 
scatter plot. Within the monocytes gate, ADCP was determined by the ability of monocytes to phagocytose gp120 coated beads. Mean intensity 





Figure 5:6: Representative gating strategy of ADNK assay. Purified natural killer cells were identified on forward scatter-side scatter plot. 
Within the natural killer cell gate, the markers CD3- CD56+ CD56- CD16+ CD16- were used to identify natural killer cells. Using this population, 
their ability to degranulate was defined with the CD107α  marker, ability to be activated by the IFNγ marker and their ability to be chemoattractive 




5.3.2: Assessing the reproducibility of the Fc-mediated assays 
 
All of the 53 HIV infected individuals included in this project were assessed for Fc-mediated 
functions. Plasma samples collected at approximately 3, 12- and 48- months post-HIV infection 
were used. Replicate assays were performed to confirm that results from these functional assays 
are reproducibility and reliable. The ADCD and ADCP assays were run on two different days 
while ADNK and ADNP assays were run on the same day but using blood from different donors. 
Reproducibility was assessed using rho values from the non-parametric Spearman’s rank 
correlation. A correlation coefficient rho value of 0.3 - 0.5 was described as weak, 0.5 - 0.7 as 
moderate and > 0.7 as strong. The significance of the association was described with a p-value of 
less than 0.05 (Table 5.1).  
 
There was a moderate to high correlation across all the assays conducted, confirming that the 
results are reliable. However, ADNKIFN-γ showed weak associations at the three time points. The 
proportion of ADNKIFN-γ detected per sample was low and may, therefore, interfere with the 









Table 5.1: Correlation coefficients values of assays done on different days (ADCD and ADCP) or 
using different blood donors (ADNK and ADNP). 
 Months PI ADCD ADCP ADNP CD107α  IFN-γ  MIP-1α 
ADCD 3 months  0.4 
(0.027) 
     
12 months 0.59 
(0.0002) 
     
48 months  0.62 
(0.007) 
     
ADCP 3 months   0.49 
(0.007) 
    
12 months  0.46 
(0.0012) 
    
48 months   0.78 
(<0.0001) 
    
ADNP 3 months    0.7 
(<0.0001) 
   
12 months   0.81 
(<0.0001) 
   
48 months    0.9 
(<0.0001) 
   
ADNK 
CD107α  
3 months     0.45  
(0.01) 
  
12 months    0.44  
(0.01) 
  





3 months      0.31  
(ns) 
 
12 months     0.2  
(ns) 
 





3 months       0.58 
(0.003) 
12 months      0.77 
(<0.0001) 
48 months      0.87 
(<0.0001) 
 
Plasma used was sampled at 3, 12- and 48- months post-HIV infection (PI). Spearman's rank correlation 
was used, and all p-values are shown in brackets in the cells. p-values <0.05 were considered significant. 
Antibody-dependent cellular phagocytosis; (ADCP), complement deposition (ADCD), neutrophil 
phagocytosis (ADNP) and natural killer cell degranulation (ADNKCD107α), activation (ADNKIFNγ) and 
ability to chemoattract (ADNKMIP-1α). Ns; not significant, months PI; months post-HIV infection. 
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5.3.3: Fc-mediated antibody functions measured longitudinally at 3-, 12- and 48-
months post-HIV infection 
 
All the measured Fc-mediated functions, ADCD, ADCP, ADNP and ADNK were readily 
detectable at 3 months post-HIV infection in all individuals. These functions significantly 
increased over time except for ADCP, which peaked at 12 months PI but dropped by 48 months. 
The increase of ADCD activity may be due to the continuous antigenic stimulation that confers 
enhanced recruitment of complement and natural killer cells.  
 
These results suggest that Fc-mediated responses arise early in infection, albeit low, but 
significantly increases by 12 months PI. Differences in Fc-mediated antibody functions were 
determined by one-way ANOVA (Kruskal–Wallis test) on the medians between the three time 
points at a 95% confidence interval. Differences in medians between paired time points were 
determined using the Mann-Whitney U test. The significance of each analysis was described with 























Figure 5:7: Fc effector function kinetics in HIV infection. Plasma samples collected at time point 1 (3 months), time point 2 (12 months) and time 
point 3 (48 months) PI were tested for antibody-dependent cellular phagocytosis (ADCP), complement deposition (ADCD), neutrophil phagocytosis 
(ADNP) and natural killer cell degranulation (CD107α ), activation (IFNγ) and ability to chemoattract (MIP-1α). Differences between the time points 




5.3.4: Quality of the specific Fc-mediated functions generated in HIV  
 
 
In order to test for the quality of individual Fc functions, each individual Fc function was 
standardized by calculating a Z score. The Z score was determined by subtracting the value of the 
individual Fc function score from the mean Fc function score and divided by the standard deviation 
of the mean. The Z score was determined by subtracting the value of the individual Fc function 
score from the mean Fc function score and divided by the standard deviation of the mean. This 
was calculated for each Fc-mediated antibody function. Quality Fc function was defined by a Z 
score greater than zero, while poor Fc function was defined by Z scores less than zero.  
 
Study participants with Z-scores greater than zero, hence reflecting good quality, consistently 
maintained such responses over the three time points., Similarly those with Fc-mediated Z-scores 
less than zero maintained the poor responses as HIV disease progressed.  
 
 Of all Fc-mediated responses, more than 24 (45%) of participants had high ADNK function Z 
scores – measured by IFNγ secretion, across all time points. On the other hand, very few 
individuals had high secretion of MIP-1α, indicative of poor macrophage activation by HIV, with 
only 15 (28.3%) demonstrating high function at 12 months PI. The proportion of individuals with 
increasing individual Fc function across the 3 timepoints were generally maintained over time 






Table 5.2: Proportion of individuals with quality specific Fc-mediated functions across the time 
points. 
 Timepoint 1  
(3 months PI) 
Timepoint 2  
(12 months PI) 
Timepoint 3  
(48 months PI) 
ADCD 19 (35.8%) 18 (33.9%) 20 (37.7%) 
ADCP 21 (39.62%) 23 (43.4%) 25 (47.2%) 
ADNP 19 (35.8%) 22 (41.5%) 22 (41.5%) 
ADNKCD107α  21 (39.62%) 13 (24.5%) 18 (33.9%) 
ADNKIFNγ 24 (45.3%) 27 (50.9%) 24 (45.3%) 
ADNKMIP-1α 21 (39.62%) 15 (28.3%) 16 (30.2%) 
 
The numbers and percentages of participants with high individual Fc-mediated functions; antibody-
dependent cellular phagocytosis (ADCP), complement deposition (ADCD), neutrophil phagocytosis 
(ADNP) and natural killer cell (ADNK) - degranulation - (CD107α), activation - (IFNγ) and ability to 
chemoattract - (MIP-1α) stratified across sampling time points. The quality of individual Fc-mediated 
function was determined by calculating a Z score to standardize individual Fc-mediated scores on R studio 
as described above. The sample size and proportion of individuals with quality Fc effector functions are 
indicated by the numbers and percentages, respectively. PI; post-HIV infection. 
 
 
A comparison of median HIV viral load measurements and CD4 T cells counts at the three time 
points between the individuals with good or poor-quality individual Fc-mediated functions was 
done. Quality ADCP function at 3 months PI was associated with significantly lower HIV viral 
copies/ml, 4567 [IQR, 46.5-24475] versus 97689 [IQR, 9153-462250], p <0.0001 in individuals 
with poor ADCP responses (Mann-Whitney test). In addition, associations between HIV viral load 
measurements and CD4 T cells counts with Fc-mediated functions were done. ADCP function at 
3 months PI negatively correlated with HIV viral load measurements at 3 months PI (Spearman’s 
correlation rho=-0.38, p=0.0051) implying that ADCP may play a role in controlling early HIV 
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viremia (Figure 5.8). However, none of the Fc-mediated functions tested showed any association 















5.3.5: Assessing for associations between different Fc-mediated functions in HIV 
 
 
To check for the coordination between different Fc-mediated antibody functions, Spearman 
correlations were used. The various Fc-mediated antibody functions were significantly correlated 
in the course of HIV infection. The strongest correlation was observed between ADNP and 
ADNKCD 107α (Spearman rho = 0.7, p<0.001), at 48 months PI. Generally, ADCP had the weakest 
association with the other Fc-mediated functions (Figure 5.8). At 3- and 12-months PI, ADNKIFNγ 
function poorly associated with all other Fc-mediated functions but moderately correlated with 
ADCD and ADNP functions at 48 months PI. Individuals who made good ADNKIFNγ function 
early in the infection maintained this throughout to 48 months PI.   
 






















 p=0.0051  







Figure 5:8: Correlation between ADCP and HIV viral load measurements at 3 months PI. Antibody-
dependant complement deposition scores at 3 months post-HIV infection (PI) negatively correlated with 
HIV viral load measurements at 3 months PI. The y-axis shows HIV viral load copies/ml in log10 while 
the x-axis represents antibody-dependent cellular phagocytosis (ADCP) scores at 3 months PI. Significance 




Additionally, ADCD was significantly associated with the other ADNK functions (ADNKCD 107α 
and ADNKMIP-1α expression) across all time points except ADNKIFNγ at 3- and 12-months PI. 
Association of the different Fc-mediated functions suggested a coordinated functional response 




















The matrix represents a pairwise comparison of Fc functions - antibody-dependent cellular phagocytosis (ADCP), complement deposition (ADCD), 
neutrophil phagocytosis (ADNP) and natural killer cell degranulation (CD107α ), activation (IFNγ) and ability to chemoattract (MIP-1α), tested at 
a) 3 months, b) 1 year (12 months PI) and c) 3-4 years post-HIV infection (48 months PI). Colour coding represents the level of association with the 
strongest positive association shown in dark red while inverse correlations appear blue. P-values < 0.001 representing strong association (***), 





























Figure 5:9: Correlation between the various Fc-mediated functions tested. 
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5.3.6: Fc-mediated polyfunctionality in a longitudinal followed up HIV cohort 
 
To establish the cumulative effect of the various Fc-mediated antibody responses per individual, 
an Fc polyfunctionality Z-scores was calculated for each participant at each sampling timepoint. 
The Z scores were calculated for each function, as described in Chapter 5, section 3.4 and were 
summed for each individual at each time point. Cumulative Z-scores with a value greater than zero 
indicated a well-coordinated function termed as “high Fc polyfunctional activity”. In contrast, 
those with cumulative Z-scores less than zero indicated a poorly coordinated function termed as 
“poor Fc polyfunctionality”.  
 
At 3 months PI, of the 53 individuals, 35.8% (19/53) had Z-scores greater than 0, indicating that 
they mounted coordinated Fc-mediated antibody responses (Figure 5.10). It is plausible that this, 
together with the early CD8+ T cell responses may have played a part in bringing down the HIV 





























Fc polyfunctionality Z-score was determined by summing up individual Fc functions Z-scores (ADCP, ADCD, ADNP and ADNK (CD107α ), 
activation (IFNγ) and ability to chemoattract (MIP-1α)) at 3 months PI. The x-axis represents the 53 individuals that are stratified by their 
polyfunctionality activity. The y-axis indicates polyfunctionality Z scores. Bars above zero (blue) indicate quality Fc polyfunctionality, while those 

























Figure 5:10: Fc polyfunctionality Z scores at 3 months post-HIV infection. 
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However, there was a decrease in the proportion of individuals who showed high Fc 
polyfunctionality at 12 months PI from 35.8% (19/53) to 30.2% (16/53) (Figure 5.11). This may 
be as a result of the immense viral escape, and the increasing numbers of HIV quasispecies that 
may deter quality Fc-mediated responses. Additionally, it may be due to the functional disruption 
of the B and Tfh cell compartments caused by direct and indirect effects of HIV. Such a functional 







































Fc polyfunctionality Z-score was determined by summing up individual Fc functions Z-scores (ADCP, ADCD, ADNP and ADNK (CD107α ), 
activation (IFNγ) and ability to chemoattract (MIP-1α)) at 12 months PI. The x-axis represents the 53 individuals that are stratified by their 
polyfunctionality activity. The y-axis indicates polyfunctionality Z scores. Bars above the zero mark (blue) indicate quality Fc polyfunctionality, 

























Figure 5:11: Fc polyfunctionality Z-scores at 12 months PI. 
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However, at 48 months PI, the proportion of individuals with Fc polyfunctionality increased to 
41.5% (22/53) (Figure 5.12).  It is plausible that this increase in polyfunctionality activity was due 
to antibody maturity in response to higher HIV viral encounter at 48 months PI. Indeed, all 





































Individual Fc-mediated functions were standardized by calculating a Z-score as described above and the Fc polyfunctionality determined by the 
addition of the Z-scores for all 6 Fc-mediated functions (ADCP, ADCD, ADNP and ADNK (CD107α ), activation (IFNγ) and ability to chemoattract 
(MIP-1α)) at 48 months PI. The x-axis represents the 53 individuals that are stratified by their polyfunctionality activity. The y-axis indicates 
polyfunctionality Z scores. Bars above the zero mark (blue) indicate quality Fc polyfunctionality, while those below (gold) indicate poor Fc 

























Figure 5:12: Fc polyfunctionality Z-scores at 48 months PI. 
 137 
5.3.7: Comparison of the levels of the markers of HIV disease progression in 
individuals with high versus low Fc polyfunctionality  
 
The median values of the markers of HIV disease progression, CD4+ T cell counts and HIV viral 
load measurements taken at 3-, 12- and 48-months PI were compared in individuals with poor 
versus quality Fc polyfunctionality determined at similar time points (3-, 12- and 48-months PI). 
 
No differences were observed in HIV viral load measurements between individuals with low 
versus high Fc polyfunctionality scores across the three time points. Similarly, individuals with 
quality Fc polyfunctionality did not preserve CD4+ T cell counts any better than those with poor 
Fc polyfunctionality at time points 3- and 12-months PI. However, individuals with poor Fc 
polyfunctionality had significantly higher median CD4+ T cell counts than those with quality Fc 
polyfunctionality at 48 months PI, 551 versus 349, p=0.02 (Mann-Whitney test) (Table 5.3). This 
finding may imply that higher viremia may enhance Fc function albeit the depletion of CD4+ T 
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Cumulative Fc polyfunctionality Z-scores calculated in section 5.3.6 were used assessed for their effect on HIV disease progression as described by 
CD4+ T cell counts and HIV viral load measurements at 3-, 12- and 48- months PI. Using matching time points for Fc polyfunctionality scores and 
the markers of HIV disease progression, the differences in medians of CD4+ T cell counts and HIV viral load measurements between individuals 
with high- and low- Fc polyfunctionality was evaluated. In each cell, are medians and p-values. Significant differences are shown in bold and blue. 











While there was generally no significant differences in HIV viral load measurements and CD4+ T 
cell counts (except at 48 months PI) between individuals with quality and poor Fc 
polyfunctionality, high Fc polyfunctionality earlier on in the infection (3 months PI) was 
associated with reduced HIV viremia later on in the infection (12 months PI), Spearman rho= -
0.529, p=0.0197. This may imply that high Fc polyfunctionality may play a role in controlling 













Figure 5:13: Correlation between HIV viral load measurements and Fc polyfunctionality. Fc 
polyfunctionality at 3 months PI inversely correlated with viral load measurements at 12 months PI. 
Indicated is the Spearman rho and the p-value. p < 0.05 was considered significant. The log10 of HIV viral 
load measurements and Fc polyfunctionality scores are shown on the y- and x-axes, respectively. 
 









































When assessing which particular individuals maintained high overall Fc polyfunctionality scores 
across all the 3 time points (sum of all individual Fc effector functions), 15.1% (8/53) of the 
participants had quality polyfunctionality. Additionally, 20.75% (11/53) individuals maintained 
high polyfunctionality at 3- and 12-months PI before these responses waned off by 48 months PI. 
Another 7.5% (4/53) individuals exhibited Fc polyfunctionality at 12 months PI and maintained 
these quality responses up to 48 months PI. In conclusion, high Fc polyfunctionality was rare in 
the cohort, and only 15.1% (8/53) of the study participants maintained these quality responses 
throughout the follow up period.    
 
5.4: Antibody neutralisation function (Fab-mediated function) 
 
5.4.1: Analysis of broadly neutralising function scores 
 
 
Antibody neutralisation function was determined as described in chapter 2, section 10. From the 
raw data, the neutralising ability was defined using a previously reported approach [117] whereby, 
a neutralisation score is calculated based on the weighted average of log-transformed 50% 
neutralisation endpoint dilutions (IC50) across the pseudoviruses tested. In this case, a panel of 6 
pseudoviruses, which were representative of a larger 105-virus panel [333] was used against 
plasma samples taken at 48 months PI and each individual got a neutralisation score accounting 
for breadth and potency. 
 
Plasma breadth was accounted for by the number of pseudoviruses neutralised, while the potency 
was determined by the concentration of plasma required to neutralise the pseudoviruses. Presence 
of neutralising ability was defined as 50% inhibition of TZMbl cell line infection by an HIV 
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pseudovirus.  A neutralisation score of ≥1 predicted ≥50% breadth on the larger panel. Scores of 
0, 0 < 0.5, 0.5 <1 predicted 0%, 0.1-19.9%, 20-49.9% breadth respectively.   
 
5.4.2: Validating the broadly neutralising antibody assay 
 
Monoclonal antibodies VRC01 (targeting CD4 binding site), F105 (targeting CD4 binding site), 
PGT121 (targeting the V3 glycan), PGDM1400 (targeting the V2 glycan), PGT151 (targeting CD4 
binding site and the fusion peptide) and 10E8 (targeting the membrane-proximal external region) 
were used as positive controls in this study. The negative control antibody used was the anti-
dengue NS1 IgG1, (DEN3.) These control antibodies were initially tested/validated for their ability 














Table 5.4: The neutralising ability of the control monoclonal antibodies against the 6-pseudovirus 

















Den3 0.611 0.141 3.664 21.410 0.012 0.195 0.031 1.048 
F105 8.367 2.428 0.002   0.001 2.340 1.070 
VRC01 0.011 0.010 0.003 0.011 0.008 0.003 0.001 2.569 
PGT121 0.034 2.500 ~ 9.5e-006 0.001 ~ 4.0e-008 0.435 0.051 0.462 
PGDM1400 0.01166 ~4.1e-008 6.27 0.001 0.003 0.001 0.004 0.832 
PGT151 0.066 0.088 2.2e-05 0.001 ~ 2.3e-008 ~ 145817 0.019  
10E8 0.9 0.057 3.584 0.115 0.028 0.007 0.001 ~ 187 
 
The table shows monoclonal antibodies tested against the pseudoviruses. The 50% inhibitory dose (ID50) 
concentrations of VRC01, F105, PGT121, PGDM1400, Den3, PG151 and 10E8 required to neutralise 
94UG103 (A), 92TH021 (AE), 92BR020 (B), JRCSF (B), IAVIC22 (C) and 93IN905 (C) pseudoviruses 
are shown in the cells. The lower the ID50 value, the more potent the monoclonal antibody is, but this has 
to be confirmed with the dose-response curve illustrated in Figure 5.14. Blank cells represent analyses 
where the ID50 values could not be computed on Pad Prism. Test; nonlinear regression- inhibitor versus 

















































Figure 5:14: The neutralisation curves of the monoclonal antibodies used in the assay validation. The 
neutralisation curves for the of monoclonal antibodies VRC01, F105, PGT121, PGT151, PGDM1400, 
PG151 and 10E8 upon running the assay are shown. Each curve is colour coded to represent the 
pseudoviruses 94UG103 (A), 92TH021 (AE), 92BR020 (B), JRCSF (B), IAVIC22 (C), 93IN905 (C), MN 
(B) and MLV and is shown in the provided key. As expected, all curves but the black one (MLV 
pseudovirus) showed a dose-response effect, denoting successful neutralisation. Similarly, Den 3 failed to 
neutralise any of the pseudoviruses. The y-axis represents neutralisation breadth, while the x-axis represents 
control antibodies concentrations. Each monoclonal antibody is labelled at the top of its graph. Test; 
nonlinear regression- inhibitor versus response (3 parameters). GraphPad Prism 7 (GraphPad Software, San 
Diego, CA, USA) was used to analyse the data. 





















































































































































5.4.3: Development of broadly neutralising antibody responses in chronic HIV 
 
After running the initial assay set up to validate the neutralising ability of the monoclonal 
antibodies, the plasma samples were run together with the monoclonal antibodies to determine the 
neutralisation breadth of each plasma sample. As expected, the broad and potent monoclonal 
antibodies were able to neutralise all the 6 pseudoviruses in the panel but not the MLV pseudovirus 
(Table 5.5 and Figure 5.15). Furthermore, these monoclonal antibodies displayed high potency 
with very low concentrations required to achieve 50% breadth. Also, and as expected, the negative 
control antibody Den 3 failed to neutralise any of the pseudoviruses tested. 
 
Table 5.5: Neutralising ability of the control monoclonal antibodies against the 6 pseudovirus 













MN (B) MLV 
 
Den3   1.661 18.77 0.020 0.087   
F105   25.49 13446  0.114 9.688  
VRC01 0.012 0.0124 0.004 0.011 0.011 0.004 0.001  
PGT121 0.034 45.04 0.001 0.001 0.001 0.562 6.302  
PGDM1400 0.007 0.001 120.1 0.001 131 0.002 64.67  
PGT151 0.011 4.316 0.001 0.001 0.001 117.9 0.560  
10E8 0.691 0.098 1.615 0.195 0.017 0.007 0.001 143.8 
 
The 50% inhibitory dose (ID50) concentrations of monoclonal antibodies VRC01, F105, PGT121, 
PGDM1400, Den3, PG151 and 10E8 required to neutralise 94UG103 (A), 92TH021 (AE), 92BR020 (B), 
JRCSF (B), IAVIC22 (C) and 93IN905 (C) during the assay. As expected, all the monoclonal antibodies 
neutralised the MN clade B virus, which is a tier 1 pseudovirus. In contrast, none of the control antibodies 
was able to neutralise the Murine retrovirus (MLV) pseudovirus. All values presented in the table are 
neutralisation titres [50% inhibitory dose (ID50)]. The lower the value, the more potent the monoclonal is, 
but this has to be confirmed with the dose-response curve illustrated in Figure 5.15. HIV clades are indicated 
in brackets on the top row. Blank cells represent analyses where the ID50 values could not be computed on 
GraphPad Prism7. Test; nonlinear regression- inhibitor versus response (3 parameters). GraphPad Prism 7 






















Figure 5:15: The neutralisation curves for the control monoclonal antibodies used in the experiments. The 
neutralisation curves for the of monoclonal antibodies VRC01, F105, PGT121, PGT151, PGDM1400, 
PG151 and 10E8 upon running the assay. Each curve is colour coded to represent the pseudoviruses 
94UG103 (A), 92TH021 (AE), 92BR020 (B), JRCSF (B), IAVIC22 (C), 93IN905 (C), MN (B) and MLV 
and are shown in the provided key. As expected, all curves but the black one (MLV pseudovirus) showed 
a dose-response effect, denoting successful neutralisation. Likewise, Den 3 failed to neutralise any of the 
pseudoviruses. The y-axis represents neutralisation breadth while the x-axis represents control antibodies 
concentrations. Each monoclonal antibody is labelled at the top of its graph. Test; nonlinear regression- 






















































































































































On assessing the 53 plasma samples, neutralising breadth was found to be rare in this cohort. This 
is consistent with the literature, where the development of breadth has been shown to be rare and 
to develop later on in HIV infection [313]. 
 
Only 28.3% (15/53) of the study individuals had breadth > 0% (neutralising any of the 6 
pseudoviruses). Of the 15 individuals who could neutralise any pseudovirus, only 33.3% (5/15) of 
participants had a score >1 (>50% breadth/ neutralised more than 3 of the viruses). Another 26.7% 
(4/15) of the study individuals displayed moderate breadth (score ≥0.5 and <1) while 26.7% (4/15) 
of the study individuals showed low neutralisation breadth (0 < score < 0.5). A majority of study 
participants, 71.2%, (38/53) displayed no breadth on the 6-virus panel (Figure 5.16, 5.17 and 


















The 50% inhibitory concentration (IC50) values for 94UG103 (A), 92TH021 (AE), 92BR020 (B), JRCSF (B), 
IAVIC22 (C), 93IN905 (C), MN (B) and MLV are shown on the left side of the figure. The higher the IC50 
value, the more potent the plasma sample is, but this has to be confirmed with a dose-response curve illustrated 
in Figure 5.14. On the right are the calculated neutralisation scores against the 6 HIV pseudoviruses tested. 
Breadth was accounted for by the number of pseudoviruses neutralised, while potency was determined by the 
concentration of plasma required to neutralise the pseudovirus. Overall neutralising ability was defined by 
establishing a neutralisation score based on the weighted average of log-transformed 50% neutralisation endpoint 
dilutions (IC50) across the pseudoviruses tested. The higher the score, the higher the breadth and potency of 
neutralisation. The left-most column represents study participants while the right-most column represents 
neutralisation breadth scores based on the 6 pseudoviruses panel (6vP). The top row represents the pseudoviruses 
used in the assay. Test; nonlinear regression- inhibitor versus response (3 parameters). GraphPad Prism 7 
(GraphPad Software, San Diego, CA, USA) was used to analyse the data. 





















Plasma samples from HIV infected individuals collected at 48 months PI were tested for neutralising ability 
on a 6-virus panel. Neutralisation scores were calculated as outlined in section 5.4.1. The key represents 
neutralisation scores and its colour coded with the provided key. Test; the fraction of total on GraphPad 













Figure 5:17: The proportions of individuals with and without neutralisation breath. 
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A closer look at examples of neutralisation curves plotted as breadth versus concentration for the 
monoclonal antibody VRC01, and representative neutralisation curves plotted as breadth versus 
































The neutralisation curves for the broad and potent VRC01 antibody and plasma samples from a neutraliser 
(X86) and a non-neutraliser (X33). All the pseudoviruses are colour-coded and shown in the key. Each 
neutralisation curve is also colour-coded matching pseudoviruses. The y-axis represents breadth while the 
x-axis for the monoclonal VRC01 represents concentration, while the x-axis for the representative samples 
represent dilutions. Test; nonlinear regression- inhibitor versus response (3 parameters). GraphPad Prism 7 





Figure 5:18: The neutralisation curves of plasma samples tested for breadth development. 
Key - Pseudoviruses 
Dilution 
Concentration 
















5.4.4: The proportion of individuals neutralising pseudoviruses from a specific clade 
 
Although this cohort was primarily infected with HIV clade A as described in chapter 2 section 1, 
most of the neutralisers showed some neutralisation activity against viruses from HIV clade C 
(IAVIIC22 and 93IN905). The pseudoviruses IAVIC22 was neutralised by 46.7% (7/15), while 
93IN905 was neutralised by 26.7% (4/15) of the neutralisers. The other remaining 4 pseudoviruses 




Figure 5:19: The proportion of individuals neutralising pseudoviruses from specific HIV clades. Plasma 
from HIV infected participants collected at 48 months PI was tested for neutralising ability on a 6-virus 
panel. HIV subtype C pseudoviruses were most commonly neutralised. The x-axis represents the 
pseudoviruses while the y-axis represents the number of neutralisers. GraphPad Prism 7 (GraphPad 


















































5.5: Associations between Fab- and Fc-mediated antibody functions 
 
 
Previous studies have suggested that there is a mechanistic link between the Fc and Fab of antibody 
functions as these are intrinsically linked within the GCs by mechanisms that use similar cytokines 
and enzymes. Germinal centres are important as antibodies undergo both class switching and 
somatic hypermutation that enhance Fc- and Fab-mediated functions, respectively in these 
environments.  
 
Associations between all the Fc-mediated functions tested at the three time points with breadth 
development at 48 months PI were done. Only ADCD function at 3 months PI negatively 
correlated with breadth at 48 months PI, rho= -0.3175, p=0.0205 (Figure 5.20). This finding may 
suggest that robust complement activity in early HIV infection may reduce viremia, which the 
development of breadth relies upon, as suggested in other studies. Alternatively, high ADCD 
activity, which is mostly modulated by IgM, could suggest poor class switching which may 
translate to poor GC reaction. Thus, development of breadth would be delayed, or in part, 
inexistent. However, ADCD function did not negatively correlate with HIV viremia at any time 




























Figure 5:20: The correlation between ADCD and neutralisation breadth. Antibody-dependent complement 
deposition at 3 months post-HIV infection negatively correlated with neutralisation breadth at 48 months 
PI. Significance was defined by p <0.05. Test; non-parametric Spearman’s correlation. PI; post-HIV 
infection. 
 
5.5: Associations between Fab- and Fc-mediated antibody functions in 
individuals with any level of breadth 
 
Since a large proportion of individuals showed no neutralising activity (breadth of > 0%), 
association analysis between Fc effector and Fab-mediated functions was restricted to individuals 
who showed any level of breadth, n=15. At both 3 months PI and 12 months PI, ADCP function 
positively correlated with breadth development at 48 months PI, rho=0.6963, p= 0.005 and rho= 




















Rho= -0.3175  
p=0.0205 







0.6095, p= 0.018 respectively (Figure 5.21, A and B). This may suggest that quality ADCP 
function in early HIV infection may be a proxy of neutralisation breadth development. 
 
On the other hand, HIV viral load measurements at 3 months PI negatively correlated with the 
neutralisation breadth at 48 months PI, rho= -0.6788, p= 0.0066 (Figure 5.21, C). This may imply 
that, in the setting of high viremia in early HIV infection, an HIV infected individual may fail to 
select for B cells that may further develop breadth, probably due to destruction of the immune 
system by HIV. All of the other parameters assessed in the neutralisers had no significant 















Figure 5:21: Associations between neutralisation breadth with ADCP and HIV viral load measurements. 
(A and B) Antibody-dependant cellular phagocytosis at 3- and 12 months PI positively correlated with 
neutralisation breadth at 48 months PI, respectively. (C) Contrariwise, the significant negative association 
between HIV viral load measurements at 3 months PI with neutralisation breadth, at 48 months PI was 
observed. Spearman’s correlation rho values were defined by p <0.05 for significance. PI; post-HIV 













This study had the advantage of using antiretroviral treatment (ART) naïve plasma samples that 
were longitudinally sampled as early as 3 months PI. Similar to previous studies in adult cohorts, 
Fc-mediated antibody function in HIV infection was readily detectable in plasma 3 months PI 
[134, 334]. Furthermore, and consistent with the literature [134], the response levels of ADCD, 
ADNP and ADNK increased over time. However, despite earlier reports of a consistently high 
level of ADCP activity over time [134], this study shows that ADCP activity gradually increases 
after infection, peaking at 12 months PI, before a slight reduction at 48 months PI.  
 
Other studies have also reported conflicting findings. For instance, it was reported that HIV-
specific ADCP activity increases significantly in the course of HIV infection [334]. Other studies 
reported a decline in ADCP activity as HIV disease progressed [335, 336] and this decline was 
associated with either the levels of CD4+ T cell counts or HIV viral load or decreased Fc-receptor 
expression on innate immune cells. Antibody-dependent cellular cytotoxicity has also been shown 
to peak at 6 months and later on decay as HIV progressed [337]. This finding is probably backed 
up by the RV144 trial, where ADCC activity decayed [240].  
 
Nevertheless, Baum and others reported an increasing ADCC titre over time in HIV infection, 
suggesting an increase of ADCC activity over time [143]. While we have differences in findings 
on the kinetics of Fc responses in HIV, it is clear that these responses are generated earlier on in 
infection. It is plausible that the differences in the kinetics may be due to the lack of a standardised 
assay in different laboratories. 
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Since the increase in activity of ADNP and ADNK could partly be explained by increasing titres 
of IgG subclasses [134, 143], it was not clear why ADCD function significantly increased over 
time since IgM mediates it. Previous work showed that IgM effectively activates complement due 
to its pentameric structure [338, 339]. Since it has well been documented that IgM is the first 
antibody to be detected following HIV infection [15], its increasing activity via ADCD function 
at 48 months PI is not apparent. However, it is feasible that due to the constant mutation and 
immune escape by HIV, any new mutant viruses during chronic HIV infection may be processed 
as a “new infection” at the GCs, prompting the generation of IgM antibodies that continuously 
mediate complement even during chronic infection.  
 
Nevertheless, the increase in Fc activity was supported by the trend of increasing proportions of 
the number of individuals with high individual Fc function over time. The increase in Fc activity 
may suggest that the length of infection may play a role in driving better Fc function. Only ADCP 
at 3 months PI negatively correlated with viral load measurements at 3 months PI. Monocytes are 
targets of HIV infection [340], and they enhance viral replication in HIV and are dysregulated 
[341], and this may interfere with their recruitment by antibodies. Consistent with literature [342], 
data here shows that ADCP activity may play a role in viremia control.  
 
It is thought that if different Fc effector functions offer a coordinated immune response, an HIV 
infected individual may better control viremia. For instance, elite controllers displayed a more 
functionally coordinated innate immune-recruiting response involving natural killer cell functions, 
monocyte and neutrophil phagocytosis, and complement [146]. Additionally, individuals who 
failed to generate bnAbs were shown to have significant discordance between Fc effector functions 
in early HIV infection, suggesting that concordance in Fc responses may be a signature for bnAbs 
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development [134]. This study showed significant correlations between Fc responses suggesting a 
functionally well-coordinated response. Furthermore, by calculating Fc polyfunctionality scores, 
Richardson and others showed that individuals with high Fc polyfunctionality seemed to have 
intact immune systems that would later lead to bnAbs development [134]. Moreover, Fc 
polyfunctionality has been implicated in the induction of multiple Fc functions simultaneously in 
elite controllers [146]. Similarly, high and well-coordinated Fc polyfunctionality responses 
targeting the V2 loop epitopes may have provided vaccine efficacy observed in RV144 and not 
VAX003 vaccine trial [343].  
 
Of the 53 study participants, only 35.8% (19/53), 30.2% (16/53) and 41.5% (22/53) exhibited high 
Fc polyfunctionality at approximately 3 months, 12 months and 48 months PI respectively. While 
Fc polyfunctionality has not been studied in-depth, it has been directly linked with the development 
of breadth [134] and with elite controllers [146]. Since both bnAbs generation and the ability to be 
an elite controller is rare, this may explain why Fc polyfunctionality is rare, since all the three are 
closely associated.  
 
Moreover, data shows that individuals who make these quality Fc-mediated responses in acute 
HIV tend to make them as the disease progresses. This may suggest that early priming of Fc 
responses may be vital in maintaining them in the course of HIV. Interestingly, similar to the 
increase of individual Fc responses over time, Fc polyfunctionality activity increased with time. 
While there was a slight drop in the proportions of those with high polyfunctionality at 12 months 
PI, these quality responses increased at 48 months PI, implying that length of infection plays a 
role. Indeed, a higher proportion of individuals, 15.1% (8/53), exhibited high polyfunctionality at 
48 months PI. 
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Nevertheless, individuals with high Fc polyfunctionality had similar median viral loads to those 
with low polyfunctionality, indicating that viremia may not play a role in driving such robust 
responses. Indeed, Fc polyfunctionality at 3 months PI negatively correlated with viral load 
measurements at 12 months PI, suggesting that in the presence of high Fc polyfunctionality, 
viremia is more likely to be low. Nevertheless, individuals with low Fc polyfunctionality had 
significantly higher CD4+ T cell counts than those with high Fc polyfunctionality at 48 months 
PI, implying that HIV viremia is necessary for driving high Fc polyfunctionality. However, at the 
other two time points, participants with low Fc polyfunctionality did not preserve CD4+ T cell 
counts as compared to individuals exhibiting high Fc polyfunctionality.  From the results, it was 
concluded that Fc polyfunctionality is rare and may be influenced by the length of HIV disease. 
 
Similarly, data indicated that the evolution of bnAbs is rare. Indeed, only 10-20% of HIV infected 
individuals develop bnAbs, albeit after 2 – 4 years of infection [159, 313].  
This study investigated the development of bnAbs responses against HIV approximately 48 
months after HIV infection and showed similar results that the development of breadth was rare 
as previous studies [159, 313].  
 
Interestingly, subtype C pseudoviruses were more readily neutralised despite most participants 
having been infected with HIV subtype A.  While this could be as a result of the cross-reactive 
nature of bnAbs, HIV subtype C virus has been associated with the development of bnAbs [159], 
and that, may in part, explain its neutralisation. However, since not everyone infected with subtype 
C virus develops bnAbs, there must be another explanation for this. 
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Unlike previous studies [313, 344, 345], no association was observed between antibody 
neutralisation function and viral load or CD4 counts. Only a small number of the cohort 
participants generated any neutralisation breadth in the follow-up period. It is therefore highly 
likely that the small sample size negated the possibility of performing any meaningful statistical 
associations.   
 
Notably, none of the Fc-mediated functions tested had significant associations with breadth except 
ADCD function. This may infer that quality complement activity 3 months post PI  may reduce 
viremia in early HIV infection, thus eliminating one of the crucial drivers of bnAbs development 
[159]. Although the lack of strong associations between bnAbs and Fc-mediated responses, trends 
of positive associations were evident and probably with a larger cohort with more individuals 
generating neutralisation breadth significance may be attained. This further emphasizes that both 
Fc and Fab are intrinsically linked and modulated distinctly in the GCs reaction, similar to previous 
suggestions [134].  
 
However, when only the subset of participants who developed any level of neutralisation was 
considered, and associated with CD4+ T cell counts, viral load measurements and Fc-mediated 
functions, ADCP function at 3- and 12- months PI significantly predicted the development of 
breadth. This strongly suggests that the quality ADCP function in early HIV infection may be a 
driver of the development of bnAbs, most likely through the preservation of CD4 cells through 
control of viremia. Indeed, ADCP at 3 months PI negatively correlated with viral load 
measurements at 3 months PI implicating its role in the control of viremia in the whole cohort 




In summary, this chapter reports: 
• Fc-mediated functions were readily detected in all individuals as early as 3 months PI, 
unlike Fab-mediated function, which was only detected in a few individuals and late in 
HIV infection.  
• ADCP function at 3- and 12- months PI significantly predicted the development of breadth, 
implying that early ADCP activity may be a driver or a signature of bnAbs development. 
• Fc polyfunctionality in early HIV infection negatively correlated with viral load 
measurements, suggesting a role of Fc polyfunctionality in controlling HIV viremia.  
 
Nevertheless, more studies will be required to understand the link between Fc and Fab functions 






















Chapter 6  Early immunological events associated 













































6.1: Literature review 
 
Despite the human immunodeficiency virus (HIV) -specific Fab- and Fc-mediated antibody 
functions being mostly studied in HIV infected adults, little is known about the cellular 
mechanisms involved in the generation of these antibody functions. Generally, it is accepted that 
most current vaccines rely on long-lasting protective antibodies that are present in serum or on the 
mucosa [346], and eliciting such an antibody-based HIV vaccine may confer protection. T 
follicular helper (Tfh) cells are CD4+ T cells specialised in providing help to B cells to enable B 
cell differentiation into affinity-matured long-lived plasma cells and memory B cells. Tfh cells are 
critical for affinity-maturation, a process where antigen-specific B cells undergo several rounds of 
somatic hypermutation in the germinal centres (GCs) to evolve high-affinity somatically mutated 
B cell receptors (BCRs) [75]. Additionally, Tfh cells are critical for antibody class switching [174], 
a process that enables antibodies to trigger various Fc-mediated activities depending on their 
isotypes [146, 347-349].  
 
Due to this critical role of both Tfh and B cells in the generation of functional antibodies, 
understanding their interactions in early HIV infection remains essential. Indeed, Tfh cells have 
been linked with the generation of broadly neutralising antibodies (bnAbs) in HIV infection [225, 
350], and antibody quantities may play a role in determining functionality. In HIV infection, high 
overall plasma immunoglobulin (Ig) G levels and anti- Envelope (Env) IgG binding titres were 
associated with the development of breadth in a large International Acquired Immunodeficiency 
Syndrome (AIDS) Vaccine Initiative (IAVI) protocol C cohort [159], suggesting an increased GCs 
activity may favour both. While both Fab and Fc regions of the antibody are encoded by different 
genes [195], recent findings show that they may be jointly regulated as they are mechanistically 
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linked in the GCs [134]. Perhaps more convincing is that both class-switch recombination and 
somatic hypermutation require the enzyme activation-induced cytidine deaminase to enable 
transcription and deoxyribonucleic acid (DNA) cleavage, respectively [351]. 
 
Moreover, since the constant region can slightly affect the antibody’s Fab function [352, 353], 
both Fab and Fc regions could be dependent on each other. As GCs are not easily accessible in 
human studies due to surgical and ethical restrictions, the chemokines CXCL13 and B cell 
activating factor (BAFF) in plasma may present a good proxy of GCs activity and can be evaluated 
to inform the interaction between Tfh and B cells in the GCs [96, 212, 213]. This helps create a 
better understanding of critical GCs immunological processes in disease. 
 
In this objective, I explored the association between the frequencies of general and HIV-specific 
B and T cells and the downstream antibody levels and functions. Also, I investigated whether the 
chemokines BAFF and CXCL13, proxies of GCs activities, were associated to the observed T and 
B cell frequencies early in infection. Both HIV-specific and general T and B cell subsets were 
associated with CXCL13 and BAFF plasma levels, HIV-specific Fab- and Fc-mediated antibody 
functions and HIV-specific antibody levels.  
 
As numerous antigens had been used to determine HIV-specific antibody levels in the Luminex 
assay, I used data from the BG505 SOSIP clade A immunogen as the representative antigen as 
antibody levels to the different antigens showed similar trends (Chapter 4, subsection 3.1). Data 
from B and T cell phenotypes, BAFF and CXCL13 levels that were determined during early HIV 
infection (3 months post HIV-infection-PI) were associated with HIV-specific IgG, IgA1, IgA2 
and IgM levels and subclasses IgG1, IgG2, IgG3 and IgG4 and non-neutralising function determined 
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at 3-, 12- and 48-months PI and antibody neutralisation breadth determined at 48 months PI, as 
described in the previous chapters.  
 
Previous studies have associated general Tfh cell subset frequencies with the quality of antibody 
responses; or where antigen-specific subsets were determined, a cross-sectional approach was 
used. The current study offers additional important information to the field by associating HIV-
specific T and B cell subsets and downstream antibody function. It is likely that cellular events 
much earlier in the disease maybe more reflective of observed antibody properties and functions 
at a particular time point. Using a longitudinal study is therefore more informative.  
 
I, therefore, hypothesised that the frequencies of HIV-specific Tfh and B cells in acute/early HIV 
infection would be good predictors of the quality of antibody responses that are observed 




To establish the association of early T and B cell subset frequencies with GCs activities, Fab- and 




6.3.1: Associations of general and HIV-specific CD4+ T cell phenotypes early in HIV 
infection with downstream GCs activities, antibody levels and functions 
 
 
Antibody levels and functions were associated with general CD4+ T cell frequencies. Fc-mediated 
functions increased with higher general CD4+ T cell frequencies, while HIV-specific antibodies 
decreased. Only IgG1 levels at 48 months post-HIV infection (PI) showed significant decrease with 
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increasing general CD4+ T cell frequencies with (Table 6.1). Antigen experienced CD4+ T cells, 
defined as CD27+ CCR7+ CD4+ were then considered, this subset positively associated with IgG 
and IgA2 levels at 48 months PI and negatively associated with antibody-dependent natural killer 
cell function, marked by  secretion (ADNK - IFN-γ) at 48 months PI and by the expression of 
macrophage inflammatory protein-1α  (ADNK - MIP-1α) at 3 months PI. 
 
Association of the subset CD45RA- CXCR5+ CD4+, which is representative of the memory Tfh 
cells which are more specific for offering B cell help was then considered. A significant positive 
association was observed with IgG antibody levels at 3 months PI, IgG and IgG1 antibody levels 
at 12 months PI and with IgA and IgG1 antibody levels at 48 months PI. Within the memory Tfh 
cells, PD-1+ CXCR3- CXCR5+ CD4+ cells are representative of activated Tfh cells, which have 
been reported to be associated with the development of breadth in HIV infection [225]. This subset 
of cells was found to be associated with antibody-dependent neutrophil phagocytosis (ADNP), IgG 
and IgG1 levels at 3 months PI and negatively with IgG2 and IgG4 levels at 12 months PI. The 
subset ICOS+ PD-1+ CXCR5+ CD4+, which is representative of activated Tfh cells, was also 
found to be associated with IgG levels at 3 months PI and with IgM levels at 48 months PI. 
 
When HIV-specific Tfh cells were considered, an increase in frequency was observed with higher 
antibody levels and Fc mediated functions and a significant association was observed for the Fc-
mediated function, ADNK - IFN-γ release at 3 months PI. Germinal centre activities marked by 





Table 6.1: Associations between CD4+ T cell subsets at 3 months PI with HIV-specific antibody 
levels and functions at 3-,12- and 48 months PI. 
CD4+ subsets measured at 3 
months post-infection 
Antibody subclass 
or function  
showing 
association to  
CD4+ T cell subset 
Time post-infection 






General CD4+ IgG1 48 -0.3399 0.0147 
 
CD27+ CCR7+ CD4+ 
(Central memory T cells) 
 
IFN-γ 48 -0.2885 0.0401 
ADNKMIP-1α 3 -0.2882 0.0403 
IgA2 48 0.3407 0.0144 
IgG 48 0.365 0.0084 
 
CD45RA- CXCR5+ CD4+  
(Memory Tfh cells) 
IgA 48 0.2768 0.0493 
IgG 3 0.3115 0.0310 
IgG 12 0.3210 0.0216 
IgG1 12 0.3073 0.0283 
IgG1 48 0.3100 0.0268 
 
 
PD-1+ CXCR3- CXCR5+ 
CD4+  
(Activated Tfh cell subset) 
ADNP 3 0.2900 0.0380 
IgG 3 0.3034 0.0304 
IgG2 12 -0.2959 0.0350 
IgG4 12 -0.3067 0.0286 
ICOS+ PD-1+ CXCR5+ 
CD4+  
(Activated Tfh cell subset) 
IgM 48 0.3207 0.0230 
IgG 3 0.3135 0.0251 
OX40+ CD25+ CXCR5+ 
CD4+  
(HIV-specific Tfh cells) 
ADNKIFN-γ 3 0.3314 0.0175 
 
T cell subsets at 3 months post-HIV infection (PI) were associated with HIV-specific antibody levels and 
functions at 3-, 12- and 48 months PI. Spearman’s rho values and their associated p-values are shown in 
the cells. Only associations with p values <0.05 are presented. PI – post HIV infection. ADNP - antibody-
dependent neutrophil phagocytosis; ADNKIFN-γ - antibody-dependent natural killer cell (ADNK) - 








6.3.2: Associations of general and HIV-specific B cell phenotypes early in HIV 
infection with downstream antibody levels and functions 
 
Apart from dysregulating the T cell compartment, HIV infection has also been shown to cause 
dysregulation and dysfunction of other lymphocyte populations, including B cell subsets [354, 
355]. To understand how these changes in the B cell compartment may influence downstream 
antibody levels and functions, B cell subsets in early HIV infection (3 months PI) were associated 
with GCs activities (based on the B cell activating factor (BAFF)) and CXCL13 levels as proxies) 
and antibody levels and functions at 3-, 12- and 48 months PI. 
 
Associations of  mature B cell (CD10- CD19+) frequencies with BAFF and CXCL13 as proxies 
of GC activity and with antibody functions showed an increase in B cells subsets with increasing 
antibody function with only the antibody-dependent cellular phagocytosis (ADCP) and IFN-γ 
functions at 3 months PI (Table 6.2) being significantly associated.  
 
When the antigen-experienced class-switched B cells (CD10- CD19+ CD20+ IgG+) were 
considered, higher frequencies were observed with reducing Fc-mediated antibody function. The 
negative association was significant for ADCP function at 48 months PI. A positive association of 
atypical B cells (CD10- CD19+ CD21- CD27-), which proliferate poorly in response to B cell 
stimuli [356], with IgA1 levels was observed at 12 months PI and with IgG2 levels at 48 months 
PI. Naïve B cells (CD10- CD19+ CD21+ CD27-) were negatively associated with the levels of 
IgM, IgG1 and IgG3 at 3 months PI, IgG3 at 12 months PI and IgG4 at 48 months PI.  
 
Activated B cells (CD10- CD19+ CD21- CD27+ ), which are the subset that migrates into the B 
cell follicles to undergo proliferation and selection and thereby exit as memory B cells or plasma 
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cells [218], showed positive correlations with CXCL13, IgG1, IgG2 and IgG3 levels at 3 months 
PI, IgG levels at 12 months PI and IgG4 levels at 3- and 12-months PI.  
 
Resting memory B cells (CD10- CD19+ CD21+ CD27+), a subset that is often decreased in HIV, 
showed inverse associations with antibody-dependent neutrophil phagocytosis (ADNP) at 3 
months PI, antibody-dependent complement deposition (ADCD) at 12- and 48-months PI and 
CXCL13 and IgG2 levels at 48 months PI.  
 
HIV-specific B cells (CD10- CD19+ CD20+ IgG+ gp120+), the cells that would be responsible 
for HIV-specific antibody generation, were considered, direct associations with IgA1, IgG, IgG2, 
IgG3, levels at 3 months PI and IgG3 levels at 48 months PI were observed. When their association 
with antibody function was considered, participants with higher frequencies tended to have lower 
















Table 6.2: Associations between various B cell subsets at 3 months PI with GC activities, antibody levels and 
functions at 3-,12- and 48 months PI. 
B cell phenotypes determine 
early in infection (3 months) 
Antibody subclass or 
function showing 
association to B cell 
subsets  
Time post-infection when the 
association is observed 
(months PI) 
Spearman’s rho value p-value 
CD10- CD19+                    (Mature 
B cells) 
 
ADCP  3 0.4316 0.0013 
 




CD10- CD19+ CD20+ IgG+ 
(Class switched B cells) 




CD10- CD19+ CD21- CD27-
(Atypical B cells) 
 








CD10- CD19+ CD21+ CD27- 
(Naïve B cells) 
 








IgG3  3, 12 * -0.271, -0.3105  
 
0.0496, 0.021  
 




CD10- CD19+ CD21- CD27+      
(Activated B cells) 
 
CXCL13  3 0.38 0.0062 
 




















IgG4  3, 48 * 0.3261, 0.2892  0.0172, 0.0357  
 
CD10- CD19+ CD21+ CD27+  
(Resting B cells) 
 




















CD10- CD19+ CD20+ IgG+ 
gp120++                                 (HIV-
specific B cells) 
 












IgG3  3, 48 0.4014, 0.3  
 
0.0029, 0.0291  
 
B cell subsets at 3 months post-HIV infection (PI) were associated with GCs activity, antibody levels and functions at 3-
,12- and 48 months PI. Spearman’s rho values and their associated p-values are shown. Only associations with p-values 
<0.05 are presented. PI – post-HIV infection. ADCP - antibody-dependent cellular phagocytosis; ADNP - antibody-
dependent neutrophil phagocytosis; ADCD - antibody-dependent complement deposition; ADNKIFN-γ - antibody-dependent 
natural killer cell (ADNK) - interferon gamma secretion; * represents where more than one time point was compared and 
the resulting Spearman rho value or p value,  for each time point shown respectively. Test; Spearman’s correlation. 
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6.3.3: Associations between early B cell cytokines levels (3 months PI) with 
downstream HIV-specific antibody quantities and functions in chronic HIV infection 
 
 
Previously, CXCL13 and BAFF have been shown to be associated with GCs activity [96, 212, 
213]. In this section, I sought to establish if CXCL13 and BAFF levels determined early in the 
infection (3 months PI) were associated with antibody levels and functions at 3-,12- and 48 months 
PI. This would be an indicator of whether early GCs quality influences antibody responses during 
chronic HIV infection. 
 
There was no correlation between BAFF levels with antibody levels and functions at 3-,12- and 
48 months PI. However, direct correlations were observed for CXCL13 levels with IgA1 and IgG3 
levels at 3 months PI, IgM levels at 12 months PI and IgA2, IgG, IgG1 and IgG2 levels at 3-, 12- 
and 48 months PI (Table 6.3). It appears that CXCL13 was a better predictor of downstream 













Table 6.3: Associations between CXCL13 levels at 3 months PI with various immune correlates 
of protection at 3-,12- and 48 months PI. 
Soluble factor 
measured at 3 
months PI  
Antibody levels and 
functions associated with 
the soluble factors 
measured  
The time when 
the association is 






































IgA1  3 0.33  0.0175 
IgM  3 0.49 0.0002 
 


















































CXCL13 levels at 3 months PI was associated with antibody levels and functions at 3-,12- and 48 months 
PI. Spearman’s rho values and their associated p-values are shown. Only associations with p-values <0.05 
are presented. PI – post-HIV infection. ADNKCD107α - antibody-dependent natural killer cell (ADNK) 
CD107α expression- Test; Spearman’s correlation. 
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6.3.4: Summary matrix associating immunological parameters measured in the 
course of HIV infection: a systems approach 
 
Significant associations were shown in tables 6.1, 6.2 and 6.3. However, in order to visualise all 
possible associations (both significant and non-significant) between cellular subsets, B cell 
cytokine levels, HIV-specific antibody titres and both HIV-specific Fab- and Fc-mediated 
antibody functions in HIV infection, a correlation matrix was used. In brief, the Spearman’s 
correlation values for each association and their p-values were determined. Using the R package 
corrplot, on RStudio 1.0.143 (PBC, Boston, MA), the associations were visualised. In order to 
regroup the variables according to the level of association as described by the Spearman’s rho 
values, the correlation matrix was reordered using the “hclust” algorithm on R. (Figure 6.1). The 
symbol “x” was used to mark out all insignificant associations (p<0.05). This unbiased systems 











Figure 6:1: Heatmap depicting the hierarchical clustering of the correlation matrix showing the associations 
between all immunological variables tested during the first 48 months post-HIV infection. As per the key 
provided on the right side of the figure, red colour indicates significant strong positive correlations (rho 
>0.7), peach colour represents moderate positive correlations (0.4 < rho < 0.7), while white represents weak 
positive correlations (0 < r <0.4). The inverse correlation is represented by the purple colour that indicates 
a moderate negative correlation (-0.5 < rho < 0), while blue depicts a strong negative correlation (-1 < rho 
< 0.5). Both axes represent immunological variables tested during the first 48 months post-HIV infection. 
The symbol “x” was used to mark out all insignificant associations in the matrix where p>0.05. PI; post-




In this chapter, I assessed the association of early general and HIV-specific T and B cell subsets 
with GCs activity, HIV-specific antibody levels and functions. The general CD4+ T cells 
frequencies were negatively associated with IgG1 levels at 48 months PI. This could suggest that, 
in the setting of high viremia that is required for robust anti-HIV antibody responses [294], CD4+ 
T cells would be depleted as earlier described [22]. Similarly, CD45RA- CXCR5+ CD4+ T cells 
negatively associated with ADNKIFN-γ function and CXCL13 levels further emphasizing the role 
of HIV viremia in driving GCs activity. This could mean that while high viremia may induce 
quality GCs function leading to higher CXCL13 levels [294], this would confer quality Fc-
mediated function (ADNKIFN-γ function) since intrinsic immune factors within the GCs are 
mechanistically linked [134].  
 
Although not HIV-specific, CD45RA- CXCR5+ CD4+ T cells were associated with HIV-specific 
antibody levels. This is in line with previous observations [99, 225], where general (non HIV-
specific) Tfh cells have been reported to offer B cells help, which may lead to high titres of 
functional antibodies. The Tfh subset PD-1+ CXCR3- CXCR5+ CD4+, which is highly functional 
and has been shown to correlate with the development of bnAbs in HIV infection, was directly 
associated with ADNP function. This supports the mechanistic link of intrinsic immune factors 
(Fc and Fab functions) within the GCs. Furthermore, PD-1+ CXCR3- CXCR5+ CD4+ T cells were 
positively associated with IgG and IgG1 levels but not IgG2 and IgG4. Since PD-1+ CXCR3- 
CXCR5+ CD4+ T cells have been linked with the generation of bnAbs in HIV, it is plausible that 
it is responsible for driving IgG1 and IgG responses. Indeed, superior IgG3/IgG1 responses have 
been reported in elite controllers who demonstrated Fc polyfunctionality [146]. Thus, this finding 
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may imply that PD-1+ CXCR3- CXCR5+ CD4+ T cells that have been shown to predict the 
development of bnAbs, may also play a role in enhancing robust IgG3/IgG1 responses.  
 
Likewise, ICOS+ PD-1+ CXCR5+ CD4+ T cells, had a direct association with IgM and IgG levels, 
suggesting its role in driving antibody generation. Indeed, ICOS+ CXCR5+ CD4+ T cell 
frequencies have been linked with the production of hepatitis C virus-specific antibodies [357], 
while CXCR5+ PD-1+ CD4+ T cells are critical for the development of bnAbs in HIV infected 
subjects [99]. Additionally, the frequencies of CD4+ CXCR5+ PD-1+ Tfh cells have been shown 
to negatively associate with CD4+ T cell counts in HIV infected individuals [358], implying that 
high viremia that drives low CD4+ T cell counts, is vital in driving high antibody levels through 
enhanced GCs activity. 
 
The alteration in the CD4+ T cell compartment due to HIV direct and indirect effects [220] also 
influenced other antibody responses. For instance, CD27+ CCR7+ CD4+ T cells negatively 
correlated with ADNKIFN-γ and ADNKMIP-1α activities but were positively associated with IgA2 and 
IgG levels. This may suggest that the preservation of CD27+ CCR7+ CD4+ T cells may be 
necessary for higher antibody titres.  
 
The direct correlation between the frequencies of mature B cells with ADNKIFN-γ and ADCP 
function suggests that a larger repertoire of B cells influences the pool from which HIV antigen-
specific B cells are selected from, and thus enhancing Fc-mediated functions. However, it is not 
clear why the class-switched B cells negatively correlated with ADCP function, since, antibody 
class switching enhances Fc-mediated functions depending on the isotypes [146, 347-349]. 
Nevertheless, since HIV disrupts the B cell compartment [354, 355], different B cell subsets had 
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dissimilar associations with antibody levels and functions. For instance, activated B cells had 
positive associations with antibody levels. This is consistent with reports that activated B cells 
initiate the GCs reaction, before exiting the B cell follicles as memory B cells or plasma cells to 
generate antibodies [119]. Moreover, activation of B cells in the first year of HIV infection has 
been reported to correlate with bnAbs development in chronic disease [99], highlighting the role 
of activated B cells in HIV disease.  
 
Resting memory and naïve B cells were negatively associated with antibody levels suggesting that 
HIV viremia may drive the activation of resting memory and naive B cells resulting in a decrease 
of their frequencies with higher viremia. Furthermore, resting B cells were negatively associated 
with CXCL13 levels, highlighting the role of viremia in activating B cells and driving GCs 
activities.  
 
Atypical B cells were positively associated with HIV-specific antibodies. HIV responses may be 
primarily from these population of cells (CD21lo/CD27− B cells), which are expanded during 
chronic infection. However atypical B cells are known to putatively express the inhibitory receptor 
FCRL4 [359], which has decreased responses to B cell stimuli [360]. It is therefore possible that 
the relationship is not causal and may be reflective on an environment with high viremia, which is 
associated with high antibody levels and increased proportion of atypical B cells. Of importance 
is that HIV-specific B cells showed direct correlations with HIV-specific antibody levels 
emphasizing the benefit of antigen-specific phenotypes in understanding antibody function.  
 
In summary, I have shown associations between early immunological events with antibody 
responses, functions and GCs activities that develop later in HIV infection. Higher frequencies of 
general T and B cell subsets were associating with higher HIV antibody levels and showed poorer 
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association to antibody functions. When BAFF and CXCL13 levels were used as a proxy for 
germinal centre reactions, CXCL13 was better associated with downstream antibody levels than 
BAFF. Similar to the phenotypic analysis, poor associations to antibody function were observed. 
It appears that CXCL13 is a better predictor of downstream antibody levels as compared to BAFF. 
 
Several studies have addressed the relationship between early and late general T and B cell subsets 
with antibody quality in chronic infection. However, aside from evaluating general T and B cell 
subsets that are not antigen-specific, majority of the studies were cross-sectional and thereby 
reporting immunological events at a single time point. Moreover, these studies only considered 
downstream neutralising antibodies functions in HIV. 
 
For instance, despite being a longitudinal study, Cohen and others associated only the general T 
cell subsets in early HIV infection with downstream bnAbs development in chronic HIV infection 
[99]. Higher frequencies of CXCR5+ PD-1+ CD4+
 
T cells in early HIV infection correlated with 
the breadth of plasma neutralising antibody responses in chronic HIV disease. Similarly, Locci 
and others used a longitudinal cohort to assess the association between general T cell subsets with 
the development of breadth. The frequencies of circulating memory PD-1+ CXCR5+ CD4+ T cells 
correlated with the development of bnAbs [225]. While both the Locci and Cohen studies used 
general T cell subsets in longitudinal cohorts, other studies have used general T cell subsets in 
cross-sectional cohorts. 
For example, Lindquist and colleagues used lymph node samples to characterize Tfh cells in ART 
naïve and ART-treated HIV positive individuals [93]. They reported a significant expansion of 
Tfh cells in chronic HIV that was driving a perturbation of B cells differentiation leading to poor 
antibody function [93]. Likewise, Ranasinghe and colleagues reported a correlation of Gag-
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specific CD4+ T cells with antibody breadth in ART naïve HIV controllers [100]. Similarly, 
CXCR3+ CXCR5+ PD-1lo CD4+ T cells were relatively associated with the breadth of neutralising 
antibody responses in HIV controllers [361]. 
 
While these studies conclusively linked T cell subsets to bnAbs development, describing HIV-
specific cell subsets and interactions, maybe a better correlate to antibody function, as these are 
the cells that specifically drive the HIV-specific responses. Also, analysing antigen-specific cell 
subsets in early infection may be a better predictor of subsequent antibody function in chronic 
HIV, since antibody function is often reflective of cellular events that occurred much earlier in an 
infection. Furthermore, previous studies have also correlated cellular events to neutralising 
antibody function and not addressing their role in non-neutralising functions. This is despite non- 
neutralising function being the only function that was associated with protection in the one vaccine 
clinical trial that showed modest efficacy [240].  
 
The current study used an ART naïve longitudinal cohort of HIV infected individuals. 
Additionally, this study used HIV-specific subsets of B and T cells to describe HIV-specific 
antibody levels and functions later on in infection. While lymph node samples were unavailable, 
the pairing of peripheral antigen-specific cellular subsets with CXCL13 and BAFF provides useful 
information about GCs activities [96]. Additionally, associating HIV-specific cellular subsets with 
Fc-mediated functions is novel, since most studies have associated cellular responses with Fab-
mediated antibody functions and not Fc-mediated functions. Therefore, this study offers insights 
in a systems biology approach that is antigen-specific, of the interaction between HIV and the 
human immune system without ART, and the resulting outcomes.  
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While HIV-specific Tfh cells had trends of association with HIV-specific Fc- and Fab-mediated 
functions, HIV-specific B cells had direct correlations with HIV-specific antibody levels. In 
principle, these findings may suggest that both HIV-specific Tfh and B cell subsets may 
influence these functions and levels. The modest sample size limited the analysis and 
significance. It is worthwhile exploring the HIV-specific responses in larger ART naïve 

















































































The effect of the human immunodeficiency virus (HIV) on the T and B cell compartments and its 
impact on germinal centres (GCs) activities has been well characterised [119, 218, 268, 354, 362, 
363]. Specifically, HIV depletes CD4+ T cells [22] and alters the B cell compartment by increasing 
tissue-like memory B cells, activated B cells, plasmablasts and decreasing of the resting memory 
B cells [119, 217, 218, 354]. Similarly, associations between T and B cell subsets with GCs 
activities, HIV-specific antibody levels and functions have been described in HIV infection [93, 
99, 100, 217, 225, 361]. However, these studies analysed general populations without 
demonstrating the contribution of HIV-specific subsets and function to downstream antibody 
responses. Additionally, some of the studies were cross-sectional, thereby reporting 
immunological events at single time points. Moreover, only antibody neutralising function has 
been previously considered [93, 99, 100, 225], with the association to Fc-mediated functions in 
HIV not included, despite their potential role in antibody based vaccine development. This is 
despite, non- neutralising activity being the only function that so far, has shown an association 
with protection in any HIV vaccine clinical trial, albeit being modest efficacy [154]. 
 
The current study analysed HIV-specific cell subsets which may provide the true reflection of the 
association with antibody responses since these are the cells that drive the HIV-specific responses. 
In addition, I determined the Fab- and Fc-mediated antibody functions. Thus, the current project 
improves our understanding in the field by using an antiretroviral treatment (ART) naïve 
longitudinally followed cohort to describe HIV-specific T and B cell subsets and to associate these 
with HIV-specific Fc- and Fab-mediated antibody functions, HIV-specific antibody levels and 




In this study, peripheral blood circulating T and B cell phenotypes and B cell cytokines levels 
(CXCL13 and BAFF) were determined in early HIV infection (3 months post-HIV infection (PI)) 
and associated with GCs activity, antibody quantities and qualities at 3-,12- and 48 months PI to 
determine cellular subsets that are predictive of quality antibody responses in chronic HIV 
infection, while the overriding aim was to determine how these interactions and functions impact 
on disease outcomes. Therefore, peripheral blood circulating T and B cell phenotypes, B cell 
cytokines levels, antibody quantities and qualities were associated with the markers of HIV disease 
progression at 3-,12- and 48 months PI. Longitudinal viral load measurements and CD4+ T cell 
counts were used as proxies for disease progression and outcome. 
 
Therefore, the overall goal of this study was to understand the early cellular mechanisms involved 
in the generation of functionally relevant antibodies in chronic HIV infection. In particular, I aimed 
to:  
 
1. To characterize peripheral blood HIV-specific T and B cell subsets during early HIV 
infection. 
2. To determine HIV-specific antibody levels, isotypes and subclasses during HIV infection 
and as a proxy of germinal centre activity, determine the plasma levels of BAFF and 
CXCL13 cytokines before and during HIV infection. 
3. To evaluate the quality of Fab and Fc-mediated antibody functions in the course of HIV 
infection. 
4. To establish if any of the early immunological events are associated with better GCs activity, 
antibody quality and quantities in chronic HIV infection. 
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Flow cytometry was used for the determination of T and B cells phenotypes in early HIV infection. 
Consistent with the literature, CD4+ T cells were depleted, and this was accompanied by a 
depletion of CD4+ effector memory T cell compartment [220]. However, there was an expansion 
of memory Tfh cells despite the depletion of CD4+ T cells, similar to other reports [86, 93]. HIV 
related exhaustion of the CD4+ T cell compartment was also evident, where there was an 
upregulation of PD-1. The upregulation of PD-1 on CD4+ T cells in HIV infected individuals has 
been described before [224] and has been reported to limit quality antibody generation in HIV 
infection [86].  
 
Additionally, different T follicular helper (Tfh) cell subsets such as ICOS+ PD-1+ CXCR5+ CD4+ 
and PD-1+ CXCR3- CXCR5+ CD4+ T cells had significant associations with HIV-specific 
antibody levels, pointing out to a coordinated GCs activity. Using HIV Envelope (ENV) peptides, 
I detected HIV-specific Tfh cells, and these cells were significantly associated with antibody-
dependent natural killer cell - interferon-gamma secretion (ADNKIFN-γ), which is an Fc-mediated 
function. Although associations to other functions did not reach significance level, Tfh frequencies 
increased with higher HIV-specific Fc- and Fab-mediated functions. The limited sample size may 
likely have influenced the power of the associations. However, these data support the inclusion of 
antigen-specific subsets in future larger cohort studies.  
 
Consistent with the literature, an expansion of atypical and activated B cell subsets and a depletion 
of resting B cells was observed in HIV infected individuals [101].  HIV-specific memory B cells 
were detected, and this subset had direct correlations with class-switched and mature B cells, the 
cells they differentiate from. This also supports that GCs activities favour the generation of 
antigen-specific B cells.  
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When T and B interactions were explored, activated B cells directly associated with CD4+ T cells, 
pointing to potentially available help that B cells require in the GCs. Consistent with the literature 
[105, 210], memory Tfh cells positively correlated with class-switched B cells further confirming 
the potential role of Tfh cells, which are critical for B cell class-switching in the GCs. However, 
no significant association was observed between B and T cell subsets with the markers of HIV 
disease progression.  
 
To determine HIV-specific antibody levels (isotypes and subclasses), an in-house enzyme-linked 
immunosorbent assay (ELISA) and multiplex assay were used. The multiplex assay was included 
to test a broader range of antigens. Also, the plasma levels of B cell activating factor (BAFF) and 
CXCL13 cytokines were determined before and during early HIV infection using commercial 
cytokine-ELISA kits. The reason for determining BAFF and CXCL13 levels before HIV infection 
was to establish if some individuals were intrinsically inclined to better GC reactions and hence 
better HIV disease outcomes. 
 
There was a significant increase in HIV-specific antibody isotypes and subclasses antibody levels 
as HIV disease progressed, which may be linked with the rise of HIV viremia [287]. Consistent 
with the literature, immunoglobulin (Ig) A isotype circulated at low levels in plasma [288], while 
IgG1 was the most predominant subclass and IgG4 was the least dominant [256, 258, 292, 293]. 
HIV-specific IgM was detected up to 48 months PI, supporting a role of constant HIV antigenic 
stimulation at the GCs that lead to a continuous IgM generation to new variants, despite the 
ongoing class switching from the previously generated responses [28, 287]. Theoretically, any new 
mutant viruses during chronic HIV infection may be processed as a “new infection” prompting the 
generation of IgM antibodies.  
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There were positive associations between antibody levels with markers of HIV disease 
progression, which implies that, while the high viral load is needed to drive the GCs activity, the 
preservation of CD4+ T cell counts is also essential to provide B cell help. Such a balance of 
immunological reactions has been suggested to be a driver of the development of broadly 
neutralising antibodies (bnAbs) [294].  
 
Unlike the increase in HIV-specific antibody isotypes and subclasses levels as HIV disease 
progressed, there was a decrease in the levels of BAFF and CXCL13 cytokines after infection, 
which remained low until 48 months post-infection. A previous South African cohort reported a 
rise in BAFF and CXCL13 levels after infection [217], contrarily to the current observation. It is 
possible that BAFF and CXCL13 peaked earlier than our sampling time point at 3 months PI. It is 
not clear why there was a decrease in these cytokines’ levels, considering that HIV is associated 
with a cytokine storm after infection. Nevertheless, CXCL13 and BAFF levels positively 
correlated, suggesting, a coordinated GCs activity.  
 
Furthermore, CXCL13 levels were directly associated with HIV viral load measurements, 
enhancing the role of viremia in driving GCs activities as described elsewhere [277, 278, 364]. 
However, BAFF had weak associations with the markers of HIV disease progression, and this has 
been described elsewhere [101]. Interestingly, a positive association of B cell cytokines and HIV-
specific antibody levels were observed, suggesting that higher levels of B cell cytokines would 
drive higher levels of antigen-specific antibodies. For instance, CXCL13 levels were positively 
associated with HIV-specific isotypes and subclasses antibody levels. The cytokine CXCL13 
organizes the B cell follicles of secondary lymphoid organs via recruiting antigen-specific B and 
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T cells to the GC through the CXCR5 receptor [295]; thus, its association with antibody levels is 
expected.  
 
Similarly, BAFF was associated with higher levels of HIV-specific IgG. Since BAFF is essential 
for B cell survival and maturation [97], it is plausible that higher levels of BAFF would favour 
higher frequencies of B cells and hence higher levels of antigen-specific antibodies. However, data 
suggested that, unlike BAFF, CXCL13 was a better marker of HIV-specific antibody levels. 
 
Flow cytometry was used to determine antibody-dependent cellular phagocytosis (ADCP), 
antibody-dependent complement deposition (ADCD), antibody-dependent neutrophil 
phagocytosis (ADNP) and natural killer cells degranulation expressed by CD107α , and secretion 
of cytokines as per MIP-1α and IFN-g levels in plasma taken from HIV infected individuals. A 
luciferase reporter assay was used to determine the neutralising breadth and potency in plasma 
samples.  
 
Similar to other adult studies, Fc-mediated antibody function in HIV infection was detectable early 
in infection (3 months PI) [134, 334]. It is possible that these early responses support CD8+ T cell 
responses in bringing down the HIV viremia to the viral set point. Fc mediated functions increased 
over time and this could be as a result of increasing titres of HIV-specific isotypes and subclasses 
antibody levels [134, 143]. Notably, individuals who made quality Fc-mediated responses in early 
HIV infection tended to maintain these responses as the disease progressed suggesting that early 
priming of Fc responses may be critical in maintaining them in the course of HIV. This may also 
indicate that the generation of functional Fc-mediated functions may be an intrinsic immunological 
process, with some individuals making them and sustaining them while others do not. 
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There were direct associations between the Fc effector functions measured, suggesting a 
coordinated Fc-mediated immune response in HIV. Such a response, though not extensively 
studied, has been suggested to play a role in HIV elite controllers’ early control of viremia. HIV 
elite controllers were reported to displayed a functionally coordinated innate immune-recruiting 
response involving natural killer cell functions, monocyte and neutrophil phagocytosis and 
complement [146]. Also, Fc polyfunctionality in early HIV infection is a signature of bnAbs 
development in chronic HIV infection [134]. From this study, it is not clear what drives Fc 
polyfunctionality in HIV, since Fc polyfunctionality correlated negatively with both HIV viral load 
and CD4+ T cell counts. However, and consistent with the literature [342], data here suggests that 
ADCP may play a role in viremia control.  
 
Unlike Fc-mediated functions, Fab-mediated function was rare. This result is similar to other 
reports where only 10-20% of HIV infected individuals have been shown to develop bnAbs [159, 
313]. There was no association between antibody neutralisation function with viral load or CD4+ 
T cell counts, unlike in other studies [313, 344, 345]. The lack of association could be due to the 
limited sample size and that only a very small fraction of individuals developed any level of 
neutralisation and this limits the level of interpretation. However, when only those individuals who 
developed any level of breadth were considered, positive associations between ADCP scores at 3- 
and 12-months PI and breadth development at 48 months PI were observed. This may suggest that 
quality ADCP function in early HIV infection may be a driver or a signature of the development 
of neutralisation breadth in chronic infection. In contrast, HIV viral load measurements at 6 months 
PI negatively correlated with the neutralisation breadth at 48 months PI, suggesting that the high 
viremia in early HIV infection may lead to the failure of the selection of B cells that may further 




Indeed, only ADCD function in early HIV infection negatively associated with the development 
of breadth. This finding may imply that quality ADCD activity in early HIV infection may reduce 
viremia, hence eliminating one of the crucial drivers of bnAbs development [159]. Although the 
lack of strong associations between bnAbs and Fc-mediated responses, there were trends of 
positive associations between the two antibody functions. This may suggest that both Fc and Fab 
functions are intrinsically linked and modulated distinctly in the GCs, similar to previous 
suggestions [134]. However, when only the participants who developed any level of neutralisation 
were considered and associated with Fc-mediated functions, ADCP function in early HIV infection 
predicted the development of breadth. This may infer that quality ADCP function in early HIV 
infection could be a driver or a signature of bnAbs generation in chronic HIV. We observed an 
association between the Fc and Fab-mediated functions, although not very strong, which suggested 
coordinated GCs activities. An increase in the sample size may probably have provided a better 
power for the association. 
 
Using a system serology approach, I associated immunological events during chronic infection 
with those measured earlier in the infection to establish how well these are predictive of 
downstream antibody functions. The Spearman’s correlation values for each association and their 
p-values were determined and visualized using the R package corrplot. The variables were then 
regrouped according to their level of association using the “hclust” algorithm on R.  
  
Memory Tfh cells in early HIV infection negatively associated with CXCL13 levels, emphasizing 
the role of HIV viremia in depleting CD4+ T cells and driving GCs activity [294]. Additionally, 
memory Tfh cells in early infection were associated with HIV-specific antibody levels in chronic 
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disease inferring that they are vital in offering B cells help [99, 225], which may lead to high titres 
of functional antibodies. Other subsets of memory Tfh cells such as PD-1+ CXCR3- CXCR5+ 
CD4+ T cells and ICOS+ PD-1+ CXCR5+ CD4+ T cells were associated with quality Fc effector 
functions and higher titres of HIV-specific antibodies. Mainly, PD-1+ CXCR3- CXCR5+ CD4+ 
T cells at 3 months PI had direct associations with IgG and IgG1 levels in chronic infection. 
Similarly, ICOS+ PD-1+ CXCR5+ CD4+ T cells in early infection had associations with IgM and 
IgG levels. This suggests that these subsets drive antibody generation, as reported elsewhere [99, 
357]. 
 
The association between central memory CD4+ T cells with HIV-specific antibody levels may 
infer that the preservation of this subset is critical in the generation of higher antibody titres. 
Additionally, HIV-specific Tfh cells had significant associations with ADNKIFN-γ activity 
indicating the role of HIV-specific Tfh cells in antibody class switching, that is essential for Fc-
mediated function.  
 
Due to the disruption of the B cell compartment by HIV [354, 355], different B cell subsets had 
different associations with antibody responses. Activation of B cells was required for the 
generation of higher titres of HIV-specific antibodies while resting B cells were negatively 
associated with CXCL13 levels, probably due to the effect of viremia. HIV viremia leads to the 
activation of resting memory B cells and drives GCs activity. Similarly, CXCL13 levels at 3 
months PI correlated with antibody levels in chronic HIV infection, highlighting the role of the 
GCs activity in antibody generation. 
 
The uniqueness of the current study is that it identified HIV-specific subsets of B and T cells in an 
ART naïve longitudinal cohort of HIV infected individuals. Additionally, this study used early 
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HIV-specific subsets of B and T cells to describe HIV-specific antibody levels and functions later 
on in infection. Since lymph node samples were unavailable, the pairing of peripheral HIV-specific 
cellular subsets with CXCL13 and BAFF was used to understand GCs activities [96]. Other studies 
either addressed general T cell subsets in longitudinal cohorts [99, 225] or used cross-sectional 
studies to assess the association with antibody function [93, 100, 361].  
 
The current study addressed HIV-specific cell subsets associations with HIV-specific antibody 
levels and functions, as these are the cells that specifically drive the HIV-specific responses. Also, 
using a longitudinal cohort where HIV-specific cell subsets in early infection are associated with 
subsequent antibody functions and levels in chronic HIV provides a biologically accurate 
association. This is because antibody functions and levels are often reflective of cellular events 
that occurred much earlier in an infection. More novel was the association of HIV-specific cellular 
subsets with Fc-mediated functions, which other studies have not done, despite Fc-mediated 
function being the only function to be associated with protection in the RV144 vaccine clinical 
trial [240]. 
 
In summary, I have shown that some T and B cells subsets predict higher titres of HIV-specific 
antibodies in chronic HIV infection. Additionally, HIV viremia drives quality GCs activities 
(higher CXCL13 levels) which translates into higher levels of HIV-specific antibodies. I have also 
demonstrated that there exists an association between early immunological events with 
downstream antibody functions and levels.  
 
This study emphasizes the need for longitudinal studies that assess antigen-specific responses, as 
this may provide additional information. Associating of early cellular events with downstream 
outcomes provides a biologically accurate association since antibody functions and levels are often 
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reflective of cellular events that occurred much earlier in an infection. Lastly, since Fab- and Fc-
mediated functions are mechanistically linked [134], associating both functions with early cellular 
frequencies and GCs activities may capture the whole scope of antigen-specific responses. These 
findings would benefit from confirmation in studies that have access to lymphoid tissues, that 
would be more reflective of the early cellular events as these occur in the lymphoid organs and 
were inaccessible in the current study. The identification of early immunological signatures that 
can predict downstream immunological outcomes would contribute in shepherding desired 
immune responses for vaccines and vaccination strategies. Figure 7.1 summarises the objectives 




Figure 7.1: A summary of the objectives and findings of this study. In objective 1, general and HIV-specific B 
and T cell phenotypes were characterised at 3 months PI, and their association assessed. In objective 2, levels of 
B cell cytokines, CXCL13 and BAFF were determined before HIV infection and at 3-, 12- and 48 months PI. In 
objective 3, antibody levels and functions (Fc- and Fab-mediated) were determined at 3-, 12- and 48 months PI. 
Associations between the cellular phenotypes and B cell cytokines at 3 months PI were done with antibody levels 




This study had limitations such as: 
• The lack of lymphoid tissues for the characterisation of T and B cell subsets. 
• The use of a bead assay rather than the actual virus in Fc-mediated assays. 
•  The use of a single HIV antigen in the activation induced marker (AIM) assay. 
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However, the associations as described above, that is, between early phenotypic and GCs 
events with downstream antibody levels and functions showed that early phenotypes associated 
better with antibody levels, with better defined subsets improving the association. CXCL13 
was also observed to be a better marker of GCs activities than BAFF and showed significant 
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Each trend line represents a study participant’s Log10 HIV viral load measurements in the course of HIV 
disease. The y-axis represents Log10 HIV viral load measurements in copies/ml, while the x-axis represents 
quarterly clinic visit time points in the cohort. GraphPad Prism 7 (GraphPad Software, San Diego, CA, 

















Each trend line represents a study participant’s CD4+ T cell counts in the course of HIV disease. The y-
axis represents CD4+ T cell counts in cells/mm
3  
while the x-axis represents quarterly clinic visit time points 
in the cohort. GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) was used to generate the line 
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INFORMED CONSENT FOR VOLUNTEER ENROLLMENT 
IN MULTI-CENTRE STUDY OF ACUTE HIV INFECTIONS 
   
TITLE: A PROSPECTIVE, OBSERVATIONAL, MULTI-CENTER STUDY TO EVALUATE 
LABORATORY, CLINICAL, IMMUNOLOGIC AND VIRAL MARKERS OF DISEASE 
PROGRESSION IN RECENTLY HIV-INFECTED VOLUNTEERS 
Rationale for this Study 
Over 33 million people worldwide are currently infected with human immunodeficiency virus 
(HIV), the virus that causes AIDS.  New people are being infected every day.  Only a limited 
amount of information is available on how HIV infects people’s immune cells and how our 
immune systems react to this infection. This is especially true for HIV infection in Africa. By 
participating in this study, you can help expand the field of knowledge on how HIV affects 
Africans and how African strains of HIV are controlled by the body. In addition, it is hoped that 
this information may help scientists to design a vaccine to prevent HIV, especially in Africa and 
other areas of the world most affected by this epidemic. Hopefully the information we collect in 
this study will also help improve clinical care of Africans infected by HIV.  
You are being asked to participate in this research study because you have become infected with 
the HIV virus just prior to entering the study. Enrollment of new volunteers into the study 
stopped at the end of 2011. Volunteers currently enrolled in this study are being requested to 
participate in a new follow-up regimen will look at how HIV infection progresses and how the 
cells in your body are trying to fight HIV- infection overtime.  In order to get this information we 
will continue to assess your health regularly and collect blood samples and analyze them but the 
timing and schedule of visits may change slightly for you.  Performing these tests will also be 
helpful in preparing KEMRI for future, larger, HIV prevention vaccine trials.  Additionally, this 
research study will refer you for treatment, care and support if you need it. The new follow-up 
regimen applies to all currently enrolled volunteers and is explained below 
 
Background 
The International AIDS Vaccine Initiative (IAVI), the Sponsor of this study, is an international, 
scientific, non-profit organization, whose mission it is to ensure the development of a safe and 
effective, preventive vaccine against HIV and to ensure that if such a vaccine is found, that it 
becomes available to those that need it most.  IAVI does not provide treatment for HIV but will 
make every attempt to ensure that you are referred for treatment.  
 
Duration of the Study  
 
The length of your participation in this study is dependent upon: 
• Your willingness and ability to participate 
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• When you enrolled in the study 
• Whether your participation can help the researchers answer scientific questions related to this 
study 
 
Individual participation may vary, but it will not exceed 10 years. If you have been HIV-infected 
for less than 1 year, you will have study visits every 3 months for the first year after you became 
infected. After that you will have visits every 6 months until the study ends. If you have been 
HIV-infected for more than 1 year, you will have visits every 6 months until the study ends. 
Additional visits may be scheduled if you need care, treatment, and counseling to get results of 
your laboratory tests. 
Your Participation Is Voluntary 
This consent form gives information about the study that will be discussed with you and read to 
you if you are unable to read, in a language you are comfortable with.  If you agree to participate 
in the new follow up regime, you will sign your name or make your mark on 2 copies of this 
form confirming that you agree to take part and you are doing so voluntarily; one copy is for you 
to keep and one will be kept at KEMRI. If you do not wish to keep your copy, it will be kept at 
the site in a secure place for you.  If you wish to have a person who is not part of the study team 
help you understand the study, they may be present with you during the consent process and they 
will be required to witness your consent. 
It is important that you know the following: 
• Your participation is voluntary.  
• You may decide to stop being part of the study at any time. 
• You will not lose any rights or benefits if you do not participate. 
STUDY PROCEDURES 
If you agree to participate in the new follow up schedule for this study and sign or mark this 
form, the following procedures will take place for first 3 years of study visits after enrolment:  
 
At every visit (after enrolment though month 36): 
 
You will be asked questions regarding your health, your sexual activities and any medications 
you are taking, and you will have routine medical examinations. For women this includes a 
pelvic examination. For individuals who report receptive anal sex, we will also offer an 
examination by proctoscopy to identify anal ulcers or proctitis.  
 
If you are referred for treatment, you will be asked questions regarding whether you followed up 
on the referral and the reasons you may not have gone for the referral visit. 
 
Up to 10 tablespoons (100 mls) of blood will be taken at each visit.  Some of this blood is 
required; 
• To determine your general health and to assist with your treatment (such as how much 
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You will be informed of your blood cell count and the number of CD4 and CD8 T cells 
in your blood.  
• To be stored for possible future testing that will help in research in AIDS vaccines and 
genetic testing related to your immune system to better understand the transmission and 
progression of HIV.  
• To be tested again to ensure that tests in the laboratory are always done correctly and 
carefully.  If your test results are not clear, as sometimes happens, some of this stored 
blood may be used to test your blood again, using special tests.   
Your study doctor may request additional samples for your treatment. You will only be given the 
results of the tests that assist with your treatment.  General information about what these tests 
have taught us about HIV will be shared with the volunteers as a group, the Ethics Committee, 
and with the Investigators.   
 
At your Month 12 visit, and annually thereafter, your blood will be tested for syphilis.  You 
will be provided these results and provided treatment if needed. 
 
You will be offered counselling on how to deal with problems related to your HIV infection, 
what it means for your sexual partners and family members, and how to avoid transmitting HIV 
to others in future.  If you wish, your partner and/or family members can have counselling with 
you. 
 
Women will have a urine sample to test for pregnancy.  You can participate in this study if you 
are or become pregnant. 
 
You are allowed to participate in other research studies at the same time you are in this study.  If 
you are already involved with on-going studies with these investigators, we will use information 
we have already collected from you rather than collect new information, provided you give us 
permission to do this.  The doctor will also ask you questions about other studies to ensure that 
the amount of blood taken will be within limits to protect your health.   
 
Study Visits after 3.5 years 
If you would like to continue in the study after 3.5 years (42 months) of study visits from 
the estimated date you acquired HIV, the researchers will assign you to 1 of 2 follow-up 
tracks.  Assignment is based on certain test results throughout the study. The tests indicate 
how your immune system is responding to the HIV virus. 
 
Track 1 (Standard Visit) 
Every 6-monthly study visit will be the same as before—the procedures will not change from 
those done for the first 3.5 years. As before, up to 10 tablespoons [or local equivalent of 100mL]  
of blood will continue to be drawn from your arm at every visit. Your blood will be collected and 
stored to determine your general health and to study how your immune cells are responding to 
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Track 2 (Clinical Visit) 
Every 6-monthly visit will be similar to your previous visits except that less clinical information 
will be collected and up to 2 tablespoons (20 mls) of blood will be drawn from your arm at every 
visit. Your blood will be collected primarily to determine your general health and provide test 
results that may be important for your clinical care. A small amount of the blood collected will 
be stored for research purposes and may be tested in the future to determine how your body is 
responding to the virus.  
 
What if I become pregnant?  
You can continue in the study if you become pregnant, and you are provided ARVs for the 
prevention of mother-to-child-transmission (PMTCT) of HIV.  Fewer blood samples for this 
study will be drawn while you are pregnant and for the 3 months after you deliver. Your study 
doctor will discuss which samples may be omitted.  If you become pregnant, you will also be 
counseled and referred for appropriate prenatal care.  
 
What if I start taking ARVs? 
If you are not pregnant and you start taking continuous long term ARVs, you will be released 
from the study if you have access to regular HIV care elsewhere in the community. If you start 
taking continuous long term ARVs and you do NOT have access to regular HIV care, you may 
complete your follow-up visits in Track 2 (Clinical Visit), if you choose to continue in the study. 
 
Stored blood 
Your stored blood may be sent to other expert laboratories for additional tests.  It is not known 
at this time to which laboratories these samples will be sent or for how long the samples will be 
stored. However, the samples may be stored for an additional 10 years after they study closure at 
the KEMRI-CGMRC and at IAVI Human Immunology Laboratory in London. Your blood that 
is stored will only be labelled by a study specific number and not with your name to ensure that 
no one, other than people running the study knows who you are.  No other tests will be 
performed without the approval of the ethics committee. Any future work not mentioned in the 
initial protocol will require additional approval from the relevant authorities.  You will not 
receive the results of tests done at special laboratories as they are research tests and are not 
linked to your name and do not affect your care. 
 
If you were a volunteer in protocol SSC#894_revised (the cohort study in Kilifi or Mtwapa), 
your stored blood from that study may be used to determine whether there was any HIV virus 
present in your blood before you became positive on the antibody test. In addition, data from this 
previous study, such as your CD4 counts and other study data may be used in this study to 
provide background information on you.  
  
Some of the stored blood may be used for genetic testing.  The genetic testing is being done to 
see if different types of immune responses may be related to genetic differences in people. The 
testing will be done in a laboratory using the stored blood identified only by a sample number.  
Your name will not appear with the sample. The results of the genetic testing will appear only in 
confidential study-related documents (and not in your medical record) nor will you be told the 
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Risks and /or Discomforts 
There may be some risk involved in drawing blood for the tests which sometimes can cause pain 
and bruising where the needle goes into your arm.  When blood is being drawn, you may feel 
dizzy or faint but this is not common. 
You may become embarrassed, worried, or anxious when discussing your sexual practices, 
including ways to prevent transmitting HIV to others.  Knowing that you have HIV or other 
infections passed during sex could make you worried or anxious.  A trained counselor will help 
you talk about these feelings or questions you may have.    
We will ensure that your privacy is protected during and after the study.  Your participation in 
this study may be associated with discrimination, particularly if you tell family, friends or others 
about your participation in this study.  It is also possible that others may learn of your 
participation in this study and work out that you have been infected with the HIV virus.  Because 
of this, others may treat you unfairly or discriminate against you. There are several research 
studies being conducted at this research centre in HIV-infected and uninfected people which 
decreases the chance of this happening.   
Benefits 
You may benefit by taking part in the study from receiving counseling, regular examinations and 
your CD4 count provided to you or your physician with your permission. You will be referred 
for appropriate care for illnesses and HIV (including ARVs and medications to prevent 
infections in people who are infected with HIV) if it cannot be provided at the clinic.  You or 
others may benefit in the future from information learned in this study.  If you acquire a sexually 
transmitted disease, you will be examined and treated in the clinic; if treatment is not available 
here, you will be referred for care elsewhere.  You may get some personal satisfaction from 
being part of research on HIV. If you are a woman, and you become pregnant, you will be 
referred for prenatal care and for PMTCT.    
Injuries 
We do not expect you to suffer any injury as a result of participating in this study, but if you do, 
KEMRI personnel will give you the necessary treatment for your injuries including emergency 
treatment without charge. If we cannot manage the injury at our site, you will be told where you 
can get additional treatment for your injuries. You will not have to pay for treatment that is 
needed due to a direct result of study participation. There is no program for monetary 
compensation or other forms of compensation for such injuries.  You do not give up any legal 
rights by signing this consent form. 
 
Referral for Care and Treatment 
Comprehensive HIV care will be provided to you at the KEMRI-Mtwapa clinic or Kilifi District 
Hospital Comprehensive Care and Research Clinic. For chronic illnesses, or other diseases not 
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Costs to You 
There is no cost to you for being in the study. However volunteers will be compensated for costs 
to cover travel expenses to the study site at Ksh 500 for each scheduled visit and any 
inconvenience caused due to study participation.   
Circumstances for Withdrawal from the Study 
You may be removed from the study without your consent for the following reasons: 
• You are not able to attend study visits or complete the study procedures 
• If the study is stopped or cancelled 
• Other administrative reasons 
Alternatives to Participation 
The study staff will inform you if there are other HIV research studies taking place in your 
community and if there are other facilities where you can go for HIV counseling, care and 
support.  
New Information 
You will be told of any new information gained during the course of the study.  You will be told 
when the results of the study may be available, and how to learn about them. 
Supervision of the Study 
This study will be approved by the site’s Ethics Review Committee - a group that looks out for 
the well-being of all study participants to ensure that the rights of volunteers are protected. In 
addition, the conduct of the study will be supervised by a group of experts called the Steering 
Committee. All information collected will be regularly checked by independent study monitors. 
Confidentiality 
Your participation in the study, all information collected about you as well as all results of 
laboratory tests will be private and not available to others outside of the people listed below.  
You will have your own special identity number known only to you and the clinic staff.  Apart 
from the study team members that you meet, other staff from National or international 
government bodies that ensure correct conduct of research, members of the Ethics Committee, 
study monitors, auditors, inspectors, and representatives of the Sponsor (IAVI) will check the 
records to make sure that the study was conducted properly.  They are required to respect your 
confidentiality.  Stored blood and clinical data will only be labeled with your study-specific 
number and not with your name.  This is to ensure that no one, other than people running the 
study, knows that the samples belong to you. Any samples and study data that are shared with 
expert laboratories will only be identified by this study number. These laboratories will never 
have access to your personal details. Your identity will not be disclosed in any publication or 
presentation of this study.  Your blood specimens will only be identified by your study number.  
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Contacting you at home 
Once you enroll in the study, we will offer 3 strategies to improve the research participation: 
 
Home visits: 
If you grant permission, clinic staff will make an appointment to visit you once at your home. 
During this visit, they will update your tracing locator form with landmarks in the vicinity of 
your home and take a GPS-way point. A GPS machine looks like a big mobile telephone and can 
take coordinates of any location with a precision of about 5 meters. These coordinates will be 
used by KEMRI-UW staff only if we need to trace you for an abnormal lab results or missed 
visit. We believe this technology will help us trace you more discretely, since tracing staff will 
need to ask fewer questions to locate your residence. Study staff will only come to your home 
with your permission. 
 
SMS-reminder message: 
If you provide us with a mobile phone number, we will send you a reminder message for your 
clinic appointment 1 day in advance. If you do not want to receive such a message, please let us 
know either now or at any time in the future. 
 
Fingerprint scan: 
To help us keep track of who is enrolled in our clinic, we will ask you to put your right index 
finger on a small machine that can scan your finger print. This will be done at each clinic visit 
and will take less than 5 seconds. This scan will translate into a unique identification number that 
will be added to your study ID card, and will be accessible only to our staff and to staff of the 
KAVI Kangemi research in Nairobi. If you are in Nairobi and need emergency care, you are 
welcome at the Kangemi clinic. Your finger scan will let the Kangemi clinic staffs know that you 
are enrolled in the KEMRI clinics in Mtwapa and Kilifi. 
If you don’t want to have your fingerprint taken, please let us know – you are free to refuse. 
 
Do you agree to have your stored blood sent to other expert laboratories for possible future 
testing to help in research for AIDS vaccines? No additional tests will be performed without the 
approval of the Ethics Committee    
 
    Yes  No  If yes, pls complete the sample storage form 
 
Do you agree to be visited at home? 
 Yes  No 
Do you agree to receive SMS reminder message for your clinic appointment? 
 Yes  No 
Do you agree to have your finger scanned each time you visit the clinic 
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Who should I contact with any questions about the study? 
The coordinators are:  
Dr. Eduard Sanders.  If you have any questions you can reach him at KEMRI (telephone: 0725 
242233).  
 
If you have a medical problem related to your participation, please contact The Director KEMRI 
(telephone: 0725 242233).  
 
Nurse/Counsellors are available at KEMRI Kilifi tel no. 0725 242233 or KEMRI Mtwapa 0722 
206418 
 
If you have a question about the ethics of this investigation you can contact Community Liaison 
Manager, (0725 242233, or 0723 342780) at KEMRI, or  
 
The Head, KEMRI Scientific and Ethics Review Unit, P. O. BOX 54840-00200, Nairobi. 
Telephone: 0717 719477 or 0776399979. Email address: seru@kemri.org 
 
RESEARCH PARTICIPANT’S STATEMENT 
This study has been explained to me, and I voluntarily consent to participate.  I have had an 
opportunity to ask questions.  I understand that future questions I may have about the research 
will be answered by one of the investigators.  I will receive a copy of this consent form. 
Name of research participant _______________________________________ 
Signature of research participant _____________________________ Date ______________ 
 
Name and signature of witness  
Name ___________________________Signature ________________Date ______________ 
(If research participant was not able to read and understand the informed consent document) 
 
Name and Signature of Person Obtaining Consent 
Name ___________________________Signature ________________Date ______________ 
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SAMPLE STORAGE AND SHIPPING CONSENT FORM SIGNATURE PAGE 
 
I, (name of volunteer) ____________________________________________________ 
agree that after the tests needed for the study are done, the remaining blood taken from me may 
be stored for an additional 10 years after study closure. I understand that a number, rather than 
my name, will be used to label this blood so it is confidential. The stored blood may be used in 
the future for quality control purposes and other tests related to KEMRI ERC approved HIV 
vaccine research and development. 
 
I also agree that my blood will be sent to external, national or international laboratories including 
the Human Immunology Laboratory of IAVI located in London. All of these tests will be for 
HIV vaccine research only. 
 
I understand that some of the blood drawn as part of this study may be used for genetic testing. 
The genetic testing is being done to see if different types of immune responses may be related to 
genetic differences in people. The testing will be done in a laboratory using the stored blood 
identified only by a sample number. My name will not appear with the sample. The results of the 
genetic testing will appear only in confidential study-related documents (and not in my medical 
record) nor will I be told the results of the testing.  
 
New genetic research tests to help understand if a vaccine might work may be done on stored 
samples in the future. If new information about HIV infection becomes known through this 
research, the information will be shared with me and the ethics committee. 
 
 
Participant Signature: _________________________ 
 
Name: _____________________________________ Date:  __________________ 
 
 
Person obtaining consent: 
 
Signature of person obtaining consent: _________________ 
 
Name: _____________________________________ Date: ___________________ 
 
 
Impartial witness (if volunteer is illiterate): 
I sign here as a witness to the consent process. I have participated in the discussion and 
witnessed the volunteer’s consent to study participation: 
 
Impartial witness Signature ______________________ 
 
Name: ______________________________________Date: ___________________ 
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6.    The dynamics of HIV-specific antibody isotypes and subclasses levels as 
detected by the Luminex assay. 





Eight HIV antigens spanning across clades A, B and C were used to detect HIV-specific responses while flu and 
tetanus antigens were used as controls. The median concentration for each sub-group and IQR values are shown. 
The y-axis represents mean fluorescence intensity (MFI) values; the x-axis represents different antigens used. PI 
represents post-HIV infection. Test, Kruskal-Wallis.  
 249 
7.  Correlation between the levels of CXCL13 in the course of HIV  
 
 









8.     The neutralisation curves for the plasma samples tested for the 


















Each curve represents a study participant as labelled at the top of the curve. Each pseudovirus is colour 
coded, and a key is provided to describe each colour. Only 15/53 individuals generated antibodies with 
breadth. The x-axis represents plasma dilutions while all the y-axis represents the breadth of each plasma 
sample tested. Any plasma sample with a breadth of >0 has been marked with a red box. Test; nonlinear 
regression- inhibitor versus response (3 parameters). GraphPad Prism 7 (GraphPad Software, San Diego, 















































































































































































































































































































































































































































































































9. List of reagents 
 
11-0049-42 FITC anti-human CD4   
17-9185-42 CD185 (CXCR5) Monoclonal Antibody (MU5UBEE), APC 
12-2799-42 
Anti-Human CD279 (PD-1) PE 
25   
304133 Brilliant Violet 605™ anti-human CD45RA 
353234 Brilliant Violet 650™ anti-human CD197 (CCR7) 
46-9948-42 CD278 (ICOS) Monoclonal Antibody (ISA-3), PerCP- 
 eFluor 710   
348220 Brilliant Violet 510™ anti-human IgD, Clone IA6-2 
350012 
PE/Cy7 anti-human CD134 
(OX40)   
12-0199-42 Anti-Human CD19 PE 100 tests   
302234 Brilliant Violet 421™ anti-human CD19 
302834 Brilliant Violet 711™ anti-human CD27, Clone O323 
560179 Mouse Anti-Human CD8 APC-H7 (SK1 Clone) Monoclonal 
 Antibody   
302638 Brilliant Violet 785™ anti-human CD25 
423101 
Zombie Aqua™ Fixable Viability 
Kit   
557917 Alexa Fluor® 700 Mouse Anti-Human CD3 
344602 Purified anti-human CD4   
 252 
4401 Cluster Tube System, 96-Well, Individual 1.2ml 
 Tubes, Polypropylene, Non-Sterile, without Rack 
PJ27S PhycoLink® Streptavidin-Allophycocyanin Conjugate 
PJRS25 PhycoLink® Streptavidin-R-Phycoerythrin 
DBLYS0B Human BAFF/BLyS/TNFSF13B 
DCX130 Recombinant Human CXCL13/BCA Quantikine ELISA 
0855371 
Complement Anti C3 Polyclonal Antibody, Anti-Guinea Pig, 
Goat 
557831 APC-CY7 Mouse Ant-Human CD14 
A9418-500G Albumin from Bovine Serum (BSA), Bio Reagent, 
 suitable for cell culture, lyophilized powder, 
 >96% (agarose gel electrophoresis) 
F8775 FluoSpheres© NeutrAvidinU labelled microspheres, 
 1.0 cm, red fluorescent (580/605), 1% solids 
F8776 FluoSpheres© NeutrAvidin Labelled Microspheres, 1.0 
 um, yellow-green fluorescent (505/515) 1% solids 
CL4051 Low-Tox® Guinea Pig Complement, Lyophilized 
0855371 Complement Anti C3 Polyclonal Antibody, Anti-Guinea 
  Pig, Goat 
00-4333-57 1X RBC Lysis Buffer 
557831 APC-Cy™7 Mouse Anti-Human CD14 
305112 Pacific Blue™ anti-human CD66b Antibody 
557943 Alexa Fluor® 700 Mouse Anti-Human CD3 
 253 
15065 RosetteSep™ Human NK Cell Enrichment Cocktail 
H8889-500ML Histopaque®-1077 Hybri-Max® liquid, Sterile- 
 Filtered, Hybridoma Tested 
86450 SepMate™-50 (IVD) 50 mL Centrifuge Tube for 
 density gradient centrifugation 
B7651-5MG Brefeldin A from Penicillium Brefeldianum, >99% 
554724 GolgiStop® 
GAS001S100 Fixation Medium (Medium A) 
GAS002S100 Permeabilization Medium - General, (MEDIUM B) 
555802 Cy-Chrome U labelled anti-human CD107α  (LAMP-1) 
557747 PE-Cy™7 Mouse Anti-Human CD56 
554702 APC Mouse Anti-Human IFN-gamma 
 31985070 Opti-Mem 
 P7539 Penicillin streptomycin solution 
H0887 HEPES solution 
1114544 Lymphoprep 
109-055-043     AP conjugated affinipure goat anti-human IgM  
109-055-098     AP conjugated affinire pure goat anti-human IgG, Fc  
31350010     Beta-mercapto ethanol  
P9187     OPD peroxidase substrate 
R0883     RPMI-1640 medium 
15575020     0.5M EDTA 
25030081     L-Glutamine 
 254 
E2691     Fugene transfection reagent 
16176     Luciferase kit 
ATCC T1B-202     THP-1 cells 
B94987      Vi-CELL reagent 
550078     PE Mouse Anti-Human MIP-1ß 
90283     Qsol buffer 
 
 
 
